
==== Front
Int J Mol SciInt J Mol SciijmsInternational Journal of Molecular Sciences1422-0067MDPI 10.3390/ijms19082210ijms-19-02210ReviewEnteric Microbiota–Gut–Brain Axis from the Perspective of Nuclear Receptors https://orcid.org/0000-0002-7455-6090Duszka Kalina 1https://orcid.org/0000-0002-5966-9089Wahli Walter 23*1 Department of Nutritional Sciences, University of Vienna, Althanstrasse 14, 1090 Vienna, Austria; kalina.duszka@univie.ac.at2 Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, Singapore 308232, Singapore3 Center for Integrative Genomics, University of Lausanne, Génopode, CH-1015 Lausanne, Switzerland* Correspondence: Walter.Wahli@ntu.edu.sg; Tel.: +65-6592-392728 7 2018 8 2018 19 8 221027 6 2018 23 7 2018 © 2018 by the authors.2018Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Nuclear receptors (NRs) play a key role in regulating virtually all body functions, thus maintaining a healthy operating body with all its complex systems. Recently, gut microbiota emerged as major factor contributing to the health of the whole organism. Enteric bacteria have multiple ways to influence their host and several of them involve communication with the brain. Mounting evidence of cooperation between gut flora and NRs is already available. However, the full potential of the microbiota interconnection with NRs remains to be uncovered. Herewith, we present the current state of knowledge on the multifaceted roles of NRs in the enteric microbiota–gut–brain axis.

nuclear receptorsmicrobiotametabolismxenobiotics
==== Body
1. Introduction
Nuclear receptors (NRs) and microbiota are two factors that together have a great impact on all body functions. With the cloning of the first NRs in the 1980s, a great era of NR research begun. The progressive discovery of the 48, 49 and 47 NRs in humans, mice and rats, respectively, and their essential role in development, metabolism, homeostasis by directing virtually each single process in these organisms, powered abundance of prospective research in this new field [1]. The prosperity of NR research partially overlapped with increasing interest in the gut microbiota and its recognized major regulatory function. An extraordinary profusion of microbiota research at the beginning of 21st century changed our perception of gut bacteria from symbiotic organisms to forming a functional “organ” modulating the host’s physiological and psychological health. Within the last years, research in the field of microbiota gradually progressed from studies based on correlations between microbiota composition and diseases (e.g., autism, obesity, metabolic and autoimmune diseases) to tracking molecular pathways of interactions between specific bacterial strains, their metabolites and the host. What we have learned so far is that gut microbiota is characterized by its high variability in composition between different hosts, which is induced by multiple factors including childbirth delivery, gender, life style, diet, age, the individual’s immune system, immunization, pharmacological interventions, antibiotic treatments, contacts with other carriers of bacteria, length of exposure to factors affecting bacterial composition, and geographical location [2,3,4,5]. Moreover, metabolites produced by the gut flora itself also influence microbial communities in the gut, modulating their composition, maintaining their optimal population size and protecting them from colonization by pathogens through the production of bacteriocins [6]. Recently, it has been shown that the human gut microbiota composition is influenced more by environmental factors than by the host’s genome. In fact, over 20% of inter-person microbiota variability is associated with factors related to diet, drugs and anthropometric characteristics [7]. Based on the current state of research, we can conclude that: (1) the gut microbiota is a complex and dynamic part of the body; (2) it is impossible to define a single and proper healthy gut bacteria composition that would fit all due to highly individual external and innate factors shaping distinct gut microbiota. Therefore, trying to compare and evaluate the determinants of microbiota composition is a complex task. Moreover, studies in germ-free (GF) mice have shown that the gut bacteria as an “organ” is not indispensable to live and thrive, at least in a laboratory environment. However, the regulatory function of the microbiota with specific roles in gut, brain and whole organism development and maintenance definitely represents an evolutionary benefit. During the long natural history of the symbiosis between host and microbiota, resident gut bacteria developed multiple ways of communicating with their host including with its central nervous system (CNS), which resulted in the development of a key microbiota–gut–brain axis. The aim of this article is to review existing evidence of the involvement of NRs in the interaction between host and gut microbiota, particularly in the context of the gut–brain axis.

2. Gut–Brain Axis
By now, the interaction between the gut microbiota and the brain is an evidence-based fact. Data suggest that the gut microbiota can affect physiological, behavioral and cognitive functions of the brain [8,9,10,11,12]. Bidirectional signaling in the enteric microbiota–gut–brain axis is regulated at neural, hormonal, and immunological levels and includes the CNS, neuroendocrine and neuroimmune systems, the enteric and autonomic (sympathetic and parasympathetic branches) nervous system, and intestinal microbiota factors. Visceral signals are transmitted directly to the CNS via afferent fibers or indirectly by the blood circulation. Response signals from the CNS are mediated via efferent fibers to the smooth muscles of the gastrointestinal (GI) tract, thereby influencing its motility and secretory functions, which modify the environment in which the bacteria reside [12,13,14,15]. Host mental state, especially under stress, has long-term effects on gut flora [16,17,18]. Stress increases gut permeability and modulates growth of both non-pathogenic and pathogenic bacteria via the effects of dopamine, adrenaline and noradrenaline produced by the host [19,20,21,22,23,24,25,26]. Importantly, adrenaline and noradrenaline also modulate the expression of bacterial virulence genes [26,27].

As mentioned above, gut–brain signaling works both ways; thus, signals sent by resident bacteria affect the whole body. The GI flora secrete an abundance of microbe-associated molecular patterns (MAMPs) and bioactive metabolites such as bacteriocins, secondary bile acids (BA), choline and short chain fatty acids (SCFAs). SCFAs are derived from the fermentation of polysaccharides and influence the colon epithelium locally, but also enter the blood circulation and modulate the host’s incretin production and energy balance [28]. By regulating the levels of satiety and hunger hormones, including ghrelin [29,30], leptin [29,31,32,33], insulin [34], somatostatin [35], peptide YY (PYY) [30] and glucagon-like protein-1 (GLP-1) [36,37], bacteria affect the host’s gut motility, nutrients absorption, glucose tolerance, food cravings and hunger. Stunningly, gut flora may impact the levels of hunger hormones by influencing the production of autoantibodies against peptide hormones involved in appetite control [38]. Bacterial colonization of the intestine has a major role in post-natal development and maturation of the endocrine, immune and nervous systems and affects the host’s physiological and psychological health [8,39,40,41,42,43,44,45]. Enteric microbiota also regulates levels of sex hormones; transferring the gut microbiota of male mice to females causes an elevation in testosterone levels and induces metabolomic changes in recipient females [46]. Commensal flora itself is capable of synthesizing and releasing many neurotransmitters and neuromodulators, or inducing enteroendocrine cells to synthetize and release neuropeptides, thereby affecting the host’s behavior and stress levels. Bacteria play a critical role in the production of free adrenaline in the gut lumen [47] and Escherichia, Bacillus and Saccharomyces spp. can generate noradrenaline [48,49]. Furthermore, the microbiota affects the hippocampus and amygdala levels of brain-derived neurotrophic factor (BDNF), a key neurotrophin involved in neuronal growth and survival [42]. Lactobacillus and Bifidobacterium species can synthetize γ-aminobutyric acid (GABA), while Lactobacillus rhamnosus (JB-1) induces region-dependent alterations in GABA(B1b) and GABA(Aα2) receptors in various parts of the brain [45,48,49]. Importantly, vagotomized mice do not display the neurochemical and behavioral effects of L. rhamnosus (JB-1), thus implicating the vagus nerve in the direct communication between bacteria and the brain [45]. Alterations in central GABA receptor expression are implicated in the pathogenesis of anxiety and depression, which are highly comorbid with functional bowel disorders. Moreover, Bacillus can produce dopamine, Lactobacillus can generate acetylcholine, and Candida, Streptococcus, Escherichia and Enterococcus spp. synthetize serotonin (5-HT) [48,49]. 5-HT is a key regulator of GI motility and secretion but also a modulator of depression and anxiety-like behavior. Approximately 95% of 5-HT in the body is compartmentalized in the gut, predominantly in enterochromaffin cells of the mucosa and in nerve terminals of the enteric nervous system. The presence of specific strains of bacteria or the GF status in mice modulate 5-HT production by the enterochromaffin cells, which affects circulating levels of 5-HT and tryptophan, a 5-HT precursor [50,51,52,53]. Interestingly, the delivery of the probiotics Bifidobacterium infantis 35624, which results in an elevation in plasma tryptophan, has been suggested as a promising anti-depressive therapy [53]. Thus, the continuous dialog between the GI flora and brain—regulating parts of postnatal development, metabolism and daily body functioning—is essential for a healthy brain and gut.

3. Nuclear Receptors
NRs together form a superfamily of proteins that function as transcription factors. In principle, their activation requires the binding of ligands, which results in increased affinity towards NR-response elements in the regulatory region of target genes leading to changes in their expression activity. Multiple NRs are expressed in the GI tract, and several microbe-produced metabolites act as ligands of NRs. Thereby, the activity of NRs may be affected by nutrient- and microbiota-derived ligands. Gut bacteria secrete metabolites including indole derivatives, hormones and secondary BAs, which act as natural ligands for the host’s NRs [54]. Thus, microbial metabolites influence the host by regulating gene expression that modulates biological effects. This interactive system allows a direct influence of the microbiota on the host’s physiology and, therefore, it can have control over the health or disease status of the host.

3.1. PPARs
Peroxisome proliferator activated receptors (PPARs) are a sub-family of ligand-activated nuclear receptors, which consists of three isotypes; PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3), each produced by a separate gene [55]. PPARs are collectively involved in the control of energy metabolism, inflammatory and immune responses. Natural ligands of PPARs include fatty acids (FA), eicosanoids and phospholipids [56,57]. Each PPAR isotype shows an individual pattern of expression in the GI tract and exerts different functions [58]. However, all three of them are known for their anti-inflammatory properties in the small intestine and colon. All PPARs mediate microbiota effects and take part in the gut–brain axis signaling; however, the way they accomplish this function is distinct (Figure 1). If their relation with the microbiota is mainly in the context of their anti-inflammatory properties, signaling to the brain is mostly related to metabolism. These two functions are highly interconnected in the GI tract as shown by our recent caloric restriction study in mice [59].

3.1.1. Peroxisome Proliferator Activated Receptor α
PPARα was initially identified as the molecular target of xenobiotics inducing peroxisome proliferation in rodents [60]. PPARα is ubiquitously expressed and is particularly abundant in organs with a high demand for catabolism of fatty acids [58]. The greatest expression of this isotype is in liver and brown adipose tissue (BAT); the stomach and duodenum also show substantial levels of PPARα. The expression of PPARα decreases along the GI tract with lowest levels in the colon [58].

PPARα coordinates several aspects of metabolism by modulating the expression of genes involved in peroxisomal and mitochondrial β-oxidation, FA transport, FA catabolism, ketogenesis and gluconeogenesis [56]. PPARα is a nutritional status sensor and allows adaptation of the rates of FA catabolism, lipogenesis and ketone body synthesis in response to nutritional status, particularly during fasting [61,62,63]. During the fed state, PPARα synchronizes pathways of de novo lipid synthesis to supply FAs for storage. In starvation, when the organism shifts to the mobilization of stored FAs, PPARα switches its activity to promote cellular FA uptake and β-oxidation. Moreover, PPARα stimulates the expression of rate-limiting enzymes of ketogenesis in the liver [64,65]. Importantly, the role in ketone body synthesis is dependent on the stimulation of PPARα expression in the liver by commensal gut microbiota [66]. Thus, microbiota-dependent PPARα activity modulates proper metabolic adjustment to nutrient availability. Given these facts, it is not surprising that PPARα has been identified as a major factor in the adjustment of metabolism during caloric restriction and daily rhythms (rest/activity and fasting/feeding) [59,67,68,69,70] 

PPARα is a major contributor to functional circadian rhythm by directly regulating transcription of the important circadian genes Bmal1 and Rev-erbα [68,71], as well as modulating PER2 activity by direct protein–protein interactions [67]. Additionally, PPARα itself is a target gene of BMAL1 and CLOCK [68,72]. As a result, numerous genes involved in lipid and cholesterol metabolism, as well as energy homeostasis, which are regulated by PPARα, display daily fluctuations in mouse liver [73,74]. It is noteworthy that PPARα, by mediating signals received from the microbiota via toll-like receptors (TLR), contributes to both the circadian expression of genes in the intestine and intestinal corticosterone production [75]. Thus, PPARα mediates signals from the GI flora, which impact the host’s physiology.

An additional link between PPARα and microbiota has been proposed recently [76]. PPARα was identified as an important factor in the inflammatory response of the intestine to commensal microbiota. According to the model proposed, PPARα regulates the expression of interleukin 22 (IL-22) and the antimicrobial peptides Reg3β, Reg3γ, and calprotectin. In mice deficient in PPARα, commensal dysbiosis in the gut occurs and results in an increased expression of inflammatory cytokines and enhanced susceptibility to intestinal inflammation [76]. These findings comply with previous reports associating intestinal PPARα with anti-inflammatory activity in the GI tract by preventing neutrophil infiltration and protecting the intestine from colitis-induced permeability [77,78,79,80].

Even more interestingly, intestinal PPARα is involved in inducing satiety signals in the brain. Oleoylethanolamide (OEA), an endogenous ligand of PPARα, is an endocannabinoid produced by enterocytes in response to fat consumption [81]. Biosynthesis of OEA in the intestine requires sympathetic innervation [82] and is modulated by BAs [83]. Accordingly, hepatic expression of PPARα is stimulated by the farnesoid X receptor (FXR), which with the support of microbiota, controls BA metabolism (for details see the further parts of this review below) [84]. Administration of OEA has an anorectic effect by acting peripherally, prolonging eating latency or reducing meal size, depending on the nutritional state, and leads to body weight reduction [81,85,86,87]. This effect is mediated by PPARα activation in the proximal small intestine [81,88,89]. Surprisingly, intraperitoneal administration of OEA acutely decreases energy expenditure, as well as ambulatory and spontaneous locomotor activity [90]. It regulates lipid metabolism by activating PPARα to stimulate lipolysis, and decreases neutral lipid content in hepatocytes as well as serum cholesterol and triglyceride levels [91]. OEA in intestinal enterocytes engages afferent sensory fibers of the vagal nerve leading to increased expression of c-fos in the nucleus solitary tract (NST) and the paraventricular nucleus (PVN) of the brainstem and hypothalamus, respectively [91], which stimulates oxytocin secretion and promotes satiety [92]. Since enterocytes in the small intestine are the first cells responding to dietary fat intake by increasing OEA production, OEA was suggested to serve as a gut-derived satiety factor [81].

3.1.2. Peroxisome Proliferator Activated Receptor β/δ
PPARβ/δ is ubiquitously expressed; nevertheless, its expression in the GI tract is very high compared with other tissues. PPARβ/δ is abundant in the gut from the duodenum to the ileum, with lesser but still detectable expression in the colon [58]. Pparβ/δ is constitutively expressed in the intestine, but inflammatory signals further stimulate its expression [93]. Intestinal PPARβ/δ induces terminal differentiation of epithelial cells in the intestine and colon and is required for the differentiation of Paneth cells [94,95,96]. Thus, PPARβ/δ is indirectly involved in secretion of antimicrobial peptides. PPARβ/δ protects against dextran sulphate sodium (DSS)-induced colitis [97]; however, its role in colon cancer has been controversial and conflicting results suggest that PPARβ/δ can either promote or attenuate this disease [98].

When activated, intestinal PPARβ/δ promotes fatty acid oxidation in adipose tissue and skeletal muscle, it improves dyslipidemia and stimulates overall energy expenditure thus protecting against diet-induced obesity and insulin resistance [99]. It regulates plasma HDLc levels, influences expression of genes involved in lipoprotein metabolism and stimulates postprandial GLP-1 production in enteroendocrine L-cells, resulting in preservation of pancreas β-cell morphology and function thereby increasing systemic insulin sensitivity [100]. However, the detailed mechanisms behind these beneficial properties remain to be explored further. Thus, besides enhancing the satiety signal GLP-1, no other link between intestinal PPARβ/δ and the CNS has been identified to date.

3.1.3. Peroxisome Proliferator Activated Receptor γ 
PPARγ is mostly known for its insulin sensitizing properties and its role as a master regulator of adipogenesis [101]. It modulates multiple processes, including cell proliferation, differentiation, glucose and lipid metabolism, and inflammation [101,102,103,104,105]. PPARγ is highly expressed in adipocytes and in the gut, and at lower levels in the pancreas, liver, kidney, and immune cells. In the GI tract, it is present at a relatively high level in the proximal parts of the small intestine and gradually decreases towards its distal parts. However, it is highly expressed in the proximal colon [58,106,107,108]. PPARγ expression and activity are induced in the gut by multiple nutrients, most importantly by fatty acids and their metabolites but also by glutamine, curcumin, capsaicin, ginsenosides and vitamin E, all of which have been reported to exhibit anti-inflammatory properties [109]. Importantly, bacterial metabolites and bacterial by-products, such as butyrate [110,111], propionate [112] and H2O2 [113] also stimulate expression or activity of PPARγ. Presence of specific bacterial strains, such as Enterococcus faecalis, Roseburia hominis, Roseburia intestinalis, Fusobacterium naviforme and Streptococcus salivarius influence the phosphorylation of PPARγ and thereby its transcriptional activity [112,114,115]. Moreover, it has been shown that the microbiota affects liver circadian rhythm by modulating the activity of PPARγ expressed in liver [116]. Thus, there is a dynamic balance involving reciprocal interactions between PPARγ and the gut microbiota, whereby PPARγ can both be activated by bacteria and regulate the intestinal microbiota composition.

PPARγ has been identified as a promising therapeutic target in fighting colon cancer as it reduces colorectal tumor development by decreasing cell proliferation [117,118,119], increasing cell differentiation [117,120], inducing apoptosis [117,118,121,122,123], and inhibiting angiogenesis [124]. PPARγ agonists mitigate inflammatory bowel disease (IBD) symptoms, reduce inflammation, and are effective in multiple models of ulcerative colitis as well as in Crohn’s disease [125,126,127,128,129,130,131,132,133,134,135,136,137,138]. PPARγ acts as anti-inflammatory mediator by regulating multiple signaling pathways, including those related to p53 [139], Bcl2 [121,123], c-Myc, [140], Cox-2 [123,141,142,143], Apc/B-catenin [144,145] and NF-κB [121,143]. Notably, PPARγ is responsible for the selective killing of bacteria associated with IBD and maintenance of innate antimicrobial immunity in the colon [146]. Hence, bacteria-mediated stimulation of gene activity by PPARγ appears to have a protective role in the prevention of gut inflammation and regulation of immune tolerance. Recently, we described a novel role of intestinal PPARγ in long chain FA processing in the intestinal epithelium [147]. This is an original finding given the fact that, so far, intestinal PPARγ has primarily been characterized in the context of inflammation and cancerogenesis. Importantly, using an intestinal epithelium-specific PPARγ knockout mouse model, we found a signaling mechanism between PPARγ expressed in intestinal epithelium and the brain [148]. Intestinal PPARγ in mice submitted to caloric restriction or a diet low in sucrose regulates body adiposity by signaling via the sympathetic nerve system. Thus, activation of intestinal PPARγ by bacterial metabolites or nutrients can impact adipose tissue via the nervous system.

3.2. Farnesoid X Receptor (FXR)
BAs produced by the liver are stored in the gall bladder and secreted into the small intestine where they contribute to the emulsification and solubilization of fats. Thus, they aid in the digestion and absorption of lipids. The expression profile of genes involved in BA synthesis, conjugation, and reabsorption is altered by the resident gut microbiota [149]. Certain secreted BAs undergo biotransformation by the gut microbiota from primary to secondary BAs [150], and this process is accompanied by a feedback mechanism of BAs on the microbiota composition [151,152]. Moreover, secondary BAs, but also some of the primary BAs, can act as ligands for the nuclear receptor FXR (NR1H4), which is expressed in enterocytes throughout the small intestine and colon [153]. BA activation of FXR leads to subsequent alteration of the BA pool size via two FXR-dependent feedback mechanisms of hepatic BA synthesis [154]. FXR regulates the transcription levels of critical genes in BA synthesis, homeostasis, transport and metabolism [155] but also affects general lipid and glucose metabolism [156], as well as hepatic autophagy [157,158]. Mice lacking FXR expression in the intestine withstand diet-induced obesity (DIO), insulin resistance and non-alcoholic fatty liver disease, and several studies associated FXR with sensitivity to metabolic diseases [149,159,160,161,162]. FXR knockout may be mimicked by a treatment with tempol (4-hydroxy-2,2,6,6-tetramethyl-piperidine-N-oxyl) a stable nitroxide which is a membrane-permeable, and metal-independent superoxide dismutase (SOD) mimetic. Tempol decreased the Lactobacillus population in gut, accompanied by reduced activity of bile salt hydrolase (BSH) normally exhibited by the bacteria. As a result, a potent antagonist of FXR, tauro-β-muricholic acid (T-β-MCA) accumulated in the intestine, demonstrating that the enteric flora can modulate the activity of FXR [159]. Moreover, the gut microbiota has been shown to promote DIO and stimulate adiposity via activation of the intestinal BA/FXR axis, which contributes to alteration of the ceramide/SREBP1C/CIDEA pathway in the liver and disrupts lipid homeostasis [149,160]. Conversely, FXR may contribute to increased adiposity by modulating the composition of the gut microbiota [149]. Thus, the tie between FXR and microbiota is tight and complex and, therefore, difficult to dissect. However, it is sufficiently documented that targeting bacteria or BA composition can result in changes of FXR activity and body weight.

A link was identified between the BAs in the gut and cystic breast tissue in humans [163,164]. The bile salt lithocholate originating from the intestine was found in aspirates of cyst fluid from the breasts of women with fibrocystic disease at much higher concentrations than in the serum [163]. Additionally, BAs such as deoxycholic acid (DCA) have been shown to stimulate both the growth and metastasis of breast cancer cells through FXR expressed in the breast cancer tissue [165], suggesting that BAs may play a role in breast tumor carcinogenesis.

Among other genes, FXR binds a response element in the regulatory region of Fgf15 (a rodent ortholog to human Fgf19) and directly regulates its transcription. FGF15 is produced in the distal small intestine, and is secreted into the portal circulation to function as a postprandial hormone [166,167]. Its levels rise following a meal with a lag comparable to that of insulin. In contrast to other enterokines (e.g., GLP-1, GIP), FGF15 does not affect insulin secretion but rather mimics insulin impact [167,168]. The peak of FGF15 occurs 90–120 min after the postprandial release of BAs, precedes the repression of BA synthesis [167], and causes the gallbladder to refill with bile [169]. Secreted FGF15 circulates to the liver, where it acts on two receptors: FGF-receptor 4 (FGFR4) and β-Klotho (KLB). This results in the activation of the Ras–ERK–p90RSK pathway, which affects the expression of genes, such as c-Fos, JunB, and c-Jun [168,170]. FGF15 inhibits BA synthesis in the liver by repressing the transcription of the cholesterol 7α-hydroxylase gene (Cyp7a1), which encodes the first and rate-limiting enzyme in the classic BA synthesis pathway [171]. FGF15 also stimulates hepatic protein and glycogen synthesis [172], contributes to the regulation of systemic lipid and glucose metabolism [173] and represses gluconeogenesis through a mechanism involving the dephosphorylation and inactivation of the transcription factor CREB [174]. Importantly, according to the current state of knowledge FGF15 represents a key factor in the FXR–gut–brain axis connection. FGF15 secreted from the intestine leads to activation of its receptors in hypothalamic AGRP/NPY neurons leading to reduction of signaling by these neurons. This regulation promotes glucose tolerance presumably mediated by the autonomic nervous system [175]. Thus, FGF15 can modulate metabolism by acting directly on the brain, which is supported by the observation according to which intra-cerebro-ventricular injection of FGF15 reduces 24 h food intake and body weight, and acutely improves glucose tolerance [176]. In ob/ob mice, FGF15 administered centrally increases glucose disposal via an insulin-independent mechanism [177]. Remarkably, FGF15-triggered nerve signaling is required for longer-term weight loss and glycemic effects while its activity in the liver and adipose tissue is not [178]. Notably, expression of human FGF19-receptors 1 and 4 in the hypothalamus of obese rats is reduced by 60% relative to lean animals [176]. It has been shown that intestinal PPARα affects FXR-FGF15 activity and BA synthesis [179] and BA feedback inhibits PPARα activity [180]. Thus, we can speculate that gut–brain communication involves the microbiota and at least two NR networks, in other words a microbiota–PPARα–FXR–FGF15–gut–brain axis.

3.3. Vitamin D Receptor
Synthesis of vitamin D is initialized when UVB light triggers photochemical, non-enzymatic conversion of 7-dehydrocholesterol to previtamin D3 in keratinocytes of the skin. Consecutively previtamin D3 undergoes thermal isomerization to vitamin D3 (cholecalciferol). Following circulation in the bloodstream, vitamin D3 is taken up by liver and modified to the prohormone calcifediol (25-hydroxyvitamin D3, 25(OH)D3). Additionally, vitamin D2 or ergocalciferol, which can be provided by nutrition, including sources like fish, egg and mushrooms, serves as another precursor that may be modified to calcifediol. Further conversion of calcifediol into calcitriol (1,25-dihydroxyvitamin D, 1,25(OH)2D) is executed by 1α-hydroxylase (CYP27B1) and takes place mostly in the kidneys. Nonetheless, 1α-hydroxylase is also expressed in other tissues including colon, breast tissue and immune cells [181,182,183,184,185]. Levels of vitamin D in the blood show a strong relationship with infection rates, bone health, cancer prophylaxis and mortality [186,187,188,189,190]. Calcifediol and calcitriol serve as ligands for the vitamin D receptor (VDR, NR1I1), the second being a more potent activator [191]. Additionally, the secondary bile acid lithocholic acid, curcumin, γ-tocotrienol, and derivatives of essential fatty acids also act as ligands of VDR [192,193]. Upon activation by ligands, VDR activates or represses expression of its target genes. VDR is particularly important for the homeostasis of minerals by regulating the intestinal uptake of calcium, iron, magnesium, zinc, copper and selenium. VDR also regulates calcium reabsorption in kidneys and promotes bone calcification. Notably, VDR also facilitates intestinal absorption of toxic elements like lead, aluminum, cadmium, cobalt and strontium [194]. VDR is expressed throughout the body with high levels in the intestine, colon, thyroid gland and kidney. Its expression in the brain remains to be clarified as there are contradictory reports on this subject [195,196,197]. Importantly, vitamin D can barely diffuse through the blood brain barrier (BBB) [198] however, 1α-hydroxylase is expressed in the CNS [199,200] suggesting a role in the brain.

VDR plays an important role in the immune response, mediates signals from the microbiota and translating them into appropriate inflammatory responses [201,202,203]. VDR influences the expression of defensins, the antimicrobial function of Paneth cells and colonization of the GI tract by bacteria [204,205,206]. Consequently, the microbiota of VDR knockout mice differs when compared to wild type mice [207]. Intestine epithelium-specific VDR knockout mice are also more susceptible to DSS-induced colitis [206]. The TLR pathway when activated by pathogen-associated membrane patterns (PAMPs) of Mycobacterium tuberculosis stimulates VDR expression. In turn, VDR is necessary for the generation of the antimicrobial peptides cathelicidins by monocytes-macrophages and the killing of intracellular Mycobacterium tuberculosis [208,209]. Moreover, the probiotic Lactobacillus rhamnosus strain GG and Lactobacillus plantarum trigger the expression and transcriptional activity of VDR and thereby protect from Salmonella-induced colitis in a VDR-dependent way [210]. Reciprocally, microbiota regulates local production of vitamin D3 in the colon by signaling through the TLR pathway [211].

VDR is a vital factor in brain development [212], neurotransmission [213], neuroprotection [214,215] and immunomodulation [216,217]. Vitamin D deficiency has been linked with occurrence of autism [218,219], schizophrenia [220,221,222], multiple sclerosis [223,224], Alzheimer’s and Parkinson’s disease [225]. However, the putative mechanisms linking VDR to neurological diseases remain to be unveiled. Moreover, a direct role of VDR in the gut–brain axis has not been established so far.

3.4. Xenobiotic Receptors
3.4.1. Aryl Hydrocarbon Receptor
Aryl hydrocarbon receptor (AHR) is not per se a member of the NR superfamily, although it shares many characteristics with family members. AHR is a ligand-activated receptor expressed in many cell types, including intestinal epithelial cells (IEC). AHR is mostly recognized as a molecule activated by the xenobiotic 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, also known as dioxin) [226,227]. However, the list of its agonists is much longer and contains various groups of molecules including diet-derived compounds (e.g., flavonoids, carotenoids, stilbenes) [228,229,230], metabolites of tryptophan produced by the host, such as kynurenine (KYN) [231] or kynurenic acid (KYNA) [232], and by the microbiota (indoles) [233,234]. Also, phenazine produced by Pseudomonas aeruginosa, and naphthoquinone phthiocol from Mycobacterium tuberculosis bind to AHR, which triggers cytokine and chemokine production [235]. Moreover, the bacterial metabolites SCFAs modulate AHR activity, however not directly as ligands, but they stabilize and facilitate AHR actions [236]. Intestinal AHR affects the differentiation and function of T cells, macrophages, and dendritic cells [237,238,239,240,241,242,243,244]. AHR expressed in CD11c+ cells modulates the development of intestinal epithelium and intestinal immunity [245] thus, in turn it may modulate gut microbiota composition. Expression of AHR is attenuated in GF mice and AHR seems to mediate the impact of microbiota on the host’s metabolic parameters. Hence, AHR has been suggested to act as a mediator in the communication between the host and its gut microbiota [246]. The most evident interaction between microbiota and AHR comes from a study on the caspase recruitment domain family member 9 (CARD9). CARD9 promotes recovery from colitis by stimulating interleukin (IL)-22 production. Hence, Card9−/− mice are more susceptible to colitis. Interestingly, the Card9−/− mice-specific microbiota fails to metabolize tryptophan into compounds acting as AHR ligands. Transfer of these bacteria to wild-type GF recipients increases their susceptibility to colitis. Intestinal inflammation in these transfer recipients is attenuated after inoculation of the mice with three Lactobacillus strains capable of metabolizing tryptophan or by treatment with an AHR agonist [247]. Thereby, host expression of genes like Card9 affects the microbiota pool and this regulation feeds back on the host’s health-status.

In the liver, PPARα and AHR affect the expression of a similar set of genes including Cd36, Hmgcs2 [246,248], Cyp2B, Cyp3A, Cyp2C11 [249] and Fgf21 [65,250,251], indicating that there is an interplay between these two factors, which has been investigated [249,252,253,254]. FGF21 has been identified as the mediator of the metabolic benefit of AHR [251]. In turn, the impact of FGF21 on metabolism is partly mediated by PPARγ [255] creating a feed-forward loop as PPARγ also induces FGF21 expression [256]. FGF21 stimulates the expression of genes involved in lipid oxidation, ketogenesis and gluconeogenesis [65,257,258]. FGF21 improves insulin and leptin sensitivity and lowers blood glucose levels by activating glucose uptake in adipocytes. Its administration results in reduced body weight due to enhanced energy expenditure, fat oxidation and lipid excretion, while reducing hepatic de novo lipogenesis and hepatosteatosis [251,259,260]. Similarly to FGF15, the role of FGF21 in metabolism and body weight regulation seems to require mostly its central, rather than peripheral signaling [178,261,262]. Along these lines, microbiota-stimulated AHR may regulate metabolism via FGF21-mediated signaling to the CNS. Interestingly, in response to sugar consumption, hepatic FGF21 is released and attenuates sugar-seeking behavior by targeting the hypothalamic PVN [263,264]. Activation of FGF21 upon sugar uptake is mediated by hepatic PPARα and carbohydrate-responsive element-binding protein (ChREBP) [263]. Beside affecting metabolism, FGF21 regulates hydration by suppressing alcohol intake in favor of water consumption and this activity is mediated in part by SIM1-positive neurons in the hypothalamus [265].

AHR is widely expressed in the CNS [266,267] and plays there a multitude of roles in cell differentiation and maintenance. AHR-1, a Caenorhabditis elegans orthologue of AHR, is responsible for the development, orientation, and axonal migration of AHR-1-expressing neurons [268]. AHR-1 impacts neural cell fate determination in C. elegans, particularly GABAergic neurons [269]. Dioxin-activated AHR plays a role in CNS development in zebrafish [270] and mice [271,272]. However, expression of a constitutively active AHR in mice retards the development of interneurons in the olfactory bulb [273]. Furthermore, both deletion or activation of AHR alters adult hippocampal neurogenesis and impairs hippocampal-dependent contextual memory [274], suggesting a need for a balanced AHR activity. AHR has been shown to affect several aspects of behavior and neurodevelopmental illness in different study models [275,276]. AHR has been shown to decrease blood brain barrier (BBB) permeability [277,278], while BBB permeability is increased in GF mice [279]. However, the mechanism behind is not clear as AHR is capable of activating occludin and claudin 1 and 4 [280], but on the other hand it inhibits connexin 43 [281], which is essential for BBB integrity [282]. This is probably another example of the dual role of AHR, which again underlines the importance of a balanced activation of AHR. Moreover, AHR mediates anti-inflammatory effects on dendritic cells [283]. Ligand-activated microglial AHR exerts bi-directional effects on the regulation of LPS-induced neuroinflammation as it can promote or inhibit inflammation [284,285]. Notably, in patients with multiple sclerosis circulating levels of AHR agonists are decreased [286].

The effects of AHR expressed in CNS can be modulated by the microbiota [286]. Astrocytes are the most abundant glial cell population in the CNS, participating in diverse functions including control of the BBB, regulation of metabolism, neuronal transmission, CNS development and inflammation [287]. In experimental autoimmune encephalomyelitis (EAE), type 1 interferon (IFN-I) signaling in astrocytes reduces disease scores and inflammation via AHR and the suppressor of cytokine signaling 2 (SOCS2). EAE scores in mice increase following ampicillin treatment, whereas dietary supplementation with the microbial metabolites of tryptophan (indoxyl-3-sulfate, indole-3-propionic acid and indole-3-aldehyde)—which as mentioned above are AHR ligands—or delivery of the bacterial enzyme tryptophanase reduces CNS inflammation in the antibiotic treated mice. Thus, IFN-Is produced in the CNS functions in combination with bacterial metabolites of dietary tryptophan to activate AHR signaling in astrocytes and suppress CNS inflammation [286].

3.4.2. Pregnane X Receptor
Pregnane X receptor (PXR, NR1I2) also known as the steroid and xenobiotic sensing nuclear receptor (SXR) is a nuclear transcription factor often referred as the master regulator of xenobiotic defense. PXR is involved in energy [288,289] as well as xenobiotic metabolism and it affects expression of phase I and phase II enzymes as well as phase III transporters [290]. PXR is expressed in barrier and excretory tissues, including intestine, liver, kidney and several regions of the brain [290,291,292] and it is synthetized as various splice variants in different organs [292,293,294]. In the liver, the function of PXR overlaps with that of FXR by regulating expression of a similar set of CYP proteins involved in both detoxification and BA metabolism. Additionally, other PXR target genes that are involved in xenobiotic metabolism also participate in BA metabolism [295]. In primary human hepatocytes, among other factors PXR regulates AHR and its target genes Cyp1A1 and Cyp1A2 [296]. Similarly to AHR, PXR is activated by microbial-specific metabolites of dietary tryptophan, and the indole derivative, indole 3-propionate (IPA) [297], which is produced by Clostridium sporogenes [52]. The ligand binding pocket of PXR has a relatively large volume capable of accommodating a variety of compounds. Moreover, PXR has the capability to expand its binding pocket to allow for larger compounds thus, various ligands are capable of its activation [298].

Secondary BAs, lithocholic acid (LCA) and its 3-keto metabolite (3-keto LCA), formed in the intestine by bacteria are ligands of mouse and human PXR [295,299]. LCA is a particularly toxic BA that causes cholestasis, a disease characterized by the impairment of bile flow and the accumulation of BA and biliary toxins in the liver and serum [300]. Moreover, pregnenolone 16α-carbonitrile (PCN), a ligand of PXR, blocks the hepatotoxicity and mortality caused by LCA exposure in rats [299,301]. Therefore, PXR, among other ligands, serves as a receptor of BA and upon activation coordinates the xenobiotic response in the detoxification of BAs.

Single nucleotide polymorphisms in Pxr are associated with increased susceptibility for developing IBD, Crohn’s disease and ulcerative colitis [302]. While PXR-deficient mice exhibit “leaky” intestine symptoms [297], ligand-activated PXR prevents leaky gut and maintains the intestinal epithelial barrier by stimulating the synthesis of junctional proteins, antagonizing TNF-α and TLR4, inhibiting the cytokine-induced myosin light chain kinase (MLCK), and activating the c-Jun N-terminal kinase½ (JNK1/2) [291,297,303,304]. Rifaximin, an antimicrobial agent used in the treatment of IBD, mediates its effects by increasing the expression of PXR. It has been shown to abrogate the DNA binding of NF-κB caused by LPS, to reduce mRNA levels of IL-8, RANTES, MIP-3α and TNFα [305]. Chrysin, a naturally occurring flavonoid with anti-inflammation activity, prevents DSS-induced colitis, an effect largely mediated by PXR [306]. Furthermore, the above mentioned PXR agonist, PCN, attenuates the intestinal barrier dysfunction observed after DSS administration in mice [304].

Absence of PXR is associated with anxiety-like behavior and recognition memory impairment in adult mice [307]. PXR knockout (KO) mice show decreased expression of tight junction protein ZO1 in the cortex and cortical microvessels [307]. In another study, activation of hPXR in mice in vivo tightened the BBB, reducing the delivery and central effect of administrated drugs. This effect is mediated by PXR-stimulated upregulation of P-glycoprotein, an ATP-driven drug export pump at the BBB [308]. P-glycoprotein is the most prominent drug efflux transporter at the BBB and plays an essential role in barrier function. Hence, most likely, similarly to AHR, microbiota derived-ligands regulate PXR activity in CNS, thus affecting the BBB.

3.4.3. Constitutive Androstane Nuclear Receptor (CAR)
CAR (NR1I3) or constitutive androstane nuclear receptor, alike AHR and PXR, serves as a xenosenor. CAR expression level is affected by various factors. It is induced on the level of expression or activity by glucocorticoids (GC) [309], AHR [310], peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) [311] and repressed by factors like epidermal growth factor (EGF) [312], TLR-2 signaling [313] and IL-1β [314]. Beside xenobiotics, CAR can be regulated by many endobiotics, including many steroids (androstanes, estrogens, and progestins) [315,316]. Importantly, expression of CAR in the intestine and in the liver depends on the presence of the microbiota [313,317]. CAR was originally characterized as a transcriptional regulator whose activation is stimulated by phenobarbital (PB) to stimulate the expression of CYP2B genes [318,319]. By now, the list of both the activators and target genes of CAR has significantly expanded and shows a high overlap with the corresponding list for PXR. These two NRs are often described together as both are expressed in organs like the small intestine, colon and liver. They both react to chemical stresses and are crucial to initial ligand recognition followed by subsequent jump-starting of xenobiotic metabolism. They work together to ensure homeostasis of cholesterol, BAs, sterols, lipids, heme and other endogenous hydrophobic molecules. Furthermore, the different splice variants of CAR, similarly to those of PXR, result in a number of deleterious or altered effects on gene transactivation, coregulator recruitment, as well as ligand binding [296,320,321,322,323]. Although CAR is less promiscuous than PXR, the smaller pocket size of CAR creates a more stable ligand-bound complex than the one of PXR, resulting in better packing of the AF-2 helix in the active conformation [324]. However, CAR is unique, relative to other NRs, in its ability to maintain a constitutive activity in the absence of a bound ligand. This ability is also referred to as an indirect activation, the exact mechanism of which remains to be elucidated [325,326]. In its inactive form, CAR, just like PXR, is bound to heat shock protein 90 (Hsp90) in the cytoplasm [327]. Upon activation and heterodimerization with the retinoid X receptor (RXR) it stimulates target gene expression in the cell nucleus [328]. A notable feature recently highlighted for CAR is that upon ligand binding it can also undergo translocation to cell membrane, which could imply additional non-genomic actions [329].

Notably, because CAR and PXR can be activated by the same ligands, upregulation of overlapping sets of genes allows for coordinated clearance and detoxification of harmful compounds [296,330]. Importantly, some drugs inhibiting CAR are agonists of PXR, thus allowing detoxification to take place even in the absence of one of the sensors. Together, the two NRs regulate expression of phase I enzymes of xenobiotics metabolism including CYP3As [331,332], CYP2Bs [319,332,333,334], and CYP2Cs [332,335,336]. They are capable of regulating approximately 90% of all phase II metabolic enzymes as both are involved in the transcriptional control of UDP-glycosyltransferases (UGTs), sulfotransferases (SULTs), glutathione-S-transferases (GSTs), acetyltransferases [324,337] as well as the drug transporters OATP1 and MDR1 involved in phase III detoxification [332].

CAR has also been linked to energy metabolism as its activation results in inhibition of lipogenesis, FA synthesis, and gluconeogenesis, as well as the increase of energy expenditure in BAT [338]. Long-term CAR activation improves glucose homeostasis and insulin sensitivity [339]. These effects are achieved by suppressing the expression of phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase) [339,340], and sterol regulatory element-binding protein 1c (SREBP1c) [341]. A very similar phenotype has been associated with PXR activation [288,289,342]. Moreover, fasting and caloric restriction induce CAR expression, which in turn coordinates an adaptive response by slowing down energy expenditure. Consequently, CAR KO animals are unable to accomplish the metabolic adjustment and lose more weight during caloric restriction interventions [343].

In the intestine, CAR gene expression is reduced in intestinal mucosal biopsies obtained from patients suffering from Crohn’s disease or ulcerative colitis with active mild or moderate inflammation, as well as in tissues isolated from colitic mice. Selective activation of CAR enhances wound healing in IEC monolayers in culture, an effect driven by enhanced cell migration. Finally, inhibition of CAR delays mucosal healing after the induction of experimental colitis, while its pharmacological activation accelerates recovery [344]. Thus, by affecting colonic health, CAR alters the natural milieu of the microbiota.

Notably, as shown by using null mice, CAR affects structural factors in the brain and the behavior of mice. These CAR-null animals show impairment in recognition memory and increased anxiety-like behavior, which is accompanied by neuronal and structural defects in the hippocampus and cortical area. Moreover, expression of the tight junction protein ZO-1 is reduced in cortical and hippocampal microvessels of the animals. Accordingly, peripheral injection of the neurotoxin kainic acid provokes a rapid onset of convulsions in CAR-null mice as compared to WT mice, indicating increased vascular permeability and susceptibility of these mice to neurotoxins [345].

In conclusion, gut flora modulates CAR activity, and CAR feeds back by reducing and promoting gut inflammation and healing, respectively. There is no evidence of direct gut–brain communication involving CAR. However, the CAR–microbiota interaction in gut, CAR’s role in the brain, and the importance of other xenobiotic receptors in gut–brain signaling provide a basis to speculate on a potential CAR-mediated signaling between the GI tract and CNS.

It seems that all of the xenobiotic receptors–AHR, PXR and CAR—interact with microbiota, and are required for the proper functioning of the brain (Figure 2) [346,347]. Importantly, these NRs are interconnected and show high level of coordination, and thus future research may show that they embody an essential pathway in gut–brain communication.

3.5. Steroid Receptors
3.5.1. Glucocorticoid Receptor
The main steroids of the adrenal cortex are mineralocorticoids (MCs), glucocorticoids (GCs in humans mainly cortisol and in rodents mainly corticosterone) and the adrenal androgens. GCs are synthesized and released as a result of stress, but also in a daily oscillating manner [348]. The circadian release of GC can be maintained regardless of sleep pattern, light stimulation and rhythm of caloric intake [349,350]. Coordinated release of GCs, mineralocorticoids and catecholamines by the adrenal glands in response to stress is governed by the hypothalamic–pituitary–adrenal (HPA) axis, also referred to as the “stress axis”. Signals such as daylight promote the release of corticotrophin-releasing hormone (CRH) from the hypothalamus. CRH then stimulates the production of the adrenocorticotropic hormone (ACTH) in the pituitary, which in turn, initiates release of GC from the adrenal cortex to blood. As GC levels rise, a negative feedback loop is engaged that reduces both CRH and ACTH expression and secretion. This feedback mechanism regulates the magnitude and duration of GC release [351].

Although endogenous GCs are predominantly produced by the adrenal glands, there is evidence for extraadrenal GCs synthesis in the skin [352], thymus [353,354], vascular wall [355], lungs [356], brain [357] as well as IEC [358]. More specifically, liver receptor homologue-1 (LRH-1) in the cells of the crypt region of the intestinal epithelial layer promotes the expression of steroidogenic enzymes and the synthesis of corticosterone [358]. Additionally, immune stress and T cell activation are also stimulators of intestinal expression of the steroidogenic enzymes required for GC synthesis [359]. Importantly, the microbiota contributes to the production of corticosterone in the intestine [75] and influences the intracellular activity of GCs [360].

GCs are essential primary stress response hormones necessary for regulating numerous physiological processes in order to maintain homeostasis, and they reduce inflammation. Overall, their major effect on glucose homeostasis is to secure plasma glucose levels for brain during stress [361]. However, GCs also mediate multiple other physiological processes, including metabolic homeostasis, skeletal growth, cardiovascular function, reproduction, and cognition [362,363,364]. Synthetic derivatives of these hormones serve in the clinics as a standard treatment for inflammatory diseases, autoimmune disorders and hematologic cancers. Depending on the concentration of GCs, different receptor responses are triggered. Basal plasma levels of GCs are mediated via the mineralocorticoid receptors (MRs, NR3C2) (see below), while elevated, stress or circadian rhythm-triggered GCs activate the glucocorticoid receptors (GRs, NR3C1) [365,366]. The GR is expressed in almost every cell in the body and in multiple brain regions including the cerebral cortex, olfactory cortex, hippocampal formation, amygdala, septal region, dorsal thalamus, hypothalamus, trapezoid body, cerebellar cortex, locus coeruleus and dorsal raphe nucleus [367,368]. GR is encoded in a single gene, however, there are multiple GR protein isoforms. Alternative splicing of the 3′-end of the GR pre-mRNA produces GRα, GRβ and GRγ [369,370,371]. Moreover, alternative translation initiation from the single GRα mRNA transcript produces an additional eight diverse GRα proteins [372]. This substantial group of functionally distinct receptor subtypes undergoes various posttranslational modifications that further diversifies their signaling properties [373,374,375]. In the cytoplasm, GC-activated GR is released from a multiprotein complex composed of HSPs and immunophilins of the FK506 family [376,377] then translocates to the cell nucleus and modulates gene transcription via the following three mechanisms: GC receptor response element (GRE)-mediated direct transactivation; inverted repeat GREs (IR nGREs)-mediated direct transrepression; and tethered indirect transrepression [378,379,380,381,382,383,384]. The capacity of the GR to function as a transcriptional activator or repressor is determined by several polymorphisms in the GR gene [385]. GR can also modulate mRNA splicing [386] and mRNA stability [387] as well as microRNA expression and processing [388]. MR and GR can create homodimers or heterodimers acquiring new transcriptional properties [389,390]. Moreover, GR exhibits nongenomic signaling by direct protein–protein interactions that result in rapid cellular responses occurring within a few seconds to minutes, which involve the signaling cascade of various kinases and do not require changes in gene expression [380,391,392,393]. The various GR forms and their signaling modes generate pleiotropic effects in distinct tissues [394,395].

GCs and circadian rhythm factors are reciprocally regulated. The central circadian clock in the suprachiasmatic nucleus (SCN) of the hypothalamus entrained by light received by the retina orchestrates diurnal rhythmic oscillation of circulating GCs by influencing the activity of the HPA axis [396,397]. Additionally, the circadian rhythm core transcription factor heterodimer Clock-Bmal1 acetylates GR in peripheral tissues and represses its transcriptional activity in a circadian pattern that is opposite to the GR activation pattern by the HPA axis [398]. In return, the HPA axis, through the GR, drives circadian and ultradian bursts of transcriptional activity of the circadian rhythm regulators (Per 1, DBP) and adjusts the rhythmicity of the peripheral clocks in response to stressors [396,399]. Thus, the circadian rhythm of the peripheral clocks may become phase-shifted by GCs. Disruption of GR expression periodicity is associated with disease states characterized by GC resistance or sensitivity [400]. Moreover, cortisol-driven circadian and ultradian patterns of transcriptional activity of the Clock and Per genes is disrupted in major depressive disorders, bipolar disorder, and stress-related GI and immune disorders [401]. Furthermore, intestinal processes including nutrient absorption, cell proliferation, intestinal motility, metabolic activities as well as intestinal GC production are rhythmically regulated in a circadian manner [75,402]. Clock genes are expressed along the GI tract, their mRNA levels increase from the duodenum onwards and show highest levels in the colon. Similar to other organs, the clock genes in the jejunum and colon show a circadian rhythm of expression [403,404,405]. Moreover, the intestinal microbiota exhibits endogenous circadian rhythmicity that is partly synchronized with the host’s dietary rhythm [406,407,408]. Remarkably, gut microbiota-derived MAMPs, acting via TLR, regulate circadian clock genes and PPARα and thereby modulate the production of intestinal corticosterone [75]. Moreover, microbial cycles disturbed by a high-fat diet results in disruption of the central and liver clocks [407].

GR regulates multiple systems including the nervous, cardiovascular, musculoskeletal, immune, respiratory, reproductive, adipose and hepatic systems. It adjusts blood glucose levels by stimulating hepatic gluconeogenesis via direct induction of the PEPCK gene [409]. It suppresses bone formation by a number of mechanisms, including reduction of osteoblast differentiation [410], induction of osteoblast apoptosis [411], and stimulation of bone resorbing osteoclasts [412]. In adipocytes, it increases adipogenesis, alters adipokine production, reduces glucose metabolism and lipogenesis under basal or fasted conditions, while it stimulates lipogenesis in the fed state [413]. GCs extinguish inflammation and this is in part executed by GR’s ability to repress pro-inflammatory gene expression [414]. Numerous transcriptional targets of GR inhibit cytokine release, and GR itself has the capacity to transrepress NF-κB activity [382,383,415] making GR activation a powerful way to resolve inflammation. For that reason, dexamethasone (DEX), a synthetic ligand of GR, has been routinely used as an anti-inflammatory, immunosuppressive agent in the treatment of IBD [416]. Chronic exposure to stress and frequent GC release results in various adverse side effects such as osteoporosis, central adiposity, diabetes, hypertension, dyslipidemia, GI diseases and neurodegeneration [417,418,419,420]. Stress is also one of the most significant risk factors for development of irritable bowel syndrome [421,422,423]. Furthermore, a deficient or blunted HPA axis is commonly observed in the clinic in a wide range of autoimmune and inflammatory diseases [424,425,426].

In the intestine, GCs impact nutrient absorption by modulating expression of digesting enzymes [427], and enhance glucose uptake by stimulating gene expression of glucose transporters [428,429]. In coordination with the microbiota, they regulate gut ontogeny [427], play a role in the differentiation of the IEC, regulate the expression of tight junction proteins and thus, maintain the intestinal epithelial barrier [430,431]. GR is capable of antagonizing TNF-α-induced increase in MLCK protein expression, a key process mediating the TNF-α increase in intestinal tight junction permeability during inflammation [430]. Thus, GCs released during stress may have a gastroprotective action [432]. It has been shown that creating a lesion in the hypothalamic PVN or administration of antiserum of ACTH inhibits increases in corticosterone and induces gastric erosions provoked by cold-restraint as well as water and immersion-restraint stress; corticosterone replacement was able to prevent these malfunctions [432].

In the CNS, GR is implicated in both short- and long-term adaptations in response to stressors and participates in brain structural and physiological changes after stress exposure [433,434,435]. GR regulates the expression of genes related to neuronal and glial metabolism, neuronal plasticity and neurotransmission, and mediates gap junction intercellular communication in neural progenitor cells [436,437,438]. Stress-activated GR in microglia triggers changes in cell morphology and increases the production and release of inflammatory cytokines, switching from brain surveillance function to eliciting unfavorable effects on neural function and behavior [439,440,441]. Chronic stress and prolonged GC exposure have profound effects on emotion and cognition. It leads to maladaptive neuronal and glial plasticity, changes brain microglia morphology resulting in neuropsychiatric disorders such as affective, behavioral, and cognitive syndromes including depression, mood imbalance, increased fear conditioning and anxiety [433,441,442,443,444,445]. Adult rats raised by interactive mothers with high licking and grooming behavior, compared animals fed and groomed by less interactive females, show increased hippocampal GR expression, reduced HPA activation and less fear behaviors in response to acute stress [446,447,448]. Over-activity of the HPA axis is characterized by elevated levels of cortisol and disruption of GCs’ negative-feedback and is commonly associated with depression and post-traumatic stress disorder (PTSD) [449,450]. Methylation of the GR gene promoter, which impacts circulating cortisol levels, is negatively associated with severity of PTSD and correlates with specific responses to stress [451]. Moreover, individuals with major mental illness, who often exhibit hypercortisolemia, may have downregulated levels of GR mRNA. For instance, GR mRNA levels are reduced in parts of the cortex of patients suffering from depression, bipolar disorder, and schizophrenia. Furthermore, schizophrenia and bipolar disorder are associated with low GR mRNA levels in parts of the hippocampus [452].

Several studies indicate an impact of stress, GCs and GR on the gut microbiota. Different types of psychological stressors including chronic social defeat, restraint conditions, crowding, heat stress, and acoustic stress can alter the composition of the GI flora [453,454,455,456,457,458]. Stress induces gut permeability enabling bacteria and bacterial antigens to cross the epithelial barrier, which can activate a mucosal immune response with impact on the microbiota composition [19,20,21]. Importantly, in lean female mice, stress exposure modifies the microbiota composition to resemble that of obese mice [459]. Maternal separation of rat pups elicits alteration of the fecal microbiota, intestinal dysbiosis, and alters the HPA axis and colonic cholinergic neural regulation [18,456]. Early life stress increases visceral sensation, plasma corticosterone and systemic immune response in the stressed animals after an LPS challenge [18]. Exposure to DEX both acutely (10 days) or chronically (over 4 weeks) in mice leads to substantial shifts in gut microbiota accompanied by a significant downregulation of colonic mucin 2 gene expression. Importantly, DEX treatment affects mucin expression only in specific-pathogen-free (SPF) but not GF mice. Thus, DEX alone is not sufficient to regulate mucin synthesis in the absence of gut microbes [460]. Moreover, a single high-dose injection of DEX increased the number of ileal anaerobic bacteria, while low-dose GC resulted in an increase in coliform bacteria [461]. These alterations in gut bacteria regulate the inflammatory state in a genetically susceptible mouse model of colitis, demonstrating a gut microbe-mediated mechanism by which GCs exert their anti-inflammatory effects in the colon. Thus, GC signaling partly mediates its effects through gut microbes.

Reciprocally, the gut microbiota also mediates stress responses, which is supported by the fact that an altered gut microbiota can lead to substantial shifts in the HPA axis response to stress [462]. Along a similar line of thought, GF mice present both a reduced anxiety phenotype and disturbed hypothalamic–pituitary–adrenal (HPA) axis [8,41,42,43]. However, in GF mice a mild restraint stress induces an excessive HPA response and higher plasma ACTH and corticosterone levels compared to the SPF controls, which can be partially reversed by colonizing the GF mice with the flora from SPF animals or with only Bifidobacterium infantis [43]. In contrast, reconstitution with the enteropathogenic Escherichia coli, but not with its mutant strain deprived of the translocated intimin receptor gene, enhances the response to stress even further, implying that commensal microbiota can affect the postnatal development of the HPA stress response in mice [43]. In another study using the forced swim test, 28 day long administration of Lactobacillus rhamnosus (JB-1) produced animals with lower levels of stress-induced corticosterone and reduced depressive and anxious behavior phenotypes [45]. This outcome was abolished with vagotomy, demonstrating that functional gut to brain direct nerve signaling is necessary for mediating stress response [45]. The HPA axis response to acute stress can also be attenuated by treatment with Lactobacillus farciminis [463]. Administration of a probiotic combination of L. helveticus R0052 and B. longum R0175 reduced anxiety-like behavior in rats and alleviated psychological distress in volunteers [44]. Moreover, administration of the prebiotics fructooligosaccharide (FOS) and galactooligosaccharide (GOS) abolished the corticosterone response to acute swim stress, attenuated anxiety related behavior in naive mice, and anxiety parameters in chronic social defeat [464]. Delivery of two strains of Lactobacillus species to mice pups ameliorated maternal separation-induced gut functional abnormalities and reduced bacterial adhesion and penetration into the colonic mucosa. Moreover, probiotic treatment improved gut dysfunction induced by maternal separation, at least in part by reducing the elevated corticosterone levels and by normalizing the activity of the HPA axis [465]. Thus, adequate stress response of the host depends on microbiota-regulated metabolism of GCs.

3.5.2. Mineralocorticoid Receptor
The MR shows an affinity for MCs like aldosterone, its precursor deoxycorticosterone, as well as for GCs. MCs are a class of steroids produced in the adrenal cortex which mainly influence electrolyte and fluid balance, hemodynamic homeostasis and tissue repair. MR is expressed in many tissues such as the kidney, colon, heart, CNS, adipose tissue, macrophages and sweat glands [466]. In the brain, MR is largely restricted to neurons in limbic areas such as the hippocampus and amygdala [368,467,468]. This contrasts with the GR, which is expressed throughout the brain [368]. The hormones estrogen [469] and progesterone [470], and the nuclear receptors GR, MR, and their MR:GR heterodimer can activate MR gene transcription [471]. The promoter of the MR gene also contains a noncanonical cAMP-responsive element, which for instance allows GPR48 stimulation of MR expression through the cAMP/PKA pathway [472]. The MR gene can generate several transcripts [473], which in humans are derived from two different promoters [471,474]. GR and MR are co-expressed in many types of tissues, often in the same cells, where they interact at the molecular and functional levels, in synergy, but sometimes also in antagonism. GR and MR can coordinate their actions, for example in regulating neuronal Ca2+ voltage-gated currents in the hippocampus [475,476,477]. In preadipocytes, selective MR activation results in the transcription of several genes, including Pparγ required for preadipocyte maturation. On the contrary, GR agonists prevent adipogenesis [478,479]. Moreover, in response to inflammation GR often dampens MR’s effects. Overstimulation of MR in the heart, vessels, kidneys, and parts of the brain may lead to increased reactive oxygen species, inflammation, and cardiovascular and renal diseases [480]. Thus, balanced MR and GR activities are crucial for adaptation to stimuli and homeostasis [481,482]. The DNA binding domains of MR and GR are nearly identical, and both receptors are capable of binding GREs as well as nGREs [483,484]. Besides competing for the same ligands MR and GR share several co-regulatory proteins required for the initiation of transcription. However, the primary functions of MR and GR and some of their ligands serve different purposes and are regulated very differently [485,486]. A fundamental role of MR includes the regulation of ion and fluid transport in order to sustain osmotic and hemodynamic homeostasis, maintenance of membrane excitability in neurons and muscle cells as well as responses to injury. MR regulates blood pressure, and its inappropriate activation leads to hypertension [487,488,489]. Treatment with MR antagonists decreases both cardiovascular risk markers and insulin resistance [487,488,489,490]. Accordingly, bacterially-derived GC metabolites have been suggested to cause hypertension [360]. Besides acting as a typical NR and modulating gene expression, MR displays several rapid nongenomic activities which do not require transcription and are mediated by classical cell signaling pathways [491,492,493,494]. The types of nongenomic signaling mediated by MR vary between different cells and depend on the activating stimuli. Typically, it includes protein kinase C (PKC), cyclic adenosine 3′,5′-monophosphate (cAMP) and phosphoinositide 3-kinases (PI3K), cumulating with downstream activation of various kinases, ion channels and pumps [491,492,493,494]. MR also acts through the EGF–EGFR–MEK1/2–ERK1/2 signaling cascade which influences cell differentiation, proliferation and repair [492,495,496]. In various tissues, nongenomic MR activation leads to intracellular Ca2+ flux [497].

MR exhibits different ligand preferences depending on the tissues: aldosterone in the kidney and colon epithelia, and GCs in most parts of the brain. In most tissues at basal levels, GCs favors binding to MR. For instance, in the hippocampus MRs bind GCs with approximately 10-fold higher affinity than its colocalized GR. When GCs levels rise due to stress or circadian cycle GCs also activate GR [366,368,498,499,500]. Thus, GR is thought to be responsible for the GCs-triggered stress response. However, MR located at the plasma membrane has been shown to also mediate stress level GC effects in a nongenomic manner in the hippocampus [501]. In the brain, GCs are more abundant than aldosterone, thus they constantly occupy MR. GCs are able to passively diffuse across the plasma membrane, and their bioavailability within the cell is controlled by two 11β-hydroxysteroid dehydrogenase enzymes. 11β-hydroxysteroid dehydrogenase-2 (11β-HSD2) converts cortisol and corticosterone to the inactive cortisone, and 11β-hydroxysteroid dehydrogenase-1 (11β-HSD1) converts cortisone back to its active form [502,503]. The two 11β-HSD enzymes show cell-specific expression, therefore controlling the level of active GCs and in turn receptor activation. 11β-HSD2 is expressed in aldosterone-sensitive tissues, including kidneys, liver, lungs, colon, salivary glands, H2D2 neurons and placenta, while 11β-HSD1 is highly expressed in key metabolic tissues like liver, adipose tissue, and CNS. Inactivation of GCs by 11β-HSD2 allows binding of aldosterone to the MR within aldosterone target cells, and at the same time, limits activation of the GR in these cells [504,505,506]. 11β-HSD1 plays an important role in switching between MR-mediated proinflammatory activation of IL-6, TNF-α and NF-κB and GR-triggered suppression of these factors in microglial cells [507]. Thus, this enzyme mediates activation of microglia and may affect the development of neurogenerative diseases. Remarkably, the microbiota is able to produce glycerrhetinic acid-like factors (GALFs), named after glycerrhetinic acid from licorice root, which can inhibit 11β-HSDs activity [360]. Therefore, by modulating the activity of the 11β-HSD enzymes, the microbiota influences whether MR or GR is activated.

Appropriate activation of the MR is essential for normal neuronal differentiation, migration, and function of the developing and adult brain [508,509,510,511]. Chronic social stress in adolescent mice evokes a decrease in the mRNA levels of MR and GR in the hippocampus. It also increases adrenal weight, elevates GCs levels, dampens the circadian rhythm and promotes anxiety-related behaviors compared to unstressed mice. The decrease in MR expression and behavioral changes are still detectable a year later, suggesting underlying epigenetic events [512]. Subjects suffering from depression and bipolar disorder display reduced total MR and increased ratio of MR to GR mRNA expression in the prefrontal and anterior cingulate cortex. On the contrary, a decreased MR to GR ratio for both mRNA and receptor is seen in the dorsolateral prefrontal cortex and PVN [513]. Moreover, chronic treatment with corticosterone triggers a depression-like phenotype in mice, however, co-administration of a MR-specific antagonist, spironolactone, mitigates depressive behavior [514]. Both MR and GR participate in corticosteroid-induced direct transcriptional repression of the 5-HT1A gene [483]. Physiological effects of 5-HT1A receptor agonists are attenuated after chronic treatment with GCs [515,516]. Therefore, both receptors influence behavior and impact depression [445,517,518].

The hippocampus, which shows the highest expression of MR in the brain, is the major integrative center for the formation of memories, learning, cognition, and coping with stress. In fact, MR activity is crucial for learning and for forming memories. MR antagonists boost cognition in heart failure patients, sometimes without an actual impact on cardiac function [519] while the decrease in MR expression in the aged hippocampus positively correlates with age-induced impairments in spatial memory [520]. However, for optimal cognitive performance, balanced activation of both MR and GR is required [521]. Interestingly, therapy with the antidepressant amitriptyline in young rats increases hippocampal MR but not GR expression, and stimulates spatial memory. The same treatment has no effect in aged rats [522]. Furthermore, long-term treatment with amitriptyline in middle-aged rats prevented the prevalence of cognitive impairments and reduced anxiety-related behaviors in aged rats [523]. In contrast, short-term use of MR antagonists in healthy humans has adverse effects on attention, memory, and cognition [524].

In summary, the microbiota modulates levels of GCs thereby affecting activity of GR and MR in multiple organs including the brain (Figure 3).

3.5.3. Estrogen Receptors
Estrogens are primarily produced in the ovaries, adrenal glands and adipose tissue and are C-18 steroid hormones derived from the reduction of C-27 cholesterol. The main forms of endogenous estrogens are estradiol (E2), which is predominant in nonpregnant women prior to menopause; estrone (E1), present after menopause; and estriol (E3), abundant during pregnancy [525]. While passing through the liver E1 and E2 estrogens undergo irreversible hydroxylation at the C-2, C-4, or C-16 positions of the steroid ring. These modifications produce estrogen metabolites varying in hormone potency and half-life. The types of estrogen and their modifications influence their preference for and capacity to activate different types of estrogen receptors (ERs) [526].

Estrogens mainly play role in reproduction, however, they are also vital modulators of metabolism and behavior. They protect against high-fat diet induced insulin resistance and glucose intolerance in mice [527]. Lower levels of estrogens in postmenopausal women [528] or in ovariectomized animals are associated with obesity [529], while estradiol-17β replacement in ovariectomized mice prevents weight gain by diminishing food intake and stimulating energy expenditure [529]. Accordingly, hormone replacement therapy in postmenopausal women reverses the progression of obesity and metabolic dysfunctions [530]. Importantly, estrogen levels strongly impact gut microbiota composition and microbiota affects body weight. In men and postmenopausal women, levels of total urinary estrogens correlate to richness and α diversity of fecal microbiota [531,532]. Ovariectomy in adult mice diminishes gut microbiota richness [533]. In rats, neonatal androgenization or adult ovariectomy causes shifts in the relative abundances of the two major phyla causing a higher Firmicutes to Bacteroidetes ratio [533]. In humans, similar gender-dependent differences were observed. Estrogens are strongly and significantly associated with the fecal Clostridia taxa, including non-Clostridiales and three genera in the Ruminococcaceae family [531], while men have higher levels of Bacteroidetes and Prevotella than women [534,535]. In mice, sex differences in gut microbiota are decreased after castration of male mice [536]. Stunningly, hormonal changes caused by early androgenisation or ovariectomy impact the microbial flora more strongly than nutritional changes from chow to a high fat diet [533], suggesting a decisive role for gonadal hormone levels in the modulation of GI flora.

A cluster of bacteria, referred to as “estrobolome” due to its capacity to metabolize estrogens, can significantly influence the host’s estrogen levels [537]. The series of reductive reactions leading to the synthesis of estrogens from cholesterol is partly catalyzed by hydroxysteroid dehydrogenases (HSD), a group of alcohol oxidoreductases. Bioinformatic annotation of HSD in all entirely sequenced bacterial genomes has proven that HSDs are found in a wide variety of microorganisms including bacteria and archaea. A large number of HSD-expressing bacteria participate in the normal human gut microbiota [538].

After circulation in the blood, estrogens and their metabolites are directed to the liver where they are conjugated through glucuronidation or sulfonation which facilitates their excretion in the bile, urine and feces [539]. β-glucuronidases and β-glucosidases, expressed by several bacterial strains, are capable of deconjugating estrogen which can then be reabsorbed by the intestine and reenter the host’s estrogen pool [540,541]. The activity of fecal bacterial β-glucuronidase activity, just like the intestinal flora composition, can be modulated by diet [542,543,544]. In rats, a decrease in fecal β-glucuronidase enzyme activity was observed after antibiotics administration [545]. In line with this observation, antibiotic therapy results in significant increases in fecal conjugated estrogens and a reduction in urinary estrogen in men and women [546,547,548]. More than half of the low G + C% gram-positive Firmicutes, which are a dominant bacterial group within the human large intestine [549], harbor β-glucosidase activity [550]. Most of Bacteroides spp. carry high β-glucuronidase and β-glucosidase activity, while the majority of Bifidobacterium spp. show only β-glucuronidase activity. The highest β-glucuronidase and β-glucosidase activities in feces correlate with the occurrence of Clostridium spp. [540,550,551]. Similarly, Peptococcus niger by means of sulfatase activity can deconjugate estrogen sulfate metabolites [552]. Furthermore, the gut microbiota is able to metabolize estrogen-like compounds from nutrition. For instance, daidzein found in soy can be metabolized to O-desmethylangolesin (ODMA) and S-equol [553], which are structurally similar to estrogen and can activate ER [554,555]. It is noteworthy that individuals harboring a gut flora capable of producing ODMA, but not S-equol, are more likely to be obese [553]. Importantly, several epidemiologic studies have suggested a possible association of antibiotic use and breast cancer risk which may be a consequence of disturbed estrogen metabolism [556,557].

Microbiota-derived estrogen may influence the host’s fertility. In GF mice, reproduction capacity is lower than in SPF mice. Inoculation of GF mice with B. distasonis and C. perfringens induces significant increase in sperm motility in male mice while in females it results in the normalization of the estrous cycle, and rises the copulation and fertilized egg implantation rates. On the contrary, the reproduction rate of mice carrying only the single Bacillus subtilis strain is comparable to GF mice, underscoring the importance for hormonal homeostasis of selected bacterial strains in the gut [558].

Estrogen exerts its activity via the estrogen receptor α (ERα, NR3A1) and β (ERβ, NR3A2) [559,560]. ERα and ERβ are highly homologous, particularly in the DNA binding domains (95%) and the ligand binding domain (55%), and show affinity for the same estrogen response elements (ERE) in DNA [560]. Although ERα and ERβ share similar ligand binding domains, ERβ possesses a relative binding affinity for several steroid hormones that differs from that of ERα [561]. ERα and ERβ are expressed in multiple organs [562] including all parts of the GI tract [563,564,565,566], but their expression levels differs in various tissues. For instance, ERα is the predominant isotype in the breast and uterus, whereas ERβ is expressed at higher levels in the urogenital tract, endothelial cells and the CNS [562,567]. ERα and ERβ are present throughout the rostral–caudal extent of the brain and spinal cord and their expression overlaps in most of the CNS with a few exceptions. For instance, although both receptors are expressed by neurons in the arcuate nucleus and hippocampus, ERα is more abundant in the arcuate nucleus, and ERβ is more prevalent in the hippocampus [568,569,570,571,572]. Importantly, ERβ mediates brain development by regulating neural progenitor cell proliferation [573] and stem cell differentiation into dopamine neurons [574].

ERα, but not ERβ, is vital to reproductive function and regulation of the preovulatory surge of luteinizing hormone (LH) in response to rising levels of estrogen [575,576,577]. However, ERβ may be involved in mediating the negative feedback control of anterior pituitary LH secretion, a process mainly governed by ERα [578]. Moreover, ERα-null female mice are deficient in sexual behavioral interactions, they are more aggressive towards other females and show reduced levels of parental behavior towards newborn pups [575]. Thus, ERα regulates reproduction not only at the physiological, but also behavioral level.

The effects of estrogens on energy balance are primarily mediated by ERα, as women or female mice with mutations in the ERα gene display hyperadiposity [579,580]. Importantly, estrogen levels directly affect nutrient uptake from the intestine [581,582]. Female mice lacking ERα in hypothalamic steroidogenic factor-1 (SF1) neurons are characterized by hypometabolism and abdominal obesity, but not hyperphagia. In contrast, loss of ERα from the hypothalamic POMC neurons leads to hyperphagia, without directly influencing energy expenditure or fat distribution [583]. Thus, estrogens act on distinct hypothalamic ERα neurons to regulate different aspects of energy homeostasis and reproduction.

While ERα is essential for reproductive neuroendocrine function, ERβ seems more important for emotional behavior. ERβ-null mice show increases of 5-HT1A receptor expression in the medial amygdala as well as lower serotonin and dopamine levels in several brain regions [584,585]. Accordingly, E2, acting via ERβ located in 5-HT cell bodies of the dorsal raphe nucleus, induces expression of tryptophan hydroxylase which is involved in the synthesis of 5-HT [586]. As a result, mice and rats treated with E2 or selective ERβ agonists and subsequently submitted to the forced swim test, spend less time immobile and struggle longer than non-treated controls, which is interpreted as a less depressive-like behavior [587,588]. This effect is not observed in ERβ-null mice [587]. Selective agonists of ERβ exert potent anxiolytic activity in rats [589,590], whereas ERβ-null mice show increased anxiety accompanied by reduced threshold for the induction of synaptic plasticity in the basolateral amygdala [584,585]. In elevated plus maze and open field tests for anxiety-like behaviors, ERβ-null mice show increased anxiety relative to their wild-type counterparts. Importantly, this phenotype of the ERβ-null mice is present only in females, indicating a specific gender-dependent sensitivity to hormonal changes expressed in behavior [584,585]. ERβ may exert its impact on behavior via the HPA axis [591] and other behavior-related hormones as it represses neuronal vasopressin [592], CRH [593] and corticosterone [590]. Notably, GCs are transported in the blood predominantly bound to corticosteroid-binding globulin (CBG), also known as transcortin, which serves as a regulator of the biological availability of GCs. CBG is produced by the liver, and interestingly, it is stimulated by estrogens, which is reflected as higher levels of total circulating corticosterone in females compared to males [594]. Importantly, the sex hormones estrogen and progesterone influence the expression of MR [469,470] and the ER inhibits the transactivational effects of the MR in several cell types [595]. In addition to MCs and GCs, progesterone is a competitive MR antagonist with a similar affinity for the MR as aldosterone [596]. Moreover, MR mRNA levels in the human hippocampus show higher concentrations in women compared to men [597]. The hormonal differences associated with MR correlate with occurrence of cardiovascular diseases in premenopausal woman. Consistently, sex differences exist in the cortisol stress response [598], in response to parental separation of pups [599], in hippocampal MR and GR expression after exposure to stress of adults rats [600,601] and in the prevalence of stress-related psychiatric disorders [602,603]. On the contrary, DEX-treated female rats increase ERβ expression in the hypothalamic PVN and supraoptic nuclei (SON) [604], whereas adrenalectomy reduces ERβ mRNA expression in the PVN, and corticosterone replacement fully reverses this effect in a dose-dependent fashion [605]. Thus, ERβ mediates and interacts with the HPA axis.

In contrast, treatment with the ERα agonist propylpyrazoletriol (PPT) was anxiogenic in the elevated plus maze test and, in a consistent manner, stimulated corticosterone stress hormone response [590,593]. These results provide an explanation to the fact that estrogen has both anxiogenic and anxiolytic effects [606,607].

Considering the vital contribution of estrogens to the regulation of fertility, metabolism and behavior described above, the regulation of estrogen bioavailability by the microbiota impacts essential functions in the host’s life.

3.6. Thyroid Hormone Receptors
An essential component of thyroid hormones (TH), iodide is actively transported and concentrated in the thyroid gland and incorporated in THs. Thyroid cells combine iodine and the amino acid tyrosine to make T3 and T4 [608,609,610,611]. Thyroxine (T4) contains four iodine atoms and the more potent triiodothyronine (T3) has three of them. T4 is the prevalent form of released THs and deiodination of its outer ring by enzymes iodothyronine deiodinases yields T3. The deiodinases are selenoproteins expressed in various tissues including the GI tract which regulate the intracellular biological activity of THs [612,613,614,615]. Thus, deficiency of deiodinases can mimic hypothyroidism.

TH secretion is regulated by a negative feedback system involving the hypothalamus, the pituitary gland and the thyroid gland. Thyrotropin releasing hormone (TRH) is synthetized in the hypothalamus and when released it is transported in the circulation and binds to receptors of the pituitary thyrotropes. The pituitary then secretes thyroid stimulating hormone (TSH) which promotes TH release from the thyroid gland. Both TRH and TSH secretions are negatively regulated by TH. Also, somatostatin and dopamine inhibit TSH release [616,617]. Importantly, both of these factors can be produced by microbiota [35,48,49].

THs serve as ligands for the thyroid hormone receptors α (TRα, NR1A1) and β (TRβ, NR1A2), which occur in several forms. TR-α1 is widely expressed with high levels in cardiac and skeletal muscles. In the brain its highest levels are in the olfactory bulb, hippocampus and parts of cerebellar cortex. TR-α2 is most abundant in the brain but it is the only TR form that is not capable of binding thyroid hormone. TR-β1 is present mainly in brain, liver and kidney and TR-β2 is limited to brain with high levels in the hypothalamic PVN and anterior pituitary [618,619]. TR can bind to DNA whether or not it is activated by appropriate ligands. In the unliganded inactivated from it recruits corepressors thereby inhibiting gene expression. Upon ligand binding, the TR changes conformation facilitating dissociation of the corepressors and the recruitment of coactivators resulting in the stimulation of target gene promoters and gene transcription [620]. TRs also exerts nongenomic actions [621].

T3 increases cardiac output and heart rate, lung ventilation, basal metabolic rate, catabolism of proteins and carbohydrates as well as growth and brain development. In the brain, THs promote a wide range of developmental processes including myelination, neuronal migration as well as neuronal and ganglion cell differentiation [611,619]. THs also affect mood and behavior [622]. Among target genes in the brain TH regulates genes coding for brain myelin basic protein [623,624], BDNF [625], glutamine synthase [626], prostaglandin D2 synthase [627], adhesion molecules, matrix proteins, factors affecting neuronal migration and apoptosis, nerve metabolism and signal transduction [628,629,630]. Both TH deficiency and excessive production lead to metabolic and neuronal malfunctions. Hyperthyroidism is characterized by increased levels of free circulating TH, weight loss, frequent bowel movements and associated diarrhea, weakness, tremors, difficulty to sleep, heat intolerance, increased heartbeat, anxiety, and memory problems. Hypothyroidism is associated with weight gain, exhaustion, constipation, indigestion, depression, anxiety, psychosis, general pains and fertility problems in females [619,631,632,633]. Hypothyroidism affects brain development and may cause neurological defects including diminished neuron development in hippocampus, cerebral cortex, visual and auditory cortex [628,634,635]. Hypothyroidism-caused developmental malfunctions can be reversed if THs are administrated within 2 weeks after birth [628]. On the contrary, absence of congenital hypothyroidism treatment in infants leads to a profound brain development delay accompanied by mental retardation. Interestingly, hypothyroid patients show lower amounts of gut Bifidobacterium and Lactobacilli while having more Enterococci than healthy subjects [636]. Additionally, patients with a history of hypothyroidism show more prevalent occurrence of small intestine bacterial overgrowth (SIBO) which may be reversed by antibiotic treatment [637].

Hypothyroidism may be due to genetic factors or dietary iodine deficiency. Iodine concentration in the thyroid gland as well as in peripheral tissues largely depends on ionic pumps and transporters, the efficiency of which is modulated by iodothyronine deiodinases as well as the availability of iodine and selenium. An inability to synthesize TH results in a decrease of the negative feedback to hypothalamus, which stimulates TSH production leading to enlargement of thyroid gland, a condition named goiter. An enlarged thyroid gland enhances its ability to trap iodine [638,639,640].

The amount of exchangeable T3 and T4 in the intestine constitutes the second largest reservoir of TH after the thyroid gland, before the liver and kidneys [641]. Short gut syndrome and bariatric surgery are both associated with reduced intestinal nutrient uptake and malnourishment, which do not influence iodine levels [642,643]. On the contrary, modulation of rat microbiota by kanamycin reduces iodine uptake [644] implying that the gut flora constitutes the functional component of the GI tract responsible for iodine absorption. Moreover, the microbiota in the small intestine, cecum, colon and feces of rats reversibly binds T3 and T4 and this capacity is abolished by antibiotic treatment [645,646]. Ex vivo studies show that Escherichia coli, one of major gut colonizers, is capable of binding T3 and T4 [647]. Thus, gut flora could serve as a reservoir, retaining and releasing TH.

Selenium is an essential microelement required for the synthesis and bioactivity of selenoproteins, including deiodinases. Consequently, this microelement affects the activity of TH. Selenium is absorbed in the duodenum and caecum [648] and in the body is most highly concentrated in the thyroid gland [649]. Gut bacteria also require selenium and when it is not taken up by the host, colonic bacteria utilize it [650]. Upon selenium shortage, the microbiota gets to the point of competing with the host for selenium [651], which may result in reduced expression of selenoproteins in the host [652] and the microbiota may inhibit the enzymatic activity of deiodinases in the cecum and colon walls [653]. Selenium supplementation results in increased diversity of gut bacterial population [652] and enhanced colonic and rectal fermentation [654] as multiple microbes are capable of producing their own selenoproteins [655,656,657,658].

THs are inactivated mainly in the liver by conjugation. Attached sulfate and glucuronic acid moieties enable secretion of the conjugated hormones in bile and decrease their reabsorption from the intestine. Moreover, sulfation facilitates irreversible deiodination and catabolism of THs [659]. However, glucuronidated and sulfated THs can be hydrolyzed to active precursors in the GI tract and various other tissues. Thus, conjugated THs can serve as a reservoir for active hormones. In rats, but not humans, stimulation of glucuronidation by drugs and toxins may results in a drop in T4 and T3 levels provoking elevated TSH secretion and resulting in goiter formation [638,660,661]. Incubation of various TH sulfate conjugates with human or rat feces results in complete hydrolysis of the conjugates. However, preheated fecal suspensions and supernatants of centrifuged fecal solution do not affect sulfation of TH. Similarly, fecal suspension obtained from GF or ampicillin-treated rats showed drastically reduced deconjugation capacity [662,663,664]. Consequently, in GF mice the enterohepatic cycle of TH including intestinal deconjugation of T3 secreted in bile and its reabsorption to circulation is abolished [665]. Deconjugation activity relies on the presence of obligate anaerobic intestinal bacteria. Bacterial strains isolated from human feces, including Peptostreptococcus productus, possess sulfatase activity [662,663,664].

The bacterial signaling that influences TH turnover and LPS which triggers septic shock also promotes non-thyroidal illness syndrome. Higher doses of LPS in mice decrease the levels of liver deiodinase mRNA, pituitary TR mRNA and protein, and reduces the amount of TSH receptor mRNA in the thyroid gland [666]. In pigs, LPS lowers TH levels in serum and most tissues. Moreover, it decreases the expression of deiodinases in the liver and kidneys as well as deiodinases activity in kidneys. LPS administration results in lowered mRNA levels of TRβ in the frontal lobe, adrenal glands and kidney cortex [667]. Thus, bacterial LPS is capable of affecting TH signaling on multiple levels in the whole organism, including in the brain.

Patients suffering from celiac disease, which is generally accompanied by GI inflammation and abnormal microbiota, show malabsorption of orally delivered T4 and in case of Hashimoto thyroiditis require higher doses of the T4 drugs [668]. Approximately one third of patients with autoimmune thyroid disease show also symptoms of atrophic gastritis [669]. Furthermore, 40% of Hashimoto thyroiditis patients exhibit lymphocytic colitis [670]. Rarefication and partial disappearance of microvilli, spaces between microvilli and thickening of microvilli were increased in intestinal mucosal biopsies from autoimmune thyroiditis patients. The patients also showed increased mucosal permeability [671]. Thus the host’s TH affects gut health and therefore also the gut flora. TH can also affect the bacteria population by influencing the number of parietal cells in the gastric mucosa, the secretion of pepsinogen and the basal acidity in the stomach [672,673]. Thereby in the stomach, TH increases the efficiency of killing bacteria taken up with the food, reducing the colonization of more distal parts of the GI tract by these foodborne microorganisms.

The direct connection of enteric bacteria and TR in the context of the gut–brain axis has not been addressed so far. However as seen above, the importance of TR in brain development and proper functioning and the crucial impact of the microbiota on TR ligands availability, provide strong support for a GI tract–CNS TR-dependent signaling.

4. Conclusions and Future Directions
As presented in this review, there are multiple studies proving the connection between a healthy gut and a healthy brain. NRs are key players in regulating virtually every process necessary for the survival and health of a living organism. By influencing NRs, gut flora participates in the regulatory roles of the nuclear receptors (Figure 4). Via signaling to the brain, the microbiota regulates metabolism, CNS development, inflammation as well as mood and behavior. Notably, it also impacts reproductive behavior and, therefore, contributes to species survival. Importantly, the human host has the capacity to voluntarily influence and improve its own microbiota by the power of nutritional or probiotic interventions. Thus, nutritional approaches, combined with physical exercise, aiming at providing or sustaining the production of NR ligands and increasing the microbiota diversity should appear as a common sense approach to promote a physically and physiologically healthy life.

Multiple NRs have been proven to interact with the microbiota and/or to play a role in the brain. However, a full picture of the involvement of NRs in the gut–brain axis is still missing. Interestingly, there is one exception. The RAR-related orphan receptor (ROR) is involved in cerebellum development [674]. Additionally, the RORγ subtype is considered to be a master regulator of lineage specification of a subset of CD4+ T helper cells (T(H)17) playing a role in the development of autoimmune diseases [675]. Importantly, microbes induce Th17 cells via RORγ, which results in activation of sensory neurons [676]. Evidence for such a direct regulation of the nervous system by bacteria has been rarely found so far. Therefore, more research is needed to fully unveil the great potential of NRs in regulating the enteric microbiota–gut–brain axis and to learn how we could benefit from modulating their activity by pharmacological or nutritional interventions.

Acknowledgments
The work performed in W.W.’s laboratory was supported by the start-up grant from the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.

Funding
This research received no external funding.

Conflicts of Interest
The authors declare no conflict of interests.

Figure 1 PPARs in gut–brain signaling. PPARs are activated by nutrient derivatives as well as bacteria-derived molecules and their signaling. PPARα serves as a receptor for oleoylethanolamide (OEA) and mediates the impact of OEA on hunger and satiety. PPARα also impacts the central nervous system (CNS) by taking part in microbiota-mediated synthesis of glucocorticoids (GCs). PPARβ/δ mediates satiety signals from gut to the CNS by stimulating the synthesis of glucagon-like protein-1 (GLP-1). Intestinal PPARγ affects adiposity via the sympathetic nervous system (SNS). Red arrows symbolize direct signals from enteric bacteria, black arrows indicate consequences of nuclear receptor (NR) signaling on the bacteria and blue arrows illustrate interactions between the pictured factors. Blue solid lines correspond to interactions within intestine or the brain while blue dotted lines mark signaling between the organs.

Figure 2 Xenobiotic receptors in the gut-brain axis. Bacterial metabolites, mainly indole and bile acids (BA) serve as ligands for xenobiotic receptors. These NRs play multifold roles in the brain by affecting the CNS development, permeability of the blood-brain barrier (BBB), memory and anxiety. Broad blue arrows illustrate the action of both PXR (pregnane X receptor) and CAR (constitutive androstane nuclear receptor), narrow blue arrows the actions of single factors, black arrows indicate bacteria-derived signals and the red arrow the impact of GI inflammation on the microbiota.

Figure 3 Interaction between glucocorticoid receptor (GR), mineralocorticoid receptor (MR) and microbiota. By regulating the activity of 11β-HSD, bacterial glycerrhetinic acid-like factors (GALFs) modulate GCs availability and GCs affinity towards GR or MR. Additionally, the microbiota regulates circadian production of GCs in the intestine thereby affecting the activity of steroid receptors in multiple tissues.

Figure 4 Summary of the interactions of NRs with enteric microbiota and the brain. Broad blue arrows indicate the involvement of groups of NRs (AHR/PXR/CAR; MR/GR), narrow blue arrows picture single factor actions. Black lines illustrate bacteria-born signals and red arrows specify impacts on the microbiota.
==== Refs
References
1. Evans R.M.  Mangelsdorf D.J.   Nuclear Receptors, RXR, and the Big Bang Cell 2014 157 255 266 10.1016/j.cell.2014.03.012 24679540 
2. Martin R.  Makino H.  Cetinyurek Yavuz A.  Ben-Amor K.  Roelofs M.  Ishikawa E.  Kubota H.  Swinkels S.  Sakai T.  Oishi K.    Early-Life Events, Including Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the Developing Gut Microbiota PLoS ONE 2016 11 e0158498 10.1371/journal.pone.0158498 27362264 
3. Yatsunenko T.  Rey F.E.  Manary M.J.  Trehan I.  Dominguez-Bello M.G.  Contreras M.  Magris M.  Hidalgo G.  Baldassano R.N.  Anokhin A.P.    Human gut microbiome viewed across age and geography Nature 2012 486 222 227 10.1038/nature11053 22699611 
4. Ianiro G.  Tilg H.  Gasbarrini A.   Antibiotics as deep modulators of gut microbiota: Between good and evil Gut 2016 65 1906 1915 10.1136/gutjnl-2016-312297 27531828 
5. Gupta V.K.  Paul S.  Dutta C.   Geography, Ethnicity or Subsistence-Specific Variations in Human Microbiome Composition and Diversity Front. Microbiol. 2017 8 1162 10.3389/fmicb.2017.01162 28690602 
6. Garcia-Gutierrez E.  Mayer M.J.  Cotter P.D.  Narbad A.   Gut microbiota as a source of novel antimicrobials Gut Microbes 2018 1–21 1 21 10.1080/19490976.2018.1455790 29584555 
7. Rothschild D.  Weissbrod O.  Barkan E.  Kurilshikov A.  Korem T.  Zeevi D.  Costea P.I.  Godneva A.  Kalka I.N.  Bar N.    Environment dominates over host genetics in shaping human gut microbiota Nature 2018 555 210 215 10.1038/nature25973 29489753 
8. Diaz Heijtz R.  Wang S.  Anuar F.  Qian Y.  Bjorkholm B.  Samuelsson A.  Hibberd M.L.  Forssberg H.  Pettersson S.   Normal gut microbiota modulates brain development and behavior Proc. Natl. Acad. Sci. USA 2011 108 3047 3052 10.1073/pnas.1010529108 21282636 
9. Jenkins T.A.  Nguyen J.C.  Polglaze K.E.  Bertrand P.P.   Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis Nutrients 2016 8 56 10.3390/nu8010056 26805875 
10. Schmidt C.   Mental health: Thinking from the gut Nature 2015 518 S12 S15 10.1038/518S13a 25715275 
11. Smith P.A.   The tantalizing links between gut microbes and the brain Nature 2015 526 312 314 10.1038/526312a 26469024 
12. Mayer E.A.  Knight R.  Mazmanian S.K.  Cryan J.F.  Tillisch K.   Gut microbes and the brain: Paradigm shift in neuroscience J. Neurosci. 2014 34 15490 15496 10.1523/JNEUROSCI.3299-14.2014 25392516 
13. Sommer F.  Backhed F.   The gut microbiota—Masters of host development and physiology Nat. Rev. Microbiol. 2013 11 227 238 10.1038/nrmicro2974 23435359 
14. Cryan J.F.  Dinan T.G.   More than a gut feeling: The microbiota regulates neurodevelopment and behavior Neuropsychopharmacology 2015 40 241 242 10.1038/npp.2014.224 25482171 
15. Rhee S.H.  Pothoulakis C.  Mayer E.A.   Principles and clinical implications of the brain-gut-enteric microbiota axis Nat. Rev. Gastroenterol. Hepatol. 2009 6 306 314 10.1038/nrgastro.2009.35 19404271 
16. Bailey M.T.  Lubach G.R.  Coe C.L.   Prenatal stress alters bacterial colonization of the gut in infant monkeys J. Pediatr. Gastroenterol. Nutr. 2004 38 414 421 10.1097/00005176-200404000-00009 15085020 
17. Bailey M.T.  Coe C.L.   Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys Dev. Psychobiol. 1999 35 146 155 10.1002/(SICI)1098-2302(199909)35:2<146::AID-DEV7>3.0.CO;2-G 10461128 
18. O’Mahony S.M.  Marchesi J.R.  Scully P.  Codling C.  Ceolho A.M.  Quigley E.M.  Cryan J.F.  Dinan T.G.   Early life stress alters behavior, immunity, and microbiota in rats: Implications for irritable bowel syndrome and psychiatric illnesses Biol. Psychiatry 2009 65 263 267 10.1016/j.biopsych.2008.06.026 18723164 
19. Kiliaan A.J.  Saunders P.R.  Bijlsma P.B.  Berin M.C.  Taminiau J.A.  Groot J.A.  Perdue M.H.   Stress stimulates transepithelial macromolecular uptake in rat jejunum Am. J. Physiol. 1998 275 G1037 G1044 10.1152/ajpgi.1998.275.5.G1037 9815034 
20. Demaude J.  Salvador-Cartier C.  Fioramonti J.  Ferrier L.  Bueno L.   Phenotypic changes in colonocytes following acute stress or activation of mast cells in mice: Implications for delayed epithelial barrier dysfunction Gut 2006 55 655 661 10.1136/gut.2005.078675 16299034 
21. Bailey M.T.  Engler H.  Sheridan J.F.   Stress induces the translocation of cutaneous and gastrointestinal microflora to secondary lymphoid organs of C57BL/6 mice J. Neuroimmunol. 2006 171 29 37 10.1016/j.jneuroim.2005.09.008 16253348 
22. Freestone P.P.  Williams P.H.  Haigh R.D.  Maggs A.F.  Neal C.P.  Lyte M.   Growth stimulation of intestinal commensal Escherichia coli by catecholamines: A possible contributory factor in trauma-induced sepsis Shock 2002 18 465 470 10.1097/00024382-200211000-00014 12412628 
23. Freestone P.P.  Haigh R.D.  Williams P.H.  Lyte M.   Involvement of enterobactin in norepinephrine-mediated iron supply from transferrin to enterohaemorrhagic Escherichia coli FEMS Microbiol. Lett. 2003 222 39 43 10.1016/S0378-1097(03)00243-X 12757944 
24. Lyte M.  Ernst S.   Catecholamine induced growth of gram negative bacteria Life Sci. 1992 50 203 212 10.1016/0024-3205(92)90273-R 1731173 
25. Lyte M.  Freestone P.P.  Neal C.P.  Olson B.A.  Haigh R.D.  Bayston R.  Williams P.H.   Stimulation of Staphylococcus epidermidis growth and biofilm formation by catecholamine inotropes Lancet 2003 361 130 135 10.1016/S0140-6736(03)12231-3 12531580 
26. Hegde M.  Wood T.K.  Jayaraman A.   The neuroendocrine hormone norepinephrine increases Pseudomonas aeruginosa  PA14 virulence through the las quorum-sensing pathway Appl. Microbiol. Biotechnol. 2009 84 763 776 10.1007/s00253-009-2045-1 19517106 
27. Sperandio V.  Torres A.G.  Jarvis B.  Nataro J.P.  Kaper J.B.   Bacteria-host communication: The language of hormones Proc. Natl. Acad. Sci. USA 2003 100 8951 8956 10.1073/pnas.1537100100 12847292 
28. Kasubuchi M.  Hasegawa S.  Hiramatsu T.  Ichimura A.  Kimura I.   Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation Nutrients 2015 7 2839 2849 10.3390/nu7042839 25875123 
29. Queipo-Ortuno M.I.  Seoane L.M.  Murri M.  Pardo M.  Gomez-Zumaquero J.M.  Cardona F.  Casanueva F.  Tinahones F.J.   Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels PLoS ONE 2013 8 e65465 10.1371/journal.pone.0065465 23724144 
30. Parnell J.A.  Reimer R.A.   Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults Am. J. Clin. Nutr. 2009 89 1751 1759 10.3945/ajcn.2009.27465 19386741 
31. Ravussin Y.  Koren O.  Spor A.  LeDuc C.  Gutman R.  Stombaugh J.  Knight R.  Ley R.E.  Leibel R.L.   Responses of gut microbiota to diet composition and weight loss in lean and obese mice Obesity 2012 20 738 747 10.1038/oby.2011.111 21593810 
32. Naruszewicz M.  Johansson M.L.  Zapolska-Downar D.  Bukowska H.   Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers Am. J. Clin. Nutr. 2002 76 1249 1255 10.1093/ajcn/76.6.1249 12450890 
33. Lam V.  Su J.  Koprowski S.  Hsu A.  Tweddell J.S.  Rafiee P.  Gross G.J.  Salzman N.H.  Baker J.E.   Intestinal microbiota determine severity of myocardial infarction in rats FASEB J. 2012 26 1727 1735 10.1096/fj.11-197921 22247331 
34. Karlsson F.H.  Tremaroli V.  Nookaew I.  Bergstrom G.  Behre C.J.  Fagerberg B.  Nielsen J.  Backhed F.   Gut metagenome in European women with normal, impaired and diabetic glucose control Nature 2013 498 99 103 10.1038/nature12198 23719380 
35. LeRoith D.  Pickens W.  Vinik A.I.  Shiloach J.   Bacillus subtilis contains multiple forms of somatostatin-like material Biochem. Biophys. Res. Commun. 1985 127 713 719 10.1016/S0006-291X(85)80001-2 2859015 
36. Yadav H.  Lee J.H.  Lloyd J.  Walter P.  Rane S.G.   Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion J. Biol. Chem. 2013 288 25088 25097 10.1074/jbc.M113.452516 23836895 
37. Wichmann A.  Allahyar A.  Greiner T.U.  Plovier H.  Lunden G.O.  Larsson T.  Drucker D.J.  Delzenne N.M.  Cani P.D.  Backhed F.   Microbial modulation of energy availability in the colon regulates intestinal transit Cell Host Microbe 2013 14 582 590 10.1016/j.chom.2013.09.012 24237703 
38. Fetissov S.O.  Hamze Sinno M.  Coeffier M.  Bole-Feysot C.  Ducrotte P.  Hokfelt T.  Dechelotte P.   Autoantibodies against appetite-regulating peptide hormones and neuropeptides: Putative modulation by gut microflora Nutrition 2008 24 348 359 10.1016/j.nut.2007.12.006 18262391 
39. Grenham S.  Clarke G.  Cryan J.F.  Dinan T.G.   Brain-gut-microbe communication in health and disease Front. Physiol. 2011 2 94 10.3389/fphys.2011.00094 22162969 
40. O’Hara A.M.  Shanahan F.   The gut flora as a forgotten organ EMBO Rep. 2006 7 688 693 10.1038/sj.embor.7400731 16819463 
41. Neufeld K.M.  Kang N.  Bienenstock J.  Foster J.A.   Reduced anxiety-like behavior and central neurochemical change in germ-free mice Neurogastroenterol. Motil. 2011 23 255 264 10.1111/j.1365-2982.2010.01620.x 21054680 
42. Bercik P.  Denou E.  Collins J.  Jackson W.  Lu J.  Jury J.  Deng Y.  Blennerhassett P.  Macri J.  McCoy K.D.    The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice Gastroenterology 2011 141 599 609 10.1053/j.gastro.2011.04.052 21683077 
43. Sudo N.  Chida Y.  Aiba Y.  Sonoda J.  Oyama N.  Yu X.N.  Kubo C.  Koga Y.   Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice J. Physiol. 2004 558 263 275 10.1113/jphysiol.2004.063388 15133062 
44. Messaoudi M.  Lalonde R.  Violle N.  Javelot H.  Desor D.  Nejdi A.  Bisson J.F.  Rougeot C.  Pichelin M.  Cazaubiel M.    Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus  R0052 and Bifidobacterium longum  R0175) in rats and human subjects Br. J. Nutr. 2011 105 755 764 10.1017/S0007114510004319 20974015 
45. Bravo J.A.  Forsythe P.  Chew M.V.  Escaravage E.  Savignac H.M.  Dinan T.G.  Bienenstock J.  Cryan J.F.   Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve Proc. Natl. Acad. Sci. USA 2011 108 16050 16055 10.1073/pnas.1102999108 21876150 
46. Markle J.G.  Frank D.N.  Mortin-Toth S.  Robertson C.E.  Feazel L.M.  Rolle-Kampczyk U.  von Bergen M.  McCoy K.D.  Macpherson A.J.  Danska J.S.   Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity Science 2013 339 1084 1088 10.1126/science.1233521 23328391 
47. Asano Y.  Hiramoto T.  Nishino R.  Aiba Y.  Kimura T.  Yoshihara K.  Koga Y.  Sudo N.   Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice Am. J. Physiol. Gastrointest. Liver Physiol. 2012 303 G1288 G1295 10.1152/ajpgi.00341.2012 23064760 
48. Lyte M.   Microbial endocrinology in the microbiome-gut-brain axis: How bacterial production and utilization of neurochemicals influence behavior PLoS Pathog. 2013 9 e1003726 10.1371/journal.ppat.1003726 24244158 
49. Lyte M.   Microbial endocrinology and the microbiota-gut-brain axis Adv. Exp. Med. Biol. 2014 817 3 24 24997027 
50. Reigstad C.S.  Salmonson C.E.  Rainey J.F. 3rd  Szurszewski J.H.  Linden D.R.  Sonnenburg J.L.  Farrugia G.  Kashyap P.C.   Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells FASEB J. 2015 29 1395 1403 10.1096/fj.14-259598 25550456 
51. Clarke G.  Grenham S.  Scully P.  Fitzgerald P.  Moloney R.D.  Shanahan F.  Dinan T.G.  Cryan J.F.   The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner Mol. Psychiatry 2013 18 666 673 10.1038/mp.2012.77 22688187 
52. Wikoff W.R.  Anfora A.T.  Liu J.  Schultz P.G.  Lesley S.A.  Peters E.C.  Siuzdak G.   Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites Proc. Natl. Acad. Sci. USA 2009 106 3698 3703 10.1073/pnas.0812874106 19234110 
53. Desbonnet L.  Garrett L.  Clarke G.  Bienenstock J.  Dinan T.G.   The probiotic Bifidobacteria infantis: An assessment of potential antidepressant properties in the rat J. Psychiatr. Res. 2008 43 164 174 10.1016/j.jpsychires.2008.03.009 18456279 
54. Donia M.S.  Fischbach M.A.   Small molecules from the human microbiota Science 2015 349 1254766 10.1126/science.1254766 26206939 
55. Nuclear Receptors Nomenclature Committee  A unified nomenclature system for the nuclear receptor superfamily Cell 1999 97 161 163 10219237 
56. Desvergne B.  Wahli W.   Peroxisome proliferator-activated receptors: Nuclear control of metabolism Endocr. Rev. 1999 20 649 688 10.1210/er.20.5.649 10529898 
57. Green S.  Wahli W.   Peroxisome proliferator-activated receptors: Finding the orphan a home Mol. Cell. Endocrinol. 1994 100 149 153 10.1016/0303-7207(94)90294-1 8056148 
58. Braissant O.  Foufelle F.  Scotto C.  Dauca M.  Wahli W.   Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and -γ in the adult rat Endocrinology 1996 137 354 366 10.1210/endo.137.1.8536636 8536636 
59. Duszka K.  Ellero-Simatos S.  Ow G.G.  Defernez M.  Paramalingam E.  Tett A.  Ying S.  König J.  Narbad A.  Kuznetsov V.A.    Complementary intestinal mucosa and microbiota responses to caloric restriction Sci. Rep. 2018 8 10.1038/s41598-018-29815-7 
60. Issemann I.  Green S.   Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 1990 347 645 650 10.1038/347645a0 2129546 
61. Hashimoto T.  Cook W.S.  Qi C.  Yeldandi A.V.  Reddy J.K.  Rao M.S.   Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting J. Biol. Chem. 2000 275 28918 28928 10.1074/jbc.M910350199 10844002 
62. Kersten S.  Seydoux J.  Peters J.M.  Gonzalez F.J.  Desvergne B.  Wahli W.   Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting J. Clin. Investig. 1999 103 1489 1498 10.1172/JCI6223 10359558 
63. Leone T.C.  Weinheimer C.J.  Kelly D.P.   A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders Proc. Natl. Acad. Sci. USA 1999 96 7473 7478 10.1073/pnas.96.13.7473 10377439 
64. Rodriguez J.C.  Gil-Gomez G.  Hegardt F.G.  Haro D.   Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids J. Biol. Chem. 1994 269 18767 18772 7913466 
65. Badman M.K.  Pissios P.  Kennedy A.R.  Koukos G.  Flier J.S.  Maratos-Flier E.   Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states Cell Metab. 2007 5 426 437 10.1016/j.cmet.2007.05.002 17550778 
66. Crawford P.A.  Crowley J.R.  Sambandam N.  Muegge B.D.  Costello E.K.  Hamady M.  Knight R.  Gordon J.I.   Regulation of myocardial ketone body metabolism by the gut microbiota during nutrient deprivation Proc. Natl. Acad. Sci. USA 2009 106 11276 11281 10.1073/pnas.0902366106 19549860 
67. Schmutz I.  Ripperger J.A.  Baeriswyl-Aebischer S.  Albrecht U.   The mammalian clock component PERIOD2 coordinates circadian output by interaction with nuclear receptors Genes Dev. 2010 24 345 357 10.1101/gad.564110 20159955 
68. Canaple L.  Rambaud J.  Dkhissi-Benyahya O.  Rayet B.  Tan N.S.  Michalik L.  Delaunay F.  Wahli W.  Laudet V.   Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor α defines a novel positive feedback loop in the rodent liver circadian clock Mol. Endocrinol. 2006 20 1715 1727 10.1210/me.2006-0052 16556735 
69. Montagner A.  Rando G.  Degueurce G.  Leuenberger N.  Michalik L.  Wahli W.   New insights into the role of PPARs Prostaglandins Leukot. Essent. Fatty Acids 2011 85 235 243 10.1016/j.plefa.2011.04.016 21778043 
70. Corton J.C.  Apte U.  Anderson S.P.  Limaye P.  Yoon L.  Latendresse J.  Dunn C.  Everitt J.I.  Voss K.A.  Swanson C.    Mimetics of caloric restriction include agonists of lipid-activated nuclear receptors J. Biol. Chem. 2004 279 46204 46212 10.1074/jbc.M406739200 15302862 
71. Fontaine C.  Dubois G.  Duguay Y.  Helledie T.  Vu-Dac N.  Gervois P.  Soncin F.  Mandrup S.  Fruchart J.C.  Fruchart-Najib J.    The orphan nuclear receptor Rev-Erbα is a peroxisome proliferator-activated receptor (PPAR) γ target gene and promotes PPARγ-induced adipocyte differentiation J. Biol. Chem. 2003 278 37672 37680 10.1074/jbc.M304664200 12821652 
72. Oishi K.  Shirai H.  Ishida N.   CLOCK is involved in the circadian transactivation of peroxisome-proliferator-activated receptor α (PPARα) in mice Biochem. J. 2005 386 575 581 10.1042/BJ20041150 15500444 
73. Gibbons G.F.  Patel D.  Wiggins D.  Knight B.L.   The functional efficiency of lipogenic and cholesterogenic gene expression in normal mice and in mice lacking the peroxisomal proliferator-activated receptor-α (PPAR-α) Adv. Enzym. Regul. 2002 42 227 247 10.1016/S0065-2571(01)00033-4 
74. Patel D.D.  Knight B.L.  Wiggins D.  Humphreys S.M.  Gibbons G.F.   Disturbances in the normal regulation of SREBP-sensitive genes in PPAR α-deficient mice J. Lipid Res. 2001 42 328 337 11254743 
75. Mukherji A.  Kobiita A.  Ye T.  Chambon P.   Homeostasis in intestinal epithelium is orchestrated by the circadian clock and microbiota cues transduced by TLRs Cell 2013 153 812 827 10.1016/j.cell.2013.04.020 23663780 
76. Manoharan I.  Suryawanshi A.  Hong Y.  Ranganathan P.  Shanmugam A.  Ahmad S.  Swafford D.  Manicassamy B.  Ramesh G.  Koni P.A.    Homeostatic PPARα Signaling Limits Inflammatory Responses to Commensal Microbiota in the Intestine J. Immunol. 2016 196 4739 4749 10.4049/jimmunol.1501489 27183583 
77. Mazzon E.  Cuzzocrea S.   Absence of functional peroxisome proliferator-activated receptor-α enhanced ileum permeability during experimental colitis Shock 2007 28 192 201 10.1097/SHK.0b013e318033eb29 17515853 
78. Riccardi L.  Mazzon E.  Bruscoli S.  Esposito E.  Crisafulli C.  Di Paola R.  Caminiti R.  Riccardi C.  Cuzzocrea S.   Peroxisome proliferator-activated receptor-α modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice Shock 2009 31 308 316 10.1097/SHK.0b013e31818339e7 18665053 
79. Esposito E.  Mazzon E.  Paterniti I.  Dal Toso R.  Pressi G.  Caminiti R.  Cuzzocrea S.   PPAR-α Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice PPAR Res. 2010 2010 917312 10.1155/2010/917312 20671911 
80. Cuzzocrea S.  Di Paola R.  Mazzon E.  Genovese T.  Muia C.  Centorrino T.  Caputi A.P.   Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors α (PPAR-α) in the development of inflammatory bowel disease in mice Lab. Investig. 2004 84 1643 1654 10.1038/labinvest.3700185 15492755 
81. Fu J.  Gaetani S.  Oveisi F.  Lo Verme J.  Serrano A.  Rodriguez De Fonseca F.  Rosengarth A.  Luecke H.  Di Giacomo B.  Tarzia G.    Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α Nature 2003 425 90 93 10.1038/nature01921 12955147 
82. Fu J.  Dipatrizio N.V.  Guijarro A.  Schwartz G.J.  Li X.  Gaetani S.  Astarita G.  Piomelli D.   Sympathetic activity controls fat-induced oleoylethanolamide signaling in small intestine J. Neurosci. 2011 31 5730 5736 10.1523/JNEUROSCI.5668-10.2011 21490214 
83. Magotti P.  Bauer I.  Igarashi M.  Babagoli M.  Marotta R.  Piomelli D.  Garau G.   Structure of human N -acylphosphatidylethanolamine-hydrolyzing phospholipase D: Regulation of fatty acid ethanolamide biosynthesis by bile acids Structure 2015 23 598 604 10.1016/j.str.2014.12.018 25684574 
84. Pineda Torra I.  Claudel T.  Duval C.  Kosykh V.  Fruchart J.C.  Staels B.   Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor Mol. Endocrinol. 2003 17 259 272 10.1210/me.2002-0120 12554753 
85. Gaetani S.  Oveisi F.  Piomelli D.   Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide Neuropsychopharmacology 2003 28 1311 1316 10.1038/sj.npp.1300166 12700681 
86. Fu J.  Oveisi F.  Gaetani S.  Lin E.  Piomelli D.   Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats Neuropharmacology 2005 48 1147 1153 10.1016/j.neuropharm.2005.02.013 15910890 
87. Caillon A.  Duszka K.  Wahli W.  Rohner-Jeanrenaud F.  Altirriba J.   The OEA effect on food intake is independent from the presence of PPARα in the intestine and the nodose ganglion, while the impact of OEA on energy expenditure requires the presence of PPARα in mice Metabolism 2018 10.1016/j.metabol.2018.06.005 29936173 
88. Lo Verme J.  Gaetani S.  Fu J.  Oveisi F.  Burton K.  Piomelli D.   Regulation of food intake by oleoylethanolamide Cell. Mol. Life Sci. 2005 62 708 716 10.1007/s00018-004-4494-0 15770421 
89. Piomelli D.   A fatty gut feeling Trends Endocrinol. Metab. 2013 24 332 341 10.1016/j.tem.2013.03.001 23567058 
90. Proulx K.  Cota D.  Castaneda T.R.  Tschop M.H.  D’Alessio D.A.  Tso P.  Woods S.C.  Seeley R.J.   Mechanisms of oleoylethanolamide-induced changes in feeding behavior and motor activity Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005 289 R729 R737 10.1152/ajpregu.00029.2005 15879057 
91. Rodriguez de Fonseca F.  Navarro M.  Gomez R.  Escuredo L.  Nava F.  Fu J.  Murillo-Rodriguez E.  Giuffrida A.  LoVerme J.  Gaetani S.    An anorexic lipid mediator regulated by feeding Nature 2001 414 209 212 10.1038/35102582 11700558 
92. Gaetani S.  Fu J.  Cassano T.  Dipasquale P.  Romano A.  Righetti L.  Cianci S.  Laconca L.  Giannini E.  Scaccianoce S.    The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin J. Neurosci. 2010 30 8096 8101 10.1523/JNEUROSCI.0036-10.2010 20554860 
93. Tan N.S.  Michalik L.  Di-Poi N.  Ng C.Y.  Mermod N.  Roberts A.B.  Desvergne B.  Wahli W.   Essential role of Smad3 in the inhibition of inflammation-induced PPARβ/δ expression EMBO J. 2004 23 4211 4221 10.1038/sj.emboj.7600437 15470497 
94. Varnat F.  Heggeler B.B.  Grisel P.  Boucard N.  Corthesy-Theulaz I.  Wahli W.  Desvergne B.   PPARβ/δ regulates paneth cell differentiation via controlling the hedgehog signaling pathway Gastroenterology 2006 131 538 553 10.1053/j.gastro.2006.05.004 16890607 
95. Peters J.M.  Hollingshead H.E.  Gonzalez F.J.   Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease Clin. Sci. 2008 115 107 127 10.1042/CS20080022 18616431 
96. Burdick A.D.  Kim D.J.  Peraza M.A.  Gonzalez F.J.  Peters J.M.   The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation Cell Signal. 2006 18 9 20 10.1016/j.cellsig.2005.07.009 16109478 
97. Hollingshead H.E.  Morimura K.  Adachi M.  Kennett M.J.  Billin A.N.  Willson T.M.  Gonzalez F.J.  Peters J.M.   PPARβ/δ protects against experimental colitis through a ligand-independent mechanism Dig. Dis. Sci. 2007 52 2912 2919 10.1007/s10620-006-9644-9 17404849 
98. Wahli W.   A gut feeling of the PXR, PPAR and NF-κB connection J. Intern. Med. 2008 263 613 619 10.1111/j.1365-2796.2008.01951.x 18479261 
99. Doktorova M.  Zwarts I.  Zutphen T.V.  Dijk T.H.  Bloks V.W.  Harkema L.  Bruin A.  Downes M.  Evans R.M.  Verkade H.J.    Intestinal PPARδ protects against diet-induced obesity, insulin resistance and dyslipidemia Sci. Rep. 2017 7 846 10.1038/s41598-017-00889-z 28404991 
100. Daoudi M.  Hennuyer N.  Borland M.G.  Touche V.  Duhem C.  Gross B.  Caiazzo R.  Kerr-Conte J.  Pattou F.  Peters J.M.    PPARβ/δ activation induces enteroendocrine L cell GLP-1 production Gastroenterology 2011 140 1564 1574 10.1053/j.gastro.2011.01.045 21300064 
101. Anghel S.I.  Wahli W.   Fat poetry: A kingdom for PPAR γ Cell Res. 2007 17 486 511 10.1038/cr.2007.48 17563755 
102. Auwerx J.   Nuclear receptors. I. PPAR γ in the gastrointestinal tract: Gain or pain? Am. J. Physiol. Gastrointest. Liver Physiol. 2002 282 G581 G585 10.1152/ajpgi.00508.2001 11897616 
103. Dubuquoy L.  Rousseaux C.  Thuru X.  Peyrin-Biroulet L.  Romano O.  Chavatte P.  Chamaillard M.  Desreumaux P.   PPARγ as a new therapeutic target in inflammatory bowel diseases Gut 2006 55 1341 1349 10.1136/gut.2006.093484 16905700 
104. Leonardini A.  Laviola L.  Perrini S.  Natalicchio A.  Giorgino F.   Cross-Talk between PPARγ and Insulin Signaling and Modulation of Insulin Sensitivity PPAR Res. 2009 2009 818945 10.1155/2009/818945 20182551 
105. Tontonoz P.  Spiegelman B.M.   Fat and beyond: The diverse biology of PPARγ Annu. Rev. Biochem. 2008 77 289 312 10.1146/annurev.biochem.77.061307.091829 18518822 
106. Escher P.  Braissant O.  Basu-Modak S.  Michalik L.  Wahli W.  Desvergne B.   Rat PPARs: Quantitative analysis in adult rat tissues and regulation in fasting and refeeding Endocrinology 2001 142 4195 4202 10.1210/endo.142.10.8458 11564675 
107. Harmon G.S.  Dumlao D.S.  Ng D.T.  Barrett K.E.  Dennis E.A.  Dong H.  Glass C.K.   Pharmacological correction of a defect in PPAR-γ signaling ameliorates disease severity in Cftr-deficient mice Nat. Med. 2010 16 313 318 10.1038/nm.2101 20154695 
108. Mansen A.  Guardiola-Diaz H.  Rafter J.  Branting C.  Gustafsson J.A.   Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa Biochem. Biophys. Res. Commun. 1996 222 844 851 10.1006/bbrc.1996.0832 8651933 
109. Marion-Letellier R.  Dechelotte P.  Iacucci M.  Ghosh S.   Dietary modulation of peroxisome proliferator-activated receptor γ Gut 2009 58 586 593 10.1136/gut.2008.162859 19017686 
110. Schwab M.  Reynders V.  Loitsch S.  Steinhilber D.  Stein J.  Schroder O.   Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF κ B signalling Mol. Immunol. 2007 44 3625 3632 10.1016/j.molimm.2007.04.010 17521736 
111. Wachtershauser A.  Loitsch S.M.  Stein J.   PPAR-γ is selectively upregulated in Caco-2 cells by butyrate Biochem. Biophys. Res. Commun. 2000 272 380 385 10.1006/bbrc.2000.2793 10833422 
112. Nepelska M.  de Wouters T.  Jacouton E.  Beguet-Crespel F.  Lapaque N.  Dore J.  Arulampalam V.  Blottiere H.M.   Commensal gut bacteria modulate phosphorylation-dependent PPARγ transcriptional activity in human intestinal epithelial cells Sci. Rep. 2017 7 43199 10.1038/srep43199 28266623 
113. Voltan S.  Martines D.  Elli M.  Brun P.  Longo S.  Porzionato A.  Macchi V.  D’Inca R.  Scarpa M.  Palu G.    Lactobacillus crispatus M247-derived H2 O2  acts as a signal transducing molecule activating peroxisome proliferator activated receptor-γ in the intestinal mucosa Gastroenterology 2008 135 1216 1227 10.1053/j.gastro.2008.07.007 18722375 
114. Are A.  Aronsson L.  Wang S.  Greicius G.  Lee Y.K.  Gustafsson J.A.  Pettersson S.  Arulampalam V.   Enterococcus faecalis from newborn babies regulate endogenous PPARγ activity and IL-10 levels in colonic epithelial cells Proc. Natl. Acad. Sci. USA 2008 105 1943 1948 10.1073/pnas.0711734105 18234854 
115. Couvigny B.  de Wouters T.  Kaci G.  Jacouton E.  Delorme C.  Dore J.  Renault P.  Blottiere H.M.  Guedon E.  Lapaque N.   Commensal Streptococcus salivarius Modulates PPARγ Transcriptional Activity in Human Intestinal Epithelial Cells PLoS ONE 2015 10 e0125371 10.1371/journal.pone.0125371 25946041 
116. Murakami M.  Tognini P.  Liu Y.  Eckel-Mahan K.L.  Baldi P.  Sassone-Corsi P.   Gut microbiota directs PPARγ-driven reprogramming of the liver circadian clock by nutritional challenge EMBO Rep. 2016 17 1292 1303 10.15252/embr.201642463 27418314 
117. Cerbone A.  Toaldo C.  Laurora S.  Briatore F.  Pizzimenti S.  Dianzani M.U.  Ferretti C.  Barrera G.   4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells Free Radic. Biol. Med. 2007 42 1661 1670 10.1016/j.freeradbiomed.2007.02.009 17462534 
118. Martinasso G.  Oraldi M.  Trombetta A.  Maggiora M.  Bertetto O.  Canuto R.A.  Muzio G.   Involvement of PPARs in Cell Proliferation and Apoptosis in Human Colon Cancer Specimens and in Normal and Cancer Cell Lines PPAR Res. 2007 2007 93416 10.1155/2007/93416 17389773 
119. Theocharis S.  Margeli A.  Vielh P.  Kouraklis G.   Peroxisome proliferator-activated receptor-γ ligands as cell-cycle modulators Cancer Treat. Rev. 2004 30 545 554 10.1016/j.ctrv.2004.04.004 15325034 
120. Xu W.P.  Zhang X.  Xie W.F.   Differentiation therapy for solid tumors J. Dig. Dis. 2014 15 159 165 10.1111/1751-2980.12122 24373518 
121. Chen G.G.  Lee J.F.  Wang S.H.  Chan U.P.  Ip P.C.  Lau W.Y.   Apoptosis induced by activation of peroxisome-proliferator activated receptor-γ is associated with Bcl-2 and NF-κB in human colon cancer Life Sci. 2002 70 2631 2646 10.1016/S0024-3205(02)01510-2 12269390 
122. Chen G.G.  Xu H.  Lee J.F.  Subramaniam M.  Leung K.L.  Wang S.H.  Chan U.P.  Spelsberg T.C.   15-hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor γ-dependent pathway Int. J. Cancer 2003 107 837 843 10.1002/ijc.11447 14566836 
123. Lee C.J.  Han J.S.  Seo C.Y.  Park T.H.  Kwon H.C.  Jeong J.S.  Kim I.H.  Yun J.  Bae Y.S.  Kwak J.Y.    Pioglitazone, a synthetic ligand for PPARγ, induces apoptosis in RB-deficient human colorectal cancer cells Apoptosis 2006 11 401 411 10.1007/s10495-006-4003-z 16520894 
124. Sharma C.  Pradeep A.  Wong L.  Rana A.  Rana B.   Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway J. Biol. Chem. 2004 279 35583 35594 10.1074/jbc.M403143200 15190077 
125. Lewis J.D.  Lichtenstein G.R.  Deren J.J.  Sands B.E.  Hanauer S.B.  Katz J.A.  Lashner B.  Present D.H.  Chuai S.  Ellenberg J.H.    Rosiglitazone for active ulcerative colitis: A randomized placebo-controlled trial Gastroenterology 2008 134 688 695 10.1053/j.gastro.2007.12.012 18325386 
126. Lewis J.D.  Lichtenstein G.R.  Stein R.B.  Deren J.J.  Judge T.A.  Fogt F.  Furth E.E.  Demissie E.J.  Hurd L.B.  Su C.G.    An open-label trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis Am. J. Gastroenterol. 2001 96 3323 3328 11774944 
127. Liang H.L.  Ouyang Q.   A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis World J. Gastroenterol. 2008 14 114 119 10.3748/wjg.14.114 18176972 
128. Bassaganya-Riera J.  Hontecillas R.   CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD Clin. Nutr. 2006 25 454 465 10.1016/j.clnu.2005.12.008 16698153 
129. Hontecillas R.  Wannemeulher M.J.  Zimmerman D.R.  Hutto D.L.  Wilson J.H.  Ahn D.U.  Bassaganya-Riera J.   Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid J. Nutr. 2002 132 2019 2027 10.1093/jn/132.7.2019 12097686 
130. Sanchez-Hidalgo M.  Martin A.R.  Villegas I.  de la Lastra C.A.   Rosiglitazone, a PPARγ ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats Eur. J. Pharmacol. 2007 562 247 258 10.1016/j.ejphar.2007.01.047 17343846 
131. Sato N.  Kozar R.A.  Zou L.  Weatherall J.M.  Attuwaybi B.  Moore-Olufemi S.D.  Weisbrodt N.W.  Moore F.A.   Peroxisome proliferator-activated receptor γ mediates protection against cyclooxygenase-2-induced gut dysfunction in a rodent model of mesenteric ischemia/reperfusion Shock 2005 24 462 469 10.1097/01.shk.0000183483.76972.ae 16247333 
132. Saubermann L.J.  Nakajima A.  Wada K.  Zhao S.  Terauchi Y.  Kadowaki T.  Aburatani H.  Matsuhashi N.  Nagai R.  Blumberg R.S.   Peroxisome proliferator-activated receptor γ agonist ligands stimulate a Th2 cytokine response and prevent acute colitis Inflamm. Bowel Dis. 2002 8 330 339 10.1097/00054725-200209000-00004 12479648 
133. Su C.G.  Wen X.  Bailey S.T.  Jiang W.  Rangwala S.M.  Keilbaugh S.A.  Flanigan A.  Murthy S.  Lazar M.A.  Wu G.D.   A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response J. Clin. Investig. 1999 104 383 389 10.1172/JCI7145 10449430 
134. Kundu P.  Ling T.W.  Korecka A.  Li Y.  D’Arienzo R.  Bunte R.M.  Berger T.  Arulampalam V.  Chambon P.  Mak T.W.    Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway PLoS Pathog. 2014 10 e1003887 10.1371/journal.ppat.1003887 24465207 
135. Michalik L.  Wahli W.   PPARs Mediate Lipid Signaling in Inflammation and Cancer PPAR Res. 2008 2008 134059 10.1155/2008/134059 19125181 
136. Shah Y.M.  Morimura K.  Gonzalez F.J.   Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitis Am. J. Physiol. Gastrointest. Liver Physiol. 2007 292 G657 G666 10.1152/ajpgi.00381.2006 17095756 
137. Leung E.  Hong J.  Fraser A.  Merriman T.  Krissansen G.   PPAR-γ and Crohn’s disease in New Zealand Gastroenterology 2006 130 2249 2250 10.1053/j.gastro.2006.04.053 16762656 
138. Wada K.  Nakajima A.  Blumberg R.S.   PPARγ and inflammatory bowel disease: A new therapeutic target for ulcerative colitis and Crohn’s disease Trends Mol. Med. 2001 7 329 331 10.1016/S1471-4914(01)02076-7 11516972 
139. Yasui Y.  Hosokawa M.  Sahara T.  Suzuki R.  Ohgiya S.  Kohno H.  Tanaka T.  Miyashita K.   Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARγ in human colon cancer Caco-2 cells Prostaglandins Leukot. Essent. Fatty Acids 2005 73 113 119 10.1016/j.plefa.2005.04.013 15961301 
140. Akinyeke T.O.  Stewart L.V.   Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARγ-independent mechanism Cancer Biol. Ther. 2011 11 1046 1058 10.4161/cbt.11.12.15709 21525782 
141. Yang W.L.  Frucht H.   Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells Carcinogenesis 2001 22 1379 1383 10.1093/carcin/22.9.1379 11532858 
142. Subbaramaiah K.  Lin D.T.  Hart J.C.  Dannenberg A.J.   Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300 J. Biol. Chem. 2001 276 12440 12448 10.1074/jbc.M007237200 11278336 
143. Vandoros G.P.  Konstantinopoulos P.A.  Sotiropoulou-Bonikou G.  Kominea A.  Papachristou G.I.  Karamouzis M.V.  Gkermpesi M.  Varakis I.  Papavassiliou A.G.   PPAR-γ is expressed and NF-kB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas J. Cancer Res. Clin. Oncol. 2006 132 76 84 10.1007/s00432-005-0042-z 16215757 
144. Girnun G.D.  Smith W.M.  Drori S.  Sarraf P.  Mueller E.  Eng C.  Nambiar P.  Rosenberg D.W.  Bronson R.T.  Edelmann W.    APC-dependent suppression of colon carcinogenesis by PPARγ Proc. Natl. Acad. Sci. USA 2002 99 13771 13776 10.1073/pnas.162480299 12370429 
145. Fujisawa T.  Nakajima A.  Fujisawa N.  Takahashi H.  Ikeda I.  Tomimoto A.  Yonemitsu K.  Nakajima N.  Kudo C.  Wada K.    Peroxisome proliferator-activated receptor γ (PPARγ) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the β-catenin/T cell factor (TCF) pathway J. Pharmacol. Sci. 2008 106 627 638 10.1254/jphs.FP0071766 18391483 
146. Peyrin-Biroulet L.  Beisner J.  Wang G.  Nuding S.  Oommen S.T.  Kelly D.  Parmentier-Decrucq E.  Dessein R.  Merour E.  Chavatte P.    Peroxisome proliferator-activated receptor γ activation is required for maintenance of innate antimicrobial immunity in the colon Proc. Natl. Acad. Sci. USA 2010 107 8772 8777 10.1073/pnas.0905745107 20421464 
147. Duszka K.  Oresic M.  Le May C.  Konig J.  Wahli W.   PPARγ Modulates Long Chain Fatty Acid Processing in the Intestinal Epithelium Int. J. Mol. Sci. 2017 18 2559 10.3390/ijms18122559 29182565 
148. Duszka K.  Picard A.  Ellero-Simatos S.  Chen J.  Defernez M.  Paramalingam E.  Pigram A.  Vanoaica L.  Canlet C.  Parini P.    Intestinal PPARγ signalling is required for sympathetic nervous system activation in response to caloric restriction Sci. Rep. 2016 6 36937 10.1038/srep36937 27853235 
149. Parseus A.  Sommer N.  Sommer F.  Caesar R.  Molinaro A.  Stahlman M.  Greiner T.U.  Perkins R.  Backhed F.   Microbiota-induced obesity requires farnesoid X receptor Gut 2017 66 429 437 10.1136/gutjnl-2015-310283 26740296 
150. Midtvedt T.   Microbial bile acid transformation Am. J. Clin. Nutr. 1974 27 1341 1347 10.1093/ajcn/27.11.1341 4217103 
151. Begley M.  Gahan C.G.  Hill C.   The interaction between bacteria and bile FEMS Microbiol. Rev. 2005 29 625 651 10.1016/j.femsre.2004.09.003 16102595 
152. Buffie C.G.  Bucci V.  Stein R.R.  McKenney P.T.  Ling L.  Gobourne A.  No D.  Liu H.  Kinnebrew M.  Viale A.    Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile  Nature 2015 517 205 208 10.1038/nature13828 25337874 
153. Inagaki T.  Moschetta A.  Lee Y.K.  Peng L.  Zhao G.  Downes M.  Yu R.T.  Shelton J.M.  Richardson J.A.  Repa J.J.    Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor Proc. Natl. Acad. Sci. USA 2006 103 3920 3925 10.1073/pnas.0509592103 16473946 
154. Kim I.  Ahn S.H.  Inagaki T.  Choi M.  Ito S.  Guo G.L.  Kliewer S.A.  Gonzalez F.J.   Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine J. Lipid Res. 2007 48 2664 2672 10.1194/jlr.M700330-JLR200 17720959 
155. Makishima M.  Okamoto A.Y.  Repa J.J.  Tu H.  Learned R.M.  Luk A.  Hull M.V.  Lustig K.D.  Mangelsdorf D.J.  Shan B.   Identification of a nuclear receptor for bile acids Science 1999 284 1362 1365 10.1126/science.284.5418.1362 10334992 
156. Nguyen A.  Bouscarel B.   Bile acids and signal transduction: Role in glucose homeostasis Cell Signal. 2008 20 2180 2197 10.1016/j.cellsig.2008.06.014 18634871 
157. Lee J.M.  Wagner M.  Xiao R.  Kim K.H.  Feng D.  Lazar M.A.  Moore D.D.   Nutrient-sensing nuclear receptors coordinate autophagy Nature 2014 516 112 115 10.1038/nature13961 25383539 
158. Seok S.  Fu T.  Choi S.E.  Li Y.  Zhu R.  Kumar S.  Sun X.  Yoon G.  Kang Y.  Zhong W.    Transcriptional regulation of autophagy by an FXR-CREB axis Nature 2014 516 108 111 10.1038/nature13949 25383523 
159. Li F.  Jiang C.  Krausz K.W.  Li Y.  Albert I.  Hao H.  Fabre K.M.  Mitchell J.B.  Patterson A.D.  Gonzalez F.J.   Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity Nat. Commun. 2013 4 2384 10.1038/ncomms3384 24064762 
160. Jiang C.  Xie C.  Li F.  Zhang L.  Nichols R.G.  Krausz K.W.  Cai J.  Qi Y.  Fang Z.Z.  Takahashi S.    Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease J. Clin. Investog. 2015 125 386 402 10.1172/JCI76738 25500885 
161. Schmitt J.  Kong B.  Stieger B.  Tschopp O.  Schultze S.M.  Rau M.  Weber A.  Mullhaupt B.  Guo G.L.  Geier A.   Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal Liver Int. 2015 35 1133 1144 10.1111/liv.12456 25156247 
162. Rao A.  Kosters A.  Mells J.E.  Zhang W.  Setchell K.D.  Amanso A.M.  Wynn G.M.  Xu T.  Keller B.T.  Yin H.    Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice Sci. Transl. Med. 2016 8 357ra122 10.1126/scitranslmed.aaf4823 27655848 
163. Raju U.  Levitz M.  Javitt N.B.   Bile acids in human breast cyst fluid: The identification of lithocholic acid J. Clin. Endocrinol. Metab. 1990 70 1030 1034 10.1210/jcem-70-4-1030 2318933 
164. Javitt N.B.  Budai K.  Miller D.G.  Cahan A.C.  Raju U.  Levitz M.   Breast-gut connection: Origin of chenodeoxycholic acid in breast cyst fluid Lancet 1994 343 633 635 10.1016/S0140-6736(94)92635-2 7906811 
165. Swales K.E.  Korbonits M.  Carpenter R.  Walsh D.T.  Warner T.D.  Bishop-Bailey D.   The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression Cancer Res. 2006 66 10120 10126 10.1158/0008-5472.CAN-06-2399 17047076 
166. Inagaki T.  Choi M.  Moschetta A.  Peng L.  Cummins C.L.  McDonald J.G.  Luo G.  Jones S.A.  Goodwin B.  Richardson J.A.    Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis Cell Metab. 2005 2 217 225 10.1016/j.cmet.2005.09.001 16213224 
167. Lundasen T.  Galman C.  Angelin B.  Rudling M.   Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man J. Intern. Med. 2006 260 530 536 10.1111/j.1365-2796.2006.01731.x 17116003 
168. Lin B.C.  Wang M.  Blackmore C.  Desnoyers L.R.   Liver-specific activities of FGF19 require Klotho β J. Biol. Chem. 2007 282 27277 27284 10.1074/jbc.M704244200 17627937 
169. Choi M.  Moschetta A.  Bookout A.L.  Peng L.  Umetani M.  Holmstrom S.R.  Suino-Powell K.  Xu H.E.  Richardson J.A.  Gerard R.D.    Identification of a hormonal basis for gallbladder filling Nat. Med. 2006 12 1253 1255 10.1038/nm1501 17072310 
170. Kurosu H.  Choi M.  Ogawa Y.  Dickson A.S.  Goetz R.  Eliseenkova A.V.  Mohammadi M.  Rosenblatt K.P.  Kliewer S.A.  Kuro-o M.   Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21 J. Biol. Chem. 2007 282 26687 26695 10.1074/jbc.M704165200 17623664 
171. Shin D.J.  Osborne T.F.   FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action J. Biol. Chem. 2009 284 11110 11120 10.1074/jbc.M808747200 19237543 
172. Kir S.  Beddow S.A.  Samuel V.T.  Miller P.  Previs S.F.  Suino-Powell K.  Xu H.E.  Shulman G.I.  Kliewer S.A.  Mangelsdorf D.J.   FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis Science 2011 331 1621 1624 10.1126/science.1198363 21436455 
173. Huang X.  Yang C.  Luo Y.  Jin C.  Wang F.  McKeehan W.L.   FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver Diabetes 2007 56 2501 2510 10.2337/db07-0648 17664243 
174. Potthoff M.J.  Boney-Montoya J.  Choi M.  He T.  Sunny N.E.  Satapati S.  Suino-Powell K.  Xu H.E.  Gerard R.D.  Finck B.N.    FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway Cell Metab. 2011 13 729 738 10.1016/j.cmet.2011.03.019 21641554 
175. Liu S.  Marcelin G.  Blouet C.  Jeong J.H.  Jo Y.H.  Schwartz G.J.  Chua S. Jr.   A gut-brain axis regulating glucose metabolism mediated by bile acids and competitive fibroblast growth factor actions at the hypothalamus Mol. Metab. 2018 8 37 50 10.1016/j.molmet.2017.12.003 29290621 
176. Ryan K.K.  Kohli R.  Gutierrez-Aguilar R.  Gaitonde S.G.  Woods S.C.  Seeley R.J.   Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats Endocrinology 2013 154 9 15 10.1210/en.2012-1891 23183168 
177. Morton G.J.  Matsen M.E.  Bracy D.P.  Meek T.H.  Nguyen H.T.  Stefanovski D.  Bergman R.N.  Wasserman D.H.  Schwartz M.W.   FGF19 action in the brain induces insulin-independent glucose lowering J. Clin. Investig. 2013 123 4799 4808 10.1172/JCI70710 24084738 
178. Lan T.  Morgan D.A.  Rahmouni K.  Sonoda J.  Fu X.  Burgess S.C.  Holland W.L.  Kliewer S.A.  Mangelsdorf D.J.   FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia Cell Metab. 2017 26 709 718.e3 10.1016/j.cmet.2017.09.005 28988823 
179. Zhou X.  Cao L.  Jiang C.  Xie Y.  Cheng X.  Krausz K.W.  Qi Y.  Sun L.  Shah Y.M.  Gonzalez F.J.    PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis Nat. Commun. 2014 5 4573 10.1038/ncomms5573 25183423 
180. Okamura A.  Koyanagi S.  Dilxiat A.  Kusunose N.  Chen J.J.  Matsunaga N.  Shibata S.  Ohdo S.   Bile acid-regulated peroxisome proliferator-activated receptor-α (PPARα) activity underlies circadian expression of intestinal peptide absorption transporter PepT1/Slc15a1 J. Biol. Chem. 2014 289 25296 25305 10.1074/jbc.M114.577023 25016014 
181. Overbergh L.  Stoffels K.  Waer M.  Verstuyf A.  Bouillon R.  Mathieu C.   Immune regulation of 25-hydroxyvitamin d -1α-hydroxylase in human monocytic THP1 cells: Mechanisms of interferon-γ-mediated induction J. Clin. Endocrinol. Metab. 2006 91 3566 3574 10.1210/jc.2006-0678 16787983 
182. Overbergh L.  Decallonne B.  Valckx D.  Verstuyf A.  Depovere J.  Laureys J.  Rutgeerts O.  Saint-Arnaud R.  Bouillon R.  Mathieu C.   Identification and immune regulation of 25-hydroxyvitamin d -1-α-hydroxylase in murine macrophages Clin. Exp. Immunol. 2000 120 139 146 10.1046/j.1365-2249.2000.01204.x 10759775 
183. Segersten U.  Holm P.K.  Bjorklund P.  Hessman O.  Nordgren H.  Binderup L.  Akerstrom G.  Hellman P.  Westin G.   25-Hydroxyvitamin D3  1α-hydroxylase expression in breast cancer and use of non-1α-hydroxylated vitamin D analogue Breast Cancer Res. 2005 7 R980 R986 10.1186/bcr1332 16280049 
184. McCarthy K.  Laban C.  Bustin S.A.  Ogunkolade W.  Khalaf S.  Carpenter R.  Jenkins P.J.   Expression of 25-hydroxyvitamin d -1-α-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue Anticancer Res. 2009 29 155 157 19331145 
185. Tangpricha V.  Flanagan J.N.  Whitlatch L.W.  Tseng C.C.  Chen T.C.  Holt P.R.  Lipkin M.S.  Holick M.F.   25-hydroxyvitamin d -1α-hydroxylase in normal and malignant colon tissue Lancet 2001 357 1673 1674 10.1016/S0140-6736(00)04831-5 11425375 
186. Garland C.F.  Kim J.J.  Mohr S.B.  Gorham E.D.  Grant W.B.  Giovannucci E.L.  Baggerly L.  Hofflich H.  Ramsdell J.W.  Zeng K.    Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D Am. J. Public Health 2014 104 e43 e50 10.2105/AJPH.2014.302034 24922127 
187. Chapuy M.C.  Preziosi P.  Maamer M.  Arnaud S.  Galan P.  Hercberg S.  Meunier P.J.   Prevalence of vitamin D insufficiency in an adult normal population Osteoporos. Int. 1997 7 439 443 10.1007/s001980050030 9425501 
188. Chatterjee M.   Vitamin D and genomic stability Mutat. Res. 2001 475 69 87 10.1016/S0027-5107(01)00080-X 11295155 
189. Schwalfenberg G.K.   A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency Mol. Nutr. Food Res. 2011 55 96 108 10.1002/mnfr.201000174 20824663 
190. Amrein K.  Quraishi S.A.  Litonjua A.A.  Gibbons F.K.  Pieber T.R.  Camargo C.A. Jr.  Giovannucci E.  Christopher K.B.   Evidence for a U-shaped relationship between prehospital vitamin D status and mortality: A cohort study J. Clin. Endocrinol. Metab. 2014 99 1461 1469 10.1210/jc.2013-3481 24423347 
191. Wu-Wong J.R.  Chen Y.W.  Nakane M.  Wolf M.   Differential effects of vitamin d receptor agonists on gene expression in neonatal rat cardiomyocytes Cardiovasc. Drugs Ther. 2011 25 215 222 10.1007/s10557-011-6287-7 21424825 
192. Adachi R.  Honma Y.  Masuno H.  Kawana K.  Shimomura I.  Yamada S.  Makishima M.   Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative J. Lipid Res. 2005 46 46 57 10.1194/jlr.M400294-JLR200 15489543 
193. Haussler M.R.  Haussler C.A.  Bartik L.  Whitfield G.K.  Hsieh J.C.  Slater S.  Jurutka P.W.   Vitamin D receptor: Molecular signaling and actions of nutritional ligands in disease prevention Nutr. Rev. 2008 66 S98 S112 10.1111/j.1753-4887.2008.00093.x 18844852 
194. Moon J.   The role of vitamin D in toxic metal absorption: A review J. Am. Coll. Nutr. 1994 13 559 564 10.1080/07315724.1994.10718447 7706586 
195. Eyles D.W.  Liu P.Y.  Josh P.  Cui X.   Intracellular distribution of the vitamin D receptor in the brain: Comparison with classic target tissues and redistribution with development Neuroscience 2014 268 1 9 10.1016/j.neuroscience.2014.02.042 24607320 
196. Wang Y.  Zhu J.  DeLuca H.F.   Where is the vitamin D receptor? Arch. Biochem. Biophys. 2012 523 123 133 10.1016/j.abb.2012.04.001 22503810 
197. Prufer K.  Veenstra T.D.  Jirikowski G.F.  Kumar R.   Distribution of 1,25-dihydroxyvitamin D3  receptor immunoreactivity in the rat brain and spinal cord J. Chem. Neuroanat. 1999 16 135 145 10.1016/S0891-0618(99)00002-2 10223312 
198. Pardridge W.M.  Sakiyama R.  Coty W.A.   Restricted transport of vitamin D and A derivatives through the rat blood-brain barrier J. Neurochem. 1985 44 1138 1141 10.1111/j.1471-4159.1985.tb08735.x 3838342 
199. Fu G.K.  Lin D.  Zhang M.Y.  Bikle D.D.  Shackleton C.H.  Miller W.L.  Portale A.A.   Cloning of human 25-hydroxyvitamin d -1 α-hydroxylase and mutations causing vitamin D-dependent rickets type 1 Mol. Endocrinol. 1997 11 1961 1970 9415400 
200. Eyles D.W.  Smith S.  Kinobe R.  Hewison M.  McGrath J.J.   Distribution of the vitamin D receptor and 1 α-hydroxylase in human brain J. Chem. Neuroanat. 2005 29 21 30 10.1016/j.jchemneu.2004.08.006 15589699 
201. Du J.  Wei X.  Ge X.  Chen Y.  Li Y.C.   Microbiota-Dependent Induction of Colonic Cyp27b1 Is Associated with Colonic Inflammation: Implications of Locally Produced 1,25-Dihydroxyvitamin D3  in Inflammatory Regulation in the Colon Endocrinology 2017 158 4064 4075 10.1210/en.2017-00578 28938443 
202. Pols T.W.H.  Puchner T.  Korkmaz H.I.  Vos M.  Soeters M.R.  de Vries C.J.M.   Lithocholic acid controls adaptive immune responses by inhibition of Th1 activation through the Vitamin D receptor PLoS ONE 2017 12 e0176715 10.1371/journal.pone.0176715 28493883 
203. He L.  Liu T.  Shi Y.  Tian F.  Hu H.  Deb D.K.  Chen Y.  Bissonnette M.  Li Y.C.   Gut Epithelial Vitamin D Receptor Regulates Microbiota-Dependent Mucosal Inflammation by Suppressing Intestinal Epithelial Cell Apoptosis Endocrinology 2018 159 967 979 10.1210/en.2017-00748 29228157 
204. Chen J.  Waddell A.  Lin Y.D.  Cantorna M.T.   Dysbiosis caused by vitamin D receptor deficiency confers colonization resistance to Citrobacter rodentium through modulation of innate lymphoid cells Mucosal Immunol. 2015 8 618 626 10.1038/mi.2014.94 25315967 
205. Su D.  Nie Y.  Zhu A.  Chen Z.  Wu P.  Zhang L.  Luo M.  Sun Q.  Cai L.  Lai Y.    Vitamin D Signaling through Induction of Paneth Cell Defensins Maintains Gut Microbiota and Improves Metabolic Disorders and Hepatic Steatosis in Animal Models Front. Physiol. 2016 7 498 10.3389/fphys.2016.00498 27895587 
206. Wu S.  Zhang Y.G.  Lu R.  Xia Y.  Zhou D.  Petrof E.O.  Claud E.C.  Chen D.  Chang E.B.  Carmeliet G.    Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis Gut 2015 64 1082 1094 10.1136/gutjnl-2014-307436 25080448 
207. Wang J.  Thingholm L.B.  Skieceviciene J.  Rausch P.  Kummen M.  Hov J.R.  Degenhardt F.  Heinsen F.A.  Ruhlemann M.C.  Szymczak S.    Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota Nat. Genet. 2016 48 1396 1406 10.1038/ng.3695 27723756 
208. Liu P.T.  Stenger S.  Li H.  Wenzel L.  Tan B.H.  Krutzik S.R.  Ochoa M.T.  Schauber J.  Wu K.  Meinken C.    Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response Science 2006 311 1770 1773 10.1126/science.1123933 16497887 
209. Liu P.T.  Stenger S.  Tang D.H.  Modlin R.L.   Cutting edge: Vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin J. Immunol. 2007 179 2060 2063 10.4049/jimmunol.179.4.2060 17675463 
210. Wu S.  Yoon S.  Zhang Y.G.  Lu R.  Xia Y.  Wan J.  Petrof E.O.  Claud E.C.  Chen D.  Sun J.   Vitamin D receptor pathway is required for probiotic protection in colitis Am. J. Physiol. Gastrointest. Liver Physiol. 2015 309 G341 G349 10.1152/ajpgi.00105.2015 26159695 
211. Bora S.A.  Kennett M.J.  Smith P.B.  Patterson A.D.  Cantorna M.T.   Regulation of vitamin D metabolism following disruption of the microbiota using broad spectrum antibiotics J. Nutr. Biochem. 2018 56 65 73 10.1016/j.jnutbio.2018.01.011 29459310 
212. Eyles D.  Brown J.  Mackay-Sim A.  McGrath J.  Feron F.   Vitamin D3  and brain development Neuroscience 2003 118 641 653 10.1016/S0306-4522(03)00040-X 12710973 
213. Jiang P.  Zhang L.H.  Cai H.L.  Li H.D.  Liu Y.P.  Tang M.M.  Dang R.L.  Zhu W.Y.  Xue Y.  He X.   Neurochemical effects of chronic administration of calcitriol in rats Nutrients 2014 6 6048 6059 10.3390/nu6126048 25533012 
214. Smith M.P.  Fletcher-Turner A.  Yurek D.M.  Cass W.A.   Calcitriol protection against dopamine loss induced by intracerebroventricular administration of 6-hydroxydopamine Neurochem. Res. 2006 31 533 539 10.1007/s11064-006-9048-4 16758362 
215. Wang J.Y.  Wu J.N.  Cherng T.L.  Hoffer B.J.  Chen H.H.  Borlongan C.V.  Wang Y.   Vitamin D3  attenuates 6-hydroxydopamine-induced neurotoxicity in rats Brain Res. 2001 904 67 75 10.1016/S0006-8993(01)02450-7 11516412 
216. Nataf S.  Garcion E.  Darcy F.  Chabannes D.  Muller J.Y.  Brachet P.   1,25 Dihydroxyvitamin D3  exerts regional effects in the central nervous system during experimental allergic encephalomyelitis J. Neuropathol. Exp. Neurol. 1996 55 904 914 10.1097/00005072-199608000-00006 8759780 
217. Garcion E.  Sindji L.  Montero-Menei C.  Andre C.  Brachet P.  Darcy F.   Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25-dihydroxyvitamin D3  Glia 1998 22 282 294 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7 9482214 
218. Cannell J.J.   Autism and vitamin D Med. Hypotheses 2008 70 750 759 10.1016/j.mehy.2007.08.016 17920208 
219. Grant W.B.  Soles C.M.   Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism Dermatoendocrinol 2009 1 223 228 10.4161/derm.1.4.9500 20592795 
220. McGrath J.   Hypothesis: Is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr. Res. 1999 40 173 177 10.1016/S0920-9964(99)00052-3 10638855 
221. Kesby J.P.  Burne T.H.  McGrath J.J.  Eyles D.W.   Developmental vitamin D deficiency alters MK 801-induced hyperlocomotion in the adult rat: An animal model of schizophrenia Biol. Psychiatry 2006 60 591 596 10.1016/j.biopsych.2006.02.033 16697353 
222. Kesby J.P.  Cui X.  O’Loan J.  McGrath J.J.  Burne T.H.  Eyles D.W.   Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats Psychopharmacology 2010 208 159 168 10.1007/s00213-009-1717-y 19921153 
223. Munger K.L.  Zhang S.M.  O’Reilly E.  Hernan M.A.  Olek M.J.  Willett W.C.  Ascherio A.   Vitamin D intake and incidence of multiple sclerosis Neurology 2004 62 60 65 10.1212/01.WNL.0000101723.79681.38 14718698 
224. Munger K.L.  Levin L.I.  Hollis B.W.  Howard N.S.  Ascherio A.   Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis JAMA 2006 296 2832 2838 10.1001/jama.296.23.2832 17179460 
225. Evatt M.L.  Delong M.R.  Khazai N.  Rosen A.  Triche S.  Tangpricha V.   Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease Arch. Neurol. 2008 65 1348 1352 10.1001/archneur.65.10.1348 18852350 
226. Hahn M.E.  Karchner S.I.  Shapiro M.A.  Perera S.A.   Molecular evolution of two vertebrate aryl hydrocarbon (dioxin) receptors (AHR1 and AHR2) and the PAS family Proc. Natl. Acad. Sci. USA 1997 94 13743 13748 10.1073/pnas.94.25.13743 9391097 
227. Diani-Moore S.  Ram P.  Li X.  Mondal P.  Youn D.Y.  Sauve A.A.  Rifkind A.B.   Identification of the aryl hydrocarbon receptor target gene TiPARP as a mediator of suppression of hepatic gluconeogenesis by 2,3,7,8-tetrachlorodibenzo-p -dioxin and of nicotinamide as a corrective agent for this effect J. Biol. Chem. 2010 285 38801 38810 10.1074/jbc.M110.131573 20876576 
228. Zhang S.  Qin C.  Safe S.H.   Flavonoids as aryl hydrocarbon receptor agonists/antagonists: Effects of structure and cell context Environ. Health Perspect. 2003 111 1877 1882 10.1289/ehp.6322 14644660 
229. Hammerschmidt-Kamper C.  Biljes D.  Merches K.  Steiner I.  Daldrup T.  Bol-Schoenmakers M.  Pieters R.H.H.  Esser C.   Indole-3-carbinol, a plant nutrient and AhR-Ligand precursor, supports oral tolerance against OVA and improves peanut allergy symptoms in mice PLoS ONE 2017 12 e0180321 10.1371/journal.pone.0180321 28666018 
230. Busbee P.B.  Rouse M.  Nagarkatti M.  Nagarkatti P.S.   Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders Nutr. Rev. 2013 71 353 369 10.1111/nure.12024 23731446 
231. Mezrich J.D.  Fechner J.H.  Zhang X.  Johnson B.P.  Burlingham W.J.  Bradfield C.A.   An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells J. Immunol. 2010 185 3190 3198 10.4049/jimmunol.0903670 20720200 
232. DiNatale B.C.  Murray I.A.  Schroeder J.C.  Flaveny C.A.  Lahoti T.S.  Laurenzana E.M.  Omiecinski C.J.  Perdew G.H.   Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling Toxicol. Sci. 2010 115 89 97 10.1093/toxsci/kfq024 20106948 
233. Hubbard T.D.  Murray I.A.  Bisson W.H.  Lahoti T.S.  Gowda K.  Amin S.G.  Patterson A.D.  Perdew G.H.   Adaptation of the human aryl hydrocarbon receptor to sense microbiota-derived indoles Sci. Rep. 2015 5 12689 10.1038/srep12689 26235394 
234. Jin U.H.  Lee S.O.  Sridharan G.  Lee K.  Davidson L.A.  Jayaraman A.  Chapkin R.S.  Alaniz R.  Safe S.   Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities Mol. Pharmacol. 2014 85 777 788 10.1124/mol.113.091165 24563545 
235. Moura-Alves P.  Fae K.  Houthuys E.  Dorhoi A.  Kreuchwig A.  Furkert J.  Barison N.  Diehl A.  Munder A.  Constant P.    AhR sensing of bacterial pigments regulates antibacterial defence Nature 2014 512 387 392 10.1038/nature13684 25119038 
236. Jin U.H.  Cheng Y.  Park H.  Davidson L.A.  Callaway E.S.  Chapkin R.S.  Jayaraman A.  Asante A.  Allred C.  Weaver E.A.    Short Chain Fatty Acids Enhance Aryl Hydrocarbon (Ah) Responsiveness in Mouse Colonocytes and Caco-2 Human Colon Cancer Cells Sci. Rep. 2017 7 10163 10.1038/s41598-017-10824-x 28860561 
237. Gandhi R.  Kumar D.  Burns E.J.  Nadeau M.  Dake B.  Laroni A.  Kozoriz D.  Weiner H.L.  Quintana F.J.   Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3+  regulatory T cells Nat. Immunol. 2010 11 846 853 10.1038/ni.1915 20676092 
238. Quintana F.J.  Murugaiyan G.  Farez M.F.  Mitsdoerffer M.  Tukpah A.M.  Burns E.J.  Weiner H.L.   An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis Proc. Natl. Acad. Sci. USA 2010 107 20768 20773 10.1073/pnas.1009201107 21068375 
239. Veldhoen M.  Hirota K.  Christensen J.  O’Garra A.  Stockinger B.   Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells J. Exp. Med. 2009 206 43 49 10.1084/jem.20081438 19114668 
240. Veldhoen M.  Hirota K.  Westendorf A.M.  Buer J.  Dumoutier L.  Renauld J.C.  Stockinger B.   The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins Nature 2008 453 106 109 10.1038/nature06881 18362914 
241. Quintana F.J.  Basso A.S.  Iglesias A.H.  Korn T.  Farez M.F.  Bettelli E.  Caccamo M.  Oukka M.  Weiner H.L.   Control of Treg  and TH 17 cell differentiation by the aryl hydrocarbon receptor Nature 2008 453 65 71 10.1038/nature06880 18362915 
242. Duarte J.H.  Di Meglio P.  Hirota K.  Ahlfors H.  Stockinger B.   Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo PLoS ONE 2013 8 e79819 10.1371/journal.pone.0079819 24244565 
243. Nguyen N.T.  Hanieh H.  Nakahama T.  Kishimoto T.   The roles of aryl hydrocarbon receptor in immune responses Int. Immunol. 2013 25 335 343 10.1093/intimm/dxt011 23580432 
244. Stockinger B.  Di Meglio P.  Gialitakis M.  Duarte J.H.   The aryl hydrocarbon receptor: Multitasking in the immune system Annu. Rev. Immunol. 2014 32 403 432 10.1146/annurev-immunol-032713-120245 24655296 
245. Chng S.H.  Kundu P.  Dominguez-Brauer C.  Teo W.L.  Kawajiri K.  Fujii-Kuriyama Y.  Mak T.W.  Pettersson S.   Ablating the aryl hydrocarbon receptor (AhR) in CD11c+ cells perturbs intestinal epithelium development and intestinal immunity Sci. Rep. 2016 6 23820 10.1038/srep23820 27068235 
246. Korecka A.  Dona A.  Lahiri S.  Tett A.J.  Al-Asmakh M.  Braniste V.  D’Arienzo R.  Abbaspour A.  Reichardt N.  Fujii-Kuriyama Y.    Bidirectional communication between the Aryl hydrocarbon Receptor (AhR) and the microbiome tunes host metabolism NPJ Biofilms Microbiomes 2016 2 16014 10.1038/npjbiofilms.2016.14 28721249 
247. Lamas B.  Richard M.L.  Leducq V.  Pham H.P.  Michel M.L.  Da Costa G.  Bridonneau C.  Jegou S.  Hoffmann T.W.  Natividad J.M.    CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands Nat. Med. 2016 22 598 605 10.1038/nm.4102 27158904 
248. Le May C.  Pineau T.  Bigot K.  Kohl C.  Girard J.  Pegorier J.P.   Reduced hepatic fatty acid oxidation in fasting PPARα null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression FEBS Lett. 2000 475 163 166 10.1016/S0014-5793(00)01648-3 10869548 
249. Shaban Z.  Soliman M.  El-Shazly S.  El-Bohi K.  Abdelazeez A.  Kehelo K.  Kim H.S.  Muzandu K.  Ishizuka M.  Kazusaka A.    AhR and PPARα: Antagonistic effects on CYP2B and CYP3A, and additive inhibitory effects on CYP2C11 Xenobiotica 2005 35 51 68 10.1080/00498250400021804 15788368 
250. Lee J.H.  Wada T.  Febbraio M.  He J.  Matsubara T.  Lee M.J.  Gonzalez F.J.  Xie W.   A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis Gastroenterology 2010 139 653 663 10.1053/j.gastro.2010.03.033 20303349 
251. Lu P.  Yan J.  Liu K.  Garbacz W.G.  Wang P.  Xu M.  Ma X.  Xie W.   Activation of aryl hydrocarbon receptor dissociates fatty liver from insulin resistance by inducing fibroblast growth factor 21 Hepatology 2015 61 1908 1919 10.1002/hep.27719 25614121 
252. Remillard R.B.  Bunce N.J.   Linking dioxins to diabetes: Epidemiology and biologic plausibility Environ. Health Perspect. 2002 110 853 858 10.1289/ehp.02110853 12204817 
253. Villard P.H.  Caverni S.  Baanannou A.  Khalil A.  Martin P.G.  Penel C.  Pineau T.  Seree E.  Barra Y.   PPARα transcriptionally induces AhR expression in Caco-2, but represses AhR pro-inflammatory effects Biochem. Biophys. Res. Commun. 2007 364 896 901 10.1016/j.bbrc.2007.10.084 17963696 
254. Fallone F.  Villard P.H.  Decome L.  Seree E.  Meo M.  Chacon C.  Durand A.  Barra Y.  Lacarelle B.   PPARα activation potentiates AhR-induced CYP1A1 expression Toxicology 2005 216 122 128 10.1016/j.tox.2005.07.020 16137816 
255. Dutchak P.A.  Katafuchi T.  Bookout A.L.  Choi J.H.  Yu R.T.  Mangelsdorf D.J.  Kliewer S.A.   Fibroblast growth factor-21 regulates PPARγ activity and the antidiabetic actions of thiazolidinediones Cell 2012 148 556 567 10.1016/j.cell.2011.11.062 22304921 
256. Oishi K.  Tomita T.   Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver Biol. Pharm. Bull. 2011 34 1120 1121 10.1248/bpb.34.1120 21720023 
257. Inagaki T.  Dutchak P.  Zhao G.  Ding X.  Gautron L.  Parameswara V.  Li Y.  Goetz R.  Mohammadi M.  Esser V.    Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21 Cell Metab. 2007 5 415 425 10.1016/j.cmet.2007.05.003 17550777 
258. Liang Q.  Zhong L.  Zhang J.  Wang Y.  Bornstein S.R.  Triggle C.R.  Ding H.  Lam K.S.  Xu A.   FGF21 maintains glucose homeostasis by mediating the cross talk between liver and brain during prolonged fasting Diabetes 2014 63 4064 4075 10.2337/db14-0541 25024372 
259. Coskun T.  Bina H.A.  Schneider M.A.  Dunbar J.D.  Hu C.C.  Chen Y.  Moller D.E.  Kharitonenkov A.   Fibroblast growth factor 21 corrects obesity in mice Endocrinology 2008 149 6018 6027 10.1210/en.2008-0816 18687777 
260. Kharitonenkov A.  Shiyanova T.L.  Koester A.  Ford A.M.  Micanovic R.  Galbreath E.J.  Sandusky G.E.  Hammond L.J.  Moyers J.S.  Owens R.A.    FGF-21 as a novel metabolic regulator J. Clin. Investig. 2005 115 1627 1635 10.1172/JCI23606 15902306 
261. Owen B.M.  Ding X.  Morgan D.A.  Coate K.C.  Bookout A.L.  Rahmouni K.  Kliewer S.A.  Mangelsdorf D.J.   FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss Cell Metab. 2014 20 670 677 10.1016/j.cmet.2014.07.012 25130400 
262. Bookout A.L.  de Groot M.H.  Owen B.M.  Lee S.  Gautron L.  Lawrence H.L.  Ding X.  Elmquist J.K.  Takahashi J.S.  Mangelsdorf D.J.    FGF21 regulates metabolism and circadian behavior by acting on the nervous system Nat. Med. 2013 19 1147 1152 10.1038/nm.3249 23933984 
263. Iroz A.  Montagner A.  Benhamed F.  Levavasseur F.  Polizzi A.  Anthony E.  Regnier M.  Fouche E.  Lukowicz C.  Cauzac M.    A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response Cell Rep. 2017 21 403 416 10.1016/j.celrep.2017.09.065 29020627 
264. Talukdar S.  Owen B.M.  Song P.  Hernandez G.  Zhang Y.  Zhou Y.  Scott W.T.  Paratala B.  Turner T.  Smith A.    FGF21 Regulates Sweet and Alcohol Preference Cell Metab. 2016 23 344 349 10.1016/j.cmet.2015.12.008 26724861 
265. Song P.  Zechner C.  Hernandez G.  Canovas J.  Xie Y.  Sondhi V.  Wagner M.  Stadlbauer V.  Horvath A.  Leber B.    The Hormone FGF21 Stimulates Water Drinking in Response to Ketogenic Diet and Alcohol Cell Metab. 2018 27 1338 1347.e4 10.1016/j.cmet.2018.04.001 29657029 
266. Filbrandt C.R.  Wu Z.  Zlokovic B.  Opanashuk L.  Gasiewicz T.A.   Presence and functional activity of the aryl hydrocarbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes Neurotoxicology 2004 25 605 616 10.1016/j.neuro.2003.08.007 15183014 
267. Jacob A.  Hartz A.M.  Potin S.  Coumoul X.  Yousif S.  Scherrmann J.M.  Bauer B.  Decleves X.   Aryl hydrocarbon receptor-dependent upregulation of Cyp1b1 by TCDD and diesel exhaust particles in rat brain microvessels Fluids Barriers CNS 2011 8 23 10.1186/2045-8118-8-23 21867498 
268. Qin H.  Powell-Coffman J.A.   The Caenorhabditis elegans aryl hydrocarbon receptor, AHR-1, regulates neuronal development Dev. Biol. 2004 270 64 75 10.1016/j.ydbio.2004.02.004 15136141 
269. Huang X.  Powell-Coffman J.A.  Jin Y.   The AHR-1 aryl hydrocarbon receptor and its co-factor the AHA-1 aryl hydrocarbon receptor nuclear translocator specify GABAergic neuron cell fate in C. elegans  Development 2004 131 819 828 10.1242/dev.00959 14757639 
270. Hill A.  Howard C.V.  Strahle U.  Cossins A.   Neurodevelopmental defects in zebrafish (Danio rerio ) at environmentally relevant dioxin (TCDD) concentrations Toxicol. Sci. 2003 76 392 399 10.1093/toxsci/kfg241 14600291 
271. Gohlke J.M.  Stockton P.S.  Sieber S.  Foley J.  Portier C.J.   AhR-mediated gene expression in the developing mouse telencephalon Reprod. Toxicol. 2009 28 321 328 10.1016/j.reprotox.2009.05.067 19465110 
272. Williamson M.A.  Gasiewicz T.A.  Opanashuk L.A.   Aryl hydrocarbon receptor expression and activity in cerebellar granule neuroblasts: Implications for development and dioxin neurotoxicity Toxicol. Sci. 2005 83 340 348 10.1093/toxsci/kfi031 15537747 
273. Kimura E.  Ding Y.  Tohyama C.   AhR signaling activation disrupts migration and dendritic growth of olfactory interneurons in the developing mouse Sci. Rep. 2016 6 26386 10.1038/srep26386 27197834 
274. Latchney S.E.  Hein A.M.  O’Banion M.K.  DiCicco-Bloom E.  Opanashuk L.A.   Deletion or activation of the aryl hydrocarbon receptor alters adult hippocampal neurogenesis and contextual fear memory J. Neurochem. 2013 125 430 445 10.1111/jnc.12130 23240617 
275. Qin H.  Zhai Z.  Powell-Coffman J.A.   The Caenorhabditis elegans AHR-1 transcription complex controls expression of soluble guanylate cyclase genes in the URX neurons and regulates aggregation behavior Dev. Biol. 2006 298 606 615 10.1016/j.ydbio.2006.07.017 16919260 
276. Pocivavsek A.  Wu H.Q.  Elmer G.I.  Bruno J.P.  Schwarcz R.   Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood Eur. J. Neurosci. 2012 35 1605 1612 10.1111/j.1460-9568.2012.08064.x 22515201 
277. Wang X.  Hawkins B.T.  Miller D.S.   Aryl hydrocarbon receptor-mediated up-regulation of ATP-driven xenobiotic efflux transporters at the blood-brain barrier FASEB J. 2011 25 644 652 10.1096/fj.10-169227 21048045 
278. Wang X.  Hawkins B.T.  Miller D.S.   Activating PKC-β1 at the blood-brain barrier reverses induction of P-glycoprotein activity by dioxin and restores drug delivery to the CNS J. Cereb. Blood Flow Metab. 2011 31 1371 1375 10.1038/jcbfm.2011.44 21487415 
279. Braniste V.  Al-Asmakh M.  Kowal C.  Anuar F.  Abbaspour A.  Toth M.  Korecka A.  Bakocevic N.  Ng L.G.  Kundu P.    The gut microbiota influences blood-brain barrier permeability in mice Sci. Transl. Med. 2014 6 263ra158 10.1126/scitranslmed.3009759 25411471 
280. Yu M.  Wang Q.  Ma Y.  Li L.  Yu K.  Zhang Z.  Chen G.  Li X.  Xiao W.  Xu P.    Aryl Hydrocarbon Receptor Activation Modulates Intestinal Epithelial Barrier Function by Maintaining Tight Junction Integrity Int. J. Biol. Sci. 2018 14 69 77 10.7150/ijbs.22259 29483826 
281. Andrysik Z.  Prochazkova J.  Kabatkova M.  Umannova L.  Simeckova P.  Kohoutek J.  Kozubik A.  Machala M.  Vondracek J.   Aryl hydrocarbon receptor-mediated disruption of contact inhibition is associated with connexin43 downregulation and inhibition of gap junctional intercellular communication Arch. Toxicol. 2013 87 491 503 10.1007/s00204-012-0963-7 23085979 
282. Ezan P.  Andre P.  Cisternino S.  Saubamea B.  Boulay A.C.  Doutremer S.  Thomas M.A.  Quenech’du N.  Giaume C.  Cohen-Salmon M.   Deletion of astroglial connexins weakens the blood-brain barrier J. Cereb. Blood Flow Metab. 2012 32 1457 1467 10.1038/jcbfm.2012.45 22472609 
283. Benson J.M.  Shepherd D.M.   Dietary ligands of the aryl hydrocarbon receptor induce anti-inflammatory and immunoregulatory effects on murine dendritic cells Toxicol. Sci. 2011 124 327 338 10.1093/toxsci/kfr249 21948866 
284. Lee Y.H.  Lin C.H.  Hsu P.C.  Sun Y.Y.  Huang Y.J.  Zhuo J.H.  Wang C.Y.  Gan Y.L.  Hung C.C.  Kuan C.Y.    Aryl hydrocarbon receptor mediates both proinflammatory and anti-inflammatory effects in lipopolysaccharide-activated microglia Glia 2015 63 1138 1154 10.1002/glia.22805 25690886 
285. Jung H.J.  Nam K.N.  Son M.S.  Kang H.  Hong J.W.  Kim J.W.  Lee E.H.   Indirubin-3′-oxime inhibits inflammatory activation of rat brain microglia Neurosci. Lett. 2011 487 139 143 10.1016/j.neulet.2010.10.009 20946938 
286. Rothhammer V.  Mascanfroni I.D.  Bunse L.  Takenaka M.C.  Kenison J.E.  Mayo L.  Chao C.C.  Patel B.  Yan R.  Blain M.    Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor Nat. Med. 2016 22 586 597 10.1038/nm.4106 27158906 
287. Sofroniew M.V.   Astrocyte barriers to neurotoxic inflammation Nat. Rev. Neurosci. 2015 16 249 263 10.1038/nrn3898 25891508 
288. Ma Y.  Liu D.   Activation of pregnane X receptor by pregnenolone 16 α-carbonitrile prevents high-fat diet-induced obesity in AKR/J mice PLoS ONE 2012 7 e38734 10.1371/journal.pone.0038734 22723881 
289. Konno Y.  Negishi M.  Kodama S.   The roles of nuclear receptors CAR and PXR in hepatic energy metabolism Drug Metab. Pharmacokinet. 2008 23 8 13 10.2133/dmpk.23.8 18305370 
290. Kliewer S.A.  Goodwin B.  Willson T.M.   The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism Endocr. Rev. 2002 23 687 702 10.1210/er.2001-0038 12372848 
291. Mencarelli A.  Migliorati M.  Barbanti M.  Cipriani S.  Palladino G.  Distrutti E.  Renga B.  Fiorucci S.   Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells Biochem. Pharmacol. 2010 80 1700 1707 10.1016/j.bcp.2010.08.022 20816942 
292. Lamba V.  Yasuda K.  Lamba J.K.  Assem M.  Davila J.  Strom S.  Schuetz E.G.   PXR (NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators Toxicol. Appl. Pharmacol. 2004 199 251 265 10.1016/j.taap.2003.12.027 15364541 
293. Fukuen S.  Fukuda T.  Matsuda H.  Sumida A.  Yamamoto I.  Inaba T.  Azuma J.   Identification of the novel splicing variants for the hPXR in human livers Biochem. Biophys. Res. Commun. 2002 298 433 438 10.1016/S0006-291X(02)02469-5 12413960 
294. Gray M.A.  Pollock C.B.  Schook L.B.  Squires E.J.   Characterization of porcine pregnane X receptor, farnesoid X receptor and their splice variants Exp. Biol. Med. 2010 235 718 736 10.1258/ebm.2010.009339 20511676 
295. Staudinger J.L.  Goodwin B.  Jones S.A.  Hawkins-Brown D.  MacKenzie K.I.  LaTour A.  Liu Y.  Klaassen C.D.  Brown K.K.  Reinhard J.    The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity Proc. Natl. Acad. Sci. USA 2001 98 3369 3374 10.1073/pnas.051551698 11248085 
296. Maglich J.M.  Stoltz C.M.  Goodwin B.  Hawkins-Brown D.  Moore J.T.  Kliewer S.A.   Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification Mol. Pharmacol. 2002 62 638 646 10.1124/mol.62.3.638 12181440 
297. Venkatesh M.  Mukherjee S.  Wang H.  Li H.  Sun K.  Benechet A.P.  Qiu Z.  Maher L.  Redinbo M.R.  Phillips R.S.    Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4 Immunity 2014 41 296 310 10.1016/j.immuni.2014.06.014 25065623 
298. Chrencik J.E.  Orans J.  Moore L.B.  Xue Y.  Peng L.  Collins J.L.  Wisely G.B.  Lambert M.H.  Kliewer S.A.  Redinbo M.R.   Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin Mol. Endocrinol. 2005 19 1125 1134 10.1210/me.2004-0346 15705662 
299. Xie W.  Radominska-Pandya A.  Shi Y.  Simon C.M.  Nelson M.C.  Ong E.S.  Waxman D.J.  Evans R.M.   An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids Proc. Natl. Acad. Sci. USA 2001 98 3375 3380 10.1073/pnas.051014398 11248086 
300. Javitt N.B.   Cholestasis in rats induced by taurolithocholate Nature 1966 210 1262 1263 10.1038/2101262a0 5967804 
301. Selye H.   Prevention by catatoxic steroids of lithocholic acid-induced biliary concrements in the rat Proc. Soc. Exp. Biol. Med. 1972 141 555 558 10.3181/00379727-141-36821 4636522 
302. Dring M.M.  Goulding C.A.  Trimble V.I.  Keegan D.  Ryan A.W.  Brophy K.M.  Smyth C.M.  Keeling P.W.  O’Donoghue D.  O’Sullivan M.    The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease Gastroenterology 2006 130 341 348 10.1053/j.gastro.2005.12.008 16472590 
303. Garg A.  Zhao A.  Erickson S.L.  Mukherjee S.  Lau A.J.  Alston L.  Chang T.K.  Mani S.  Hirota S.A.   Pregnane X Receptor Activation Attenuates Inflammation-Associated Intestinal Epithelial Barrier Dysfunction by Inhibiting Cytokine-Induced Myosin Light-Chain Kinase Expression and c-Jun N-Terminal Kinase 1/2 Activation J. Pharmacol. Exp. Ther. 2016 359 91 101 10.1124/jpet.116.234096 27440420 
304. Terc J.  Hansen A.  Alston L.  Hirota S.A.   Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis Eur. J. Pharm. Sci. 2014 55 12 19 10.1016/j.ejps.2014.01.007 24486481 
305. Mencarelli A.  Renga B.  Palladino G.  Claudio D.  Ricci P.  Distrutti E.  Barbanti M.  Baldelli F.  Fiorucci S.   Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells Eur. J. Pharmacol. 2011 668 317 324 10.1016/j.ejphar.2011.06.058 21806984 
306. Dou W.  Zhang J.  Zhang E.  Sun A.  Ding L.  Chou G.  Wang Z.  Mani S.   Chrysin ameliorates chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling pathway J. Pharmacol. Exp. Ther. 2013 345 473 482 10.1124/jpet.112.201863 23536316 
307. Boussadia B.  Lakhal L.  Payrastre L.  Ghosh C.  Pascussi J.M.  Gangarossa G.  Marchi N.   Pregnane X Receptor Deletion Modifies Recognition Memory and Electroencephalographic Activity Neuroscience 2018 370 130 138 10.1016/j.neuroscience.2017.07.038 28743453 
308. Bauer B.  Yang X.  Hartz A.M.  Olson E.R.  Zhao R.  Kalvass J.C.  Pollack G.M.  Miller D.S.   In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation Mol. Pharmacol. 2006 70 1212 1219 10.1124/mol.106.023796 16837625 
309. Pascussi J.M.  Busson-Le Coniat M.  Maurel P.  Vilarem M.J.   Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: Identification of a distal glucocorticoid response element Mol. Endocrinol. 2003 17 42 55 10.1210/me.2002-0244 12511605 
310. Patel R.D.  Hollingshead B.D.  Omiecinski C.J.  Perdew G.H.   Aryl-hydrocarbon receptor activation regulates constitutive androstane receptor levels in murine and human liver Hepatology 2007 46 209 218 10.1002/hep.21671 17596880 
311. Ding X.  Lichti K.  Kim I.  Gonzalez F.J.  Staudinger J.L.   Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor α, and the coactivator peroxisome proliferator-activated receptor γ coactivator-1α J. Biol. Chem. 2006 281 26540 26551 10.1074/jbc.M600931200 16825189 
312. Mutoh S.  Sobhany M.  Moore R.  Perera L.  Pedersen L.  Sueyoshi T.  Negishi M.   Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling Sci. Signal. 2013 6 ra31 10.1126/scisignal.2003705 23652203 
313. Lundin A.  Bok C.M.  Aronsson L.  Bjorkholm B.  Gustafsson J.A.  Pott S.  Arulampalam V.  Hibberd M.  Rafter J.  Pettersson S.   Gut flora, Toll-like receptors and nuclear receptors: A tripartite communication that tunes innate immunity in large intestine Cell. Microbiol. 2008 10 1093 1103 10.1111/j.1462-5822.2007.01108.x 18088401 
314. Assenat E.  Gerbal-Chaloin S.  Larrey D.  Saric J.  Fabre J.M.  Maurel P.  Vilarem M.J.  Pascussi J.M.   Interleukin 1β inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance Hepatology 2004 40 951 960 10.1002/hep.20387 15382119 
315. Kawamoto T.  Kakizaki S.  Yoshinari K.  Negishi M.   Estrogen activation of the nuclear orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene Mol. Endocrinol. 2000 14 1897 1905 10.1210/mend.14.11.0547 11075820 
316. Banerjee M.  Robbins D.  Chen T.   Modulation of xenobiotic receptors by steroids Molecules 2013 18 7389 7406 10.3390/molecules18077389 23884115 
317. Bjorkholm B.  Bok C.M.  Lundin A.  Rafter J.  Hibberd M.L.  Pettersson S.   Intestinal microbiota regulate xenobiotic metabolism in the liver PLoS ONE 2009 4 e6958 10.1371/journal.pone.0006958 19742318 
318. Kawamoto T.  Sueyoshi T.  Zelko I.  Moore R.  Washburn K.  Negishi M.   Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene Mol. Cell. Biol. 1999 19 6318 6322 10.1128/MCB.19.9.6318 10454578 
319. Honkakoski P.  Zelko I.  Sueyoshi T.  Negishi M.   The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene Mol. Cell. Biol. 1998 18 5652 5658 10.1128/MCB.18.10.5652 9742082 
320. Auerbach S.S.  Ramsden R.  Stoner M.A.  Verlinde C.  Hassett C.  Omiecinski C.J.   Alternatively spliced isoforms of the human constitutive androstane receptor Nucleic Acids Res. 2003 31 3194 3207 10.1093/nar/gkg419 12799447 
321. Koyano S.  Kurose K.  Saito Y.  Ozawa S.  Hasegawa R.  Komamura K.  Ueno K.  Kamakura S.  Kitakaze M.  Nakajima T.    Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): One variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region Drug Metab. Dispos. 2004 32 149 154 10.1124/dmd.32.1.149 14709632 
322. Lamba J.K.  Lamba V.  Yasuda K.  Lin Y.S.  Assem M.  Thompson E.  Strom S.  Schuetz E.   Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences J. Pharmacol. Exp. Ther. 2004 311 811 821 10.1124/jpet.104.069310 15194709 
323. Lin Y.S.  Yasuda K.  Assem M.  Cline C.  Barber J.  Li C.W.  Kholodovych V.  Ai N.  Chen J.D.  Welsh W.J.    The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation Drug Metab. Dispos. 2009 37 1295 1304 10.1124/dmd.108.025213 19251824 
324. Wallace B.D.  Redinbo M.R.   Xenobiotic-sensing nuclear receptors involved in drug metabolism: A structural perspective Drug Metab. Rev. 2013 45 79 100 10.3109/03602532.2012.740049 23210723 
325. Dussault I.  Lin M.  Hollister K.  Fan M.  Termini J.  Sherman M.A.  Forman B.M.   A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity Mol. Cell. Biol. 2002 22 5270 5280 10.1128/MCB.22.15.5270-5280.2002 12101224 
326. Jyrkkarinne J.  Windshugel B.  Ronkko T.  Tervo A.J.  Kublbeck J.  Lahtela-Kakkonen M.  Sippl W.  Poso A.  Honkakoski P.   Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship J. Med. Chem. 2008 51 7181 7192 10.1021/jm800731b 18983136 
327. Yoshinari K.  Kobayashi K.  Moore R.  Kawamoto T.  Negishi M.   Identification of the nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 2A in response to phenobarbital FEBS Lett. 2003 548 17 20 10.1016/S0014-5793(03)00720-8 12885400 
328. Chen S.  Wang K.  Wan Y.J.   Retinoids activate RXR/CAR-mediated pathway and induce CYP3A Biochem. Pharmacol. 2010 79 270 276 10.1016/j.bcp.2009.08.012 19686701 
329. Koike C.  Moore R.  Negishi M.   Localization of the nuclear receptor CAR at the cell membrane of mouse liver FEBS Lett. 2005 579 6733 6736 10.1016/j.febslet.2005.10.070 16310787 
330. Moore L.B.  Parks D.J.  Jones S.A.  Bledsoe R.K.  Consler T.G.  Stimmel J.B.  Goodwin B.  Liddle C.  Blanchard S.G.  Willson T.M.    Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands J. Biol. Chem. 2000 275 15122 15127 10.1074/jbc.M001215200 10748001 
331. Goodwin B.  Hodgson E.  D’Costa D.J.  Robertson G.R.  Liddle C.   Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor Mol. Pharmacol. 2002 62 359 365 10.1124/mol.62.2.359 12130689 
332. Wortham M.  Czerwinski M.  He L.  Parkinson A.  Wan Y.J.   Expression of constitutive androstane receptor, hepatic nuclear factor 4 α, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver Drug Metab. Dispos. 2007 35 1700 1710 10.1124/dmd.107.016436 17576804 
333. Wang H.  Faucette S.  Sueyoshi T.  Moore R.  Ferguson S.  Negishi M.  LeCluyse E.L.   A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression J. Biol. Chem. 2003 278 14146 14152 10.1074/jbc.M212482200 12571232 
334. Ueda A.  Hamadeh H.K.  Webb H.K.  Yamamoto Y.  Sueyoshi T.  Afshari C.A.  Lehmann J.M.  Negishi M.   Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital Mol. Pharmacol. 2002 61 1 6 10.1124/mol.61.1.1 11752199 
335. Ferguson S.S.  LeCluyse E.L.  Negishi M.  Goldstein J.A.   Regulation of human CYP2C9 by the constitutive androstane receptor: Discovery of a new distal binding site Mol. Pharmacol. 2002 62 737 746 10.1124/mol.62.3.737 12181452 
336. Gerbal-Chaloin S.  Daujat M.  Pascussi J.M.  Pichard-Garcia L.  Vilarem M.J.  Maurel P.   Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor J. Biol. Chem. 2002 277 209 217 10.1074/jbc.M107228200 11679585 
337. Sugatani J.  Kojima H.  Ueda A.  Kakizaki S.  Yoshinari K.  Gong Q.H.  Owens I.S.  Negishi M.  Sueyoshi T.   The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR Hepatology 2001 33 1232 1238 10.1053/jhep.2001.24172 11343253 
338. Gao J.  He J.  Zhai Y.  Wada T.  Xie W.   The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity J. Biol. Chem. 2009 284 25984 25992 10.1074/jbc.M109.016808 19617349 
339. Yarushkin A.A.  Kachaylo E.M.  Pustylnyak V.O.   The constitutive androstane receptor activator 4-[(4R ,6R )-4,6-diphenyl-1,3-dioxan-2-yl]-N ,N -dimethylaniline inhibits the gluconeogenic genes PEPCK and G6Pase through the suppression of HNF4α and FOXO1 transcriptional activity Br. J. Pharmacol. 2013 168 1923 1932 10.1111/bph.12090 23231652 
340. Kachaylo E.M.  Yarushkin A.A.  Pustylnyak V.O.   Constitutive androstane receptor activation by 2,4,6-triphenyldioxane-1,3 suppresses the expression of the gluconeogenic genes Eur. J. Pharmacol. 2012 679 139 143 10.1016/j.ejphar.2012.01.007 22296760 
341. Roth A.  Looser R.  Kaufmann M.  Blattler S.M.  Rencurel F.  Huang W.  Moore D.D.  Meyer U.A.   Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive androstane receptor and pregnane X receptor increase Insig-1 expression Mol. Pharmacol. 2008 73 1282 1289 10.1124/mol.107.041012 18187584 
342. Nakamura K.  Moore R.  Negishi M.  Sueyoshi T.   Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver J. Biol. Chem. 2007 282 9768 9776 10.1074/jbc.M610072200 17267396 
343. Maglich J.M.  Watson J.  McMillen P.J.  Goodwin B.  Willson T.M.  Moore J.T.   The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction J. Biol. Chem. 2004 279 19832 19838 10.1074/jbc.M313601200 15004031 
344. Hudson G.M.  Flannigan K.L.  Erickson S.L.  Vicentini F.A.  Zamponi A.  Hirota C.L.  Alston L.  Altier C.  Ghosh S.  Rioux K.P.    Constitutive androstane receptor regulates the intestinal mucosal response to injury Br. J. Pharmacol. 2017 174 1857 1871 10.1111/bph.13787 28320072 
345. Boussadia B.  Gangarossa G.  Mselli-Lakhal L.  Rousset M.C.  de Bock F.  Lassere F.  Ghosh C.  Pascussi J.M.  Janigro D.  Marchi N.   Lack of CAR impacts neuronal function and cerebrovascular integrity in vivo Exp. Neurol. 2016 283 39 48 10.1016/j.expneurol.2016.05.018 27240521 
346. Litwa E.  Rzemieniec J.  Wnuk A.  Lason W.  Krzeptowski W.  Kajta M.   RXRα, PXR and CAR xenobiotic receptors mediate the apoptotic and neurotoxic actions of nonylphenol in mouse hippocampal cells J. Steroid Biochem. Mol. Biol. 2016 156 43 52 10.1016/j.jsbmb.2015.11.018 26643981 
347. Du Z.H.  Xia J.  Sun X.C.  Li X.N.  Zhang C.  Zhao H.S.  Zhu S.Y.  Li J.L.   A novel nuclear xenobiotic receptors (AhR/PXR/CAR)-mediated mechanism of DEHP-induced cerebellar toxicity in quails (Coturnix japonica) via disrupting CYP enzyme system homeostasis Environ. Pollut. 2017 226 435 443 10.1016/j.envpol.2017.04.015 28413083 
348. Chung S.  Son G.H.  Kim K.   Circadian rhythm of adrenal glucocorticoid: Its regulation and clinical implications Biochim. Biophys. Acta 2011 1812 581 591 10.1016/j.bbadis.2011.02.003 21320597 
349. Van Cauter E.  Blackman J.D.  Roland D.  Spire J.P.  Refetoff S.  Polonsky K.S.   Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep J. Clin. Investig. 1991 88 934 942 10.1172/JCI115396 1885778 
350. Czeisler C.A.  Klerman E.B.   Circadian and sleep-dependent regulation of hormone release in humans Recent Prog. Horm. Res. 1999 54 97 130 10548874 
351. Smith S.M.  Vale W.W.   The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress Dialogues Clin. Neurosci. 2006 8 383 395 17290797 
352. Thiboutot D.  Jabara S.  McAllister J.M.  Sivarajah A.  Gilliland K.  Cong Z.  Clawson G.   Human skin is a steroidogenic tissue: Steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1) J. Investig. Dermatol. 2003 120 905 914 10.1046/j.1523-1747.2003.12244.x 12787114 
353. Lechner O.  Wiegers G.J.  Oliveira-Dos-Santos A.J.  Dietrich H.  Recheis H.  Waterman M.  Boyd R.  Wick G.   Glucocorticoid production in the murine thymus Eur. J. Immunol. 2000 30 337 346 10.1002/1521-4141(200002)30:2<337::AID-IMMU337>3.0.CO;2-L 10671188 
354. Pazirandeh A.  Xue Y.  Rafter I.  Sjovall J.  Jondal M.  Okret S.   Paracrine glucocorticoid activity produced by mouse thymic epithelial cells FASEB J. 1999 13 893 901 10.1096/fasebj.13.8.893 10224232 
355. Takeda Y.  Miyamori I.  Yoneda T.  Iki K.  Hatakeyama H.  Blair I.A.  Hsieh F.Y.  Takeda R.   Synthesis of corticosterone in the vascular wall Endocrinology 1994 135 2283 2286 10.1210/endo.135.5.7956952 7956952 
356. Hostettler N.  Bianchi P.  Gennari-Moser C.  Kassahn D.  Schoonjans K.  Corazza N.  Brunner T.   Local glucocorticoid production in the mouse lung is induced by immune cell stimulation Allergy 2012 67 227 234 10.1111/j.1398-9995.2011.02749.x 22111694 
357. Gomez-Sanchez C.E.  Zhou M.Y.  Cozza E.N.  Morita H.  Eddleman F.C.  Gomez-Sanchez E.P.   Corticosteroid synthesis in the central nervous system Endocr. Res. 1996 22 463 470 10.1080/07435809609043732 8969897 
358. Mueller M.  Cima I.  Noti M.  Fuhrer A.  Jakob S.  Dubuquoy L.  Schoonjans K.  Brunner T.   The nuclear receptor LRH-1 critically regulates extra-adrenal glucocorticoid synthesis in the intestine J. Exp. Med. 2006 203 2057 2062 10.1084/jem.20060357 16923850 
359. Cima I.  Corazza N.  Dick B.  Fuhrer A.  Herren S.  Jakob S.  Ayuni E.  Mueller C.  Brunner T.   Intestinal epithelial cells synthesize glucocorticoids and regulate T cell activation J. Exp. Med. 2004 200 1635 1646 10.1084/jem.20031958 15596520 
360. Morris D.J.  Ridlon J.M.   Glucocorticoids and gut bacteria: “The GALF Hypothesis” in the metagenomic era Steroids 2017 125 1 13 10.1016/j.steroids.2017.06.002 28624548 
361. Kuo T.  McQueen A.  Chen T.C.  Wang J.C.   Regulation of Glucose Homeostasis by Glucocorticoids Adv. Exp. Med. Biol. 2015 872 99 126 26215992 
362. Sapolsky R.M.  Romero L.M.  Munck A.U.   How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions Endocr. Rev. 2000 21 55 89 10.1210/er.21.1.55 10696570 
363. Barnes P.J.   Anti-inflammatory actions of glucocorticoids: Molecular mechanisms Clin. Sci. 1998 94 557 572 10.1042/cs0940557 9854452 
364. Vegiopoulos A.  Herzig S.   Glucocorticoids, metabolism and metabolic diseases Mol. Cell. Endocrinol. 2007 275 43 61 10.1016/j.mce.2007.05.015 17624658 
365. McEwen B.S.  De Kloet E.R.  Rostene W.   Adrenal steroid receptors and actions in the nervous system Physiol. Rev. 1986 66 1121 1188 10.1152/physrev.1986.66.4.1121 3532143 
366. Spencer R.L.  Young E.A.  Choo P.H.  McEwen B.S.   Adrenal steroid type I and type II receptor binding: Estimates of in vivo receptor number, occupancy, and activation with varying level of steroid Brain Res. 1990 514 37 48 10.1016/0006-8993(90)90433-C 2357528 
367. Morimoto M.  Morita N.  Ozawa H.  Yokoyama K.  Kawata M.   Distribution of glucocorticoid receptor immunoreactivity and mRNA in the rat brain: An immunohistochemical and in situ hybridization study Neurosci. Res. 1996 26 235 269 10.1016/S0168-0102(96)01105-4 9121734 
368. Reul J.M.  de Kloet E.R.   Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation Endocrinology 1985 117 2505 2511 10.1210/endo-117-6-2505 2998738 
369. Encio I.J.  Detera-Wadleigh S.D.   The genomic structure of the human glucocorticoid receptor J. Biol. Chem. 1991 266 7182 7188 1707881 
370. Hollenberg S.M.  Weinberger C.  Ong E.S.  Cerelli G.  Oro A.  Lebo R.  Thompson E.B.  Rosenfeld M.G.  Evans R.M.   Primary structure and expression of a functional human glucocorticoid receptor cDNA Nature 1985 318 635 641 10.1038/318635a0 2867473 
371. Beger C.  Gerdes K.  Lauten M.  Tissing W.J.  Fernandez-Munoz I.  Schrappe M.  Welte K.   Expression and structural analysis of glucocorticoid receptor isoform γ in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach Br. J. Haematol. 2003 122 245 252 10.1046/j.1365-2141.2003.04426.x 12846893 
372. Lu N.Z.  Cidlowski J.A.   Translational regulatory mechanisms generate N-terminal glucocorticoid receptor isoforms with unique transcriptional target genes Mol. Cell 2005 18 331 342 10.1016/j.molcel.2005.03.025 15866175 
373. Kumar R.  Calhoun W.J.   Differential regulation of the transcriptional activity of the glucocorticoid receptor through site-specific phosphorylation Biologics 2008 2 845 854 10.2147/BTT.S3820 19707462 
374. Ito K.  Yamamura S.  Essilfie-Quaye S.  Cosio B.  Ito M.  Barnes P.J.  Adcock I.M.   Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression J. Exp. Med. 2006 203 7 13 10.1084/jem.20050466 16380507 
375. Duma D.  Jewell C.M.  Cidlowski J.A.   Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification J. Steroid Biochem. Mol. Biol. 2006 102 11 21 10.1016/j.jsbmb.2006.09.009 17070034 
376. Grad I.  Picard D.   The glucocorticoid responses are shaped by molecular chaperones Mol. Cell. Endocrinol. 2007 275 2 12 10.1016/j.mce.2007.05.018 17628337 
377. Pratt W.B.  Toft D.O.   Steroid receptor interactions with heat shock protein and immunophilin chaperones Endocr. Rev. 1997 18 306 360 10.1210/er.18.3.306 9183567 
378. Beato M.   Gene regulation by steroid hormones Cell 1989 56 335 344 10.1016/0092-8674(89)90237-7 2644044 
379. Freedman L.P.   Anatomy of the steroid receptor zinc finger region Endocr. Rev. 1992 13 129 145 10.1210/edrv-13-2-129 1618160 
380. Revollo J.R.  Cidlowski J.A.   Mechanisms generating diversity in glucocorticoid receptor signaling Ann. N. Y. Acad. Sci. 2009 1179 167 178 10.1111/j.1749-6632.2009.04986.x 19906239 
381. Surjit M.  Ganti K.P.  Mukherji A.  Ye T.  Hua G.  Metzger D.  Li M.  Chambon P.   Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor Cell 2011 145 224 241 10.1016/j.cell.2011.03.027 21496643 
382. Adcock I.M.  Nasuhara Y.  Stevens D.A.  Barnes P.J.   Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: Preferential targetting of NF-κB and lack of I-κB involvement Br. J. Pharmacol. 1999 127 1003 1011 10.1038/sj.bjp.0702613 10433509 
383. Scheinman R.I.  Gualberto A.  Jewell C.M.  Cidlowski J.A.  Baldwin A.S. Jr.   Characterization of mechanisms involved in transrepression of NF-κ B by activated glucocorticoid receptors Mol. Cell. Biol. 1995 15 943 953 10.1128/MCB.15.2.943 7823959 
384. Tan C.K.  Wahli W.   A trilogy of glucocorticoid receptor actions Proc. Natl. Acad. Sci. USA 2016 113 1115 1117 10.1073/pnas.1524215113 26792523 
385. Van Rossum E.F.  Lamberts S.W.   Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition Recent Prog. Horm. Res. 2004 59 333 357 10.1210/rp.59.1.333 14749509 
386. Park E.  Lee M.S.  Baik S.M.  Cho E.B.  Son G.H.  Seong J.Y.  Lee K.H.  Kim K.   Nova-1 mediates glucocorticoid-induced inhibition of pre-mRNA splicing of gonadotropin-releasing hormone transcripts J. Biol. Chem. 2009 284 12792 12800 10.1074/jbc.M807386200 19282286 
387. Park O.H.  Do E.  Kim Y.K.   A new function of glucocorticoid receptor: Regulation of mRNA stability BMB Rep. 2015 48 367 368 10.5483/BMBRep.2015.48.7.131 26169194 
388. Smith L.K.  Shah R.R.  Cidlowski J.A.   Glucocorticoids modulate microRNA expression and processing during lymphocyte apoptosis J. Biol. Chem. 2010 285 36698 36708 10.1074/jbc.M110.162123 20847043 
389. Savory J.G.  Prefontaine G.G.  Lamprecht C.  Liao M.  Walther R.F.  Lefebvre Y.A.  Hache R.J.   Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces Mol. Cell. Biol. 2001 21 781 793 10.1128/MCB.21.3.781-793.2001 11154266 
390. Liu W.  Wang J.  Sauter N.K.  Pearce D.   Steroid receptor heterodimerization demonstrated in vitro and in vivo Proc. Natl. Acad. Sci. USA 1995 92 12480 12484 10.1073/pnas.92.26.12480 8618925 
391. Croxtall J.D.  Choudhury Q.  Flower R.J.   Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism Br. J. Pharmacol. 2000 130 289 298 10.1038/sj.bjp.0703272 10807665 
392. Solito E.  Mulla A.  Morris J.F.  Christian H.C.  Flower R.J.  Buckingham J.C.   Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinase Endocrinology 2003 144 1164 1174 12639897 
393. Groeneweg F.L.  Karst H.  de Kloet E.R.  Joels M.   Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signalling Mol. Cell. Endocrinol. 2012 350 299 309 10.1016/j.mce.2011.06.020 21736918 
394. Kadmiel M.  Cidlowski J.A.   Glucocorticoid receptor signaling in health and disease Trends Pharmacol. Sci. 2013 34 518 530 10.1016/j.tips.2013.07.003 23953592 
395. Whirledge S.  DeFranco D.B.   Glucocorticoid Signaling in Health and Disease: Insights from Tissue-Specific GR Knockout Mice Endocrinology 2018 159 46 64 10.1210/en.2017-00728 29029225 
396. Nader N.  Chrousos G.P.  Kino T.   Interactions of the circadian CLOCK system and the HPA axis Trends Endocrinol. Metab. 2010 21 277 286 10.1016/j.tem.2009.12.011 20106676 
397. Grimaldi B.  Nakahata Y.  Sahar S.  Kaluzova M.  Gauthier D.  Pham K.  Patel N.  Hirayama J.  Sassone-Corsi P.   Chromatin remodeling and circadian control: Master regulator CLOCK is an enzyme Cold Spring Harb. Symp. Quant. Biol. 2007 72 105 112 10.1101/sqb.2007.72.049 18419267 
398. Nader N.  Chrousos G.P.  Kino T.   Circadian rhythm transcription factor CLOCK regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge region lysine cluster: Potential physiological implications FASEB J. 2009 23 1572 1583 10.1096/fj.08-117697 19141540 
399. Balsalobre A.  Brown S.A.  Marcacci L.  Tronche F.  Kellendonk C.  Reichardt H.M.  Schutz G.  Schibler U.   Resetting of circadian time in peripheral tissues by glucocorticoid signaling Science 2000 289 2344 2347 10.1126/science.289.5488.2344 11009419 
400. Ramamoorthy S.  Cidlowski J.A.   Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance Endocr. Dev. 2013 24 41 56 23392094 
401. Wiley J.W.  Higgins G.A.  Athey B.D.   Stress and glucocorticoid receptor transcriptional programming in time and space: Implications for the brain-gut axis Neurogastroenterol. Motil. 2016 28 12 25 10.1111/nmo.12706 26690871 
402. Hussain M.M.  Pan X.   Clock genes, intestinal transport and plasma lipid homeostasis Trends Endocrinol. Metab. 2009 20 177 185 10.1016/j.tem.2009.01.001 19349191 
403. Hoogerwerf W.A.  Hellmich H.L.  Cornelissen G.  Halberg F.  Shahinian V.B.  Bostwick J.  Savidge T.C.  Cassone V.M.   Clock gene expression in the murine gastrointestinal tract: Endogenous rhythmicity and effects of a feeding regimen Gastroenterology 2007 133 1250 1260 10.1053/j.gastro.2007.07.009 17919497 
404. Sladek M.  Rybova M.  Jindrakova Z.  Zemanova Z.  Polidarova L.  Mrnka L.  O’Neill J.  Pacha J.  Sumova A.   Insight into the circadian clock within rat colonic epithelial cells Gastroenterology 2007 133 1240 1249 10.1053/j.gastro.2007.05.053 17675004 
405. Pan X.  Hussain M.M.   Clock is important for food and circadian regulation of macronutrient absorption in mice J. Lipid Res. 2009 50 1800 1813 10.1194/jlr.M900085-JLR200 19387090 
406. Thaiss C.A.  Zeevi D.  Levy M.  Zilberman-Schapira G.  Suez J.  Tengeler A.C.  Abramson L.  Katz M.N.  Korem T.  Zmora N.    Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis Cell 2014 159 514 529 10.1016/j.cell.2014.09.048 25417104 
407. Leone V.  Gibbons S.M.  Martinez K.  Hutchison A.L.  Huang E.Y.  Cham C.M.  Pierre J.F.  Heneghan A.F.  Nadimpalli A.  Hubert N.    Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism Cell Host Microbe 2015 17 681 689 10.1016/j.chom.2015.03.006 25891358 
408. Thaiss C.A.  Levy M.  Korem T.  Dohnalova L.  Shapiro H.  Jaitin D.A.  David E.  Winter D.R.  Gury-BenAri M.  Tatirovsky E.    Microbiota Diurnal Rhythmicity Programs Host Transcriptome Oscillations Cell 2016 167 1495 1510.e12 10.1016/j.cell.2016.11.003 27912059 
409. Imai E.  Stromstedt P.E.  Quinn P.G.  Carlstedt-Duke J.  Gustafsson J.A.  Granner D.K.   Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene Mol. Cell. Biol. 1990 10 4712 4719 10.1128/MCB.10.9.4712 2388623 
410. Rauch A.  Seitz S.  Baschant U.  Schilling A.F.  Illing A.  Stride B.  Kirilov M.  Mandic V.  Takacz A.  Schmidt-Ullrich R.    Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor Cell Metab. 2010 11 517 531 10.1016/j.cmet.2010.05.005 20519123 
411. Zou W.  Yang S.  Zhang T.  Sun H.  Wang Y.  Xue H.  Zhou D.   Hypoxia enhances glucocorticoid-induced apoptosis and cell cycle arrest via the PI3K/Akt signaling pathway in osteoblastic cells J. Bone Miner. Metab. 2015 33 615 624 10.1007/s00774-014-0627-1 25230819 
412. Kim H.J.  Zhao H.  Kitaura H.  Bhattacharyya S.  Brewer J.A.  Muglia L.J.  Ross F.P.  Teitelbaum S.L.   Glucocorticoids suppress bone formation via the osteoclast J. Clin. Investig. 2006 116 2152 2160 10.1172/JCI28084 16878176 
413. Lee M.J.  Pramyothin P.  Karastergiou K.  Fried S.K.   Deconstructing the roles of glucocorticoids in adipose tissue biology and the development of central obesity Biochim. Biophys. Acta 2014 1842 473 481 10.1016/j.bbadis.2013.05.029 23735216 
414. Chinenov Y.  Gupte R.  Rogatsky I.   Nuclear receptors in inflammation control: Repression by GR and beyond Mol. Cell. Endocrinol. 2013 380 55 64 10.1016/j.mce.2013.04.006 23623868 
415. Busillo J.M.  Cidlowski J.A.   The five Rs of glucocorticoid action during inflammation: Ready, reinforce, repress, resolve, and restore Trends Endocrinol. Metab. 2013 24 109 119 10.1016/j.tem.2012.11.005 23312823 
416. Faubion W.A. Jr.  Loftus E.V. Jr.  Harmsen W.S.  Zinsmeister A.R.  Sandborn W.J.   The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study Gastroenterology 2001 121 255 260 10.1053/gast.2001.26279 11487534 
417. Howell M.P.  Muglia L.J.   Effects of genetically altered brain glucocorticoid receptor action on behavior and adrenal axis regulation in mice Front. Neuroendocrinol. 2006 27 275 284 10.1016/j.yfrne.2006.05.001 16814372 
418. Kleiman A.  Tuckermann J.P.   Glucocorticoid receptor action in beneficial and side effects of steroid therapy: Lessons from conditional knockout mice Mol. Cell. Endocrinol. 2007 275 98 108 10.1016/j.mce.2007.05.009 17587493 
419. Gallant C.  Kenny P.   Oral glucocorticoids and their complications. A review J. Am. Acad. Dermatol. 1986 14 161 177 10.1016/S0190-9622(86)70018-2 3512634 
420. Heimdal K.  Hirschberg H.  Slettebo H.  Watne K.  Nome O.   High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression J. Neurooncol. 1992 12 141 144 10.1007/BF00172664 1560260 
421. Dinan T.G.  Cryan J.  Shanahan F.  Keeling P.W.  Quigley E.M.   IBS: An epigenetic perspective Nat. Rev. Gastroenterol. Hepatol. 2010 7 465 471 10.1038/nrgastro.2010.99 20585338 
422. Elsenbruch S.   Abdominal pain in Irritable Bowel Syndrome: A review of putative psychological, neural and neuro-immune mechanisms Brain Behav. Immun. 2011 25 386 394 10.1016/j.bbi.2010.11.010 21094682 
423. Mayer E.A.   The neurobiology of stress and gastrointestinal disease Gut 2000 47 861 869 10.1136/gut.47.6.861 11076888 
424. Crofford L.J.  Pillemer S.R.  Kalogeras K.T.  Cash J.M.  Michelson D.  Kling M.A.  Sternberg E.M.  Gold P.W.  Chrousos G.P.  Wilder R.L.   Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia Arthritis Rheum. 1994 37 1583 1592 10.1002/art.1780371105 7980669 
425. Johnson E.O.  Vlachoyiannopoulos P.G.  Skopouli F.N.  Tzioufas A.G.  Moutsopoulos H.M.   Hypofunction of the stress axis in Sjogren’s syndrome J. Rheumatol. 1998 25 1508 1514 9712092 
426. Buske-Kirschbaum A.  Jobst S.  Wustmans A.  Kirschbaum C.  Rauh W.  Hellhammer D.   Attenuated free cortisol response to psychosocial stress in children with atopic dermatitis Psychosom. Med. 1997 59 419 426 10.1097/00006842-199707000-00012 9251162 
427. Nanthakumar N.N.  Meng D.  Newburg D.S.   Glucocorticoids and microbiota regulate ontogeny of intestinal fucosyltransferase 2 requisite for gut homeostasis Glycobiology 2013 23 1131 1141 10.1093/glycob/cwt050 23887940 
428. Reichardt S.D.  Foller M.  Rexhepaj R.  Pathare G.  Minnich K.  Tuckermann J.P.  Lang F.  Reichardt H.M.   Glucocorticoids enhance intestinal glucose uptake via the dimerized glucocorticoid receptor in enterocytes Endocrinology 2012 153 1783 1794 10.1210/en.2011-1747 22294744 
429. Thiesen A.  Wild G.E.  Tappenden K.A.  Drozdowski L.  Keelan M.  Thomson B.K.  McBurney M.I.  Clandinin M.T.  Thomson A.B.   The locally acting glucocorticosteroid budesonide enhances intestinal sugar uptake following intestinal resection in rats Gut 2003 52 252 259 10.1136/gut.52.2.252 12524409 
430. Boivin M.A.  Ye D.  Kennedy J.C.  Al-Sadi R.  Shepela C.  Ma T.Y.   Mechanism of glucocorticoid regulation of the intestinal tight junction barrier Am. J. Physiol. Gastrointest. Liver Physiol. 2007 292 G590 G598 10.1152/ajpgi.00252.2006 17068119 
431. Lu L.  Li T.  Williams G.  Petit E.  Borowsky M.  Walker W.A.   Hydrocortisone induces changes in gene expression and differentiation in immature human enterocytes Am. J. Physiol. Gastrointest. Liver Physiol. 2011 300 G425 G432 10.1152/ajpgi.00011.2010 21148402 
432. Filaretova L.P.  Filaretov A.A.  Makara G.B.   Corticosterone increase inhibits stress-induced gastric erosions in rats Am. J. Physiol. 1998 274 G1024 G1030 10.1152/ajpgi.1998.274.6.G1024 9696701 
433. Vyas A.  Mitra R.  Shankaranarayana Rao B.S.  Chattarji S.   Chronic stress induces contrasting patterns of dendritic remodeling in hippocampal and amygdaloid neurons J. Neurosci. 2002 22 6810 6818 10.1523/JNEUROSCI.22-15-06810.2002 12151561 
434. Stewart M.G.  Davies H.A.  Sandi C.  Kraev I.V.  Rogachevsky V.V.  Peddie C.J.  Rodriguez J.J.  Cordero M.I.  Donohue H.S.  Gabbott P.L.    Stress suppresses and learning induces plasticity in CA3 of rat hippocampus: A three-dimensional ultrastructural study of thorny excrescences and their postsynaptic densities Neuroscience 2005 131 43 54 10.1016/j.neuroscience.2004.10.031 15680690 
435. Watanabe Y.  Gould E.  McEwen B.S.   Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons Brain Res. 1992 588 341 345 10.1016/0006-8993(92)91597-8 1393587 
436. Samarasinghe R.A.  Di Maio R.  Volonte D.  Galbiati F.  Lewis M.  Romero G.  DeFranco D.B.   Nongenomic glucocorticoid receptor action regulates gap junction intercellular communication and neural progenitor cell proliferation Proc. Natl. Acad. Sci. USA 2011 108 16657 16662 10.1073/pnas.1102821108 21930911 
437. Popoli M.  Yan Z.  McEwen B.S.  Sanacora G.   The stressed synapse: The impact of stress and glucocorticoids on glutamate transmission Nat. Rev. Neurosci. 2011 13 22 37 10.1038/nrn3138 22127301 
438. Arango-Lievano M.  Lambert W.M.  Bath K.G.  Garabedian M.J.  Chao M.V.  Jeanneteau F.   Neurotrophic-priming of glucocorticoid receptor signaling is essential for neuronal plasticity to stress and antidepressant treatment Proc. Natl. Acad. Sci. USA 2015 112 15737 15742 10.1073/pnas.1509045112 26630005 
439. Blandino P. Jr.  Barnum C.J.  Deak T.   The involvement of norepinephrine and microglia in hypothalamic and splenic IL-1β responses to stress J. Neuroimmunol. 2006 173 87 95 10.1016/j.jneuroim.2005.11.021 16386803 
440. Emmetsberger J.  Tsirka S.E.   Microglial inhibitory factor (MIF/TKP) mitigates secondary damage following spinal cord injury Neurobiol. Dis. 2012 47 295 309 10.1016/j.nbd.2012.05.001 22613732 
441. Wohleb E.S.  Hanke M.L.  Corona A.W.  Powell N.D.  Stiner L.M.  Bailey M.T.  Nelson R.J.  Godbout J.P.  Sheridan J.F.   β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat J. Neurosci. 2011 31 6277 6288 10.1523/JNEUROSCI.0450-11.2011 21525267 
442. Alexander J.K.  DeVries A.C.  Kigerl K.A.  Dahlman J.M.  Popovich P.G.   Stress exacerbates neuropathic pain via glucocorticoid and NMDA receptor activation Brain Behav. Immun. 2009 23 851 860 10.1016/j.bbi.2009.04.001 19361551 
443. Wang S.  Lim G.  Zeng Q.  Sung B.  Yang L.  Mao J.   Central glucocorticoid receptors modulate the expression and function of spinal NMDA receptors after peripheral nerve injury J. Neurosci. 2005 25 488 495 10.1523/JNEUROSCI.4127-04.2005 15647493 
444. Sandi C.  Merino J.J.  Cordero M.I.  Touyarot K.  Venero C.   Effects of chronic stress on contextual fear conditioning and the hippocampal expression of the neural cell adhesion molecule, its polysialylation, and L1 Neuroscience 2001 102 329 339 10.1016/S0306-4522(00)00484-X 11166119 
445. Dubovsky A.N.  Arvikar S.  Stern T.A.  Axelrod L.   The neuropsychiatric complications of glucocorticoid use: Steroid psychosis revisited Psychosomatics 2012 53 103 115 10.1016/j.psym.2011.12.007 22424158 
446. Weaver I.C.  Cervoni N.  Champagne F.A.  D’Alessio A.C.  Sharma S.  Seckl J.R.  Dymov S.  Szyf M.  Meaney M.J.   Epigenetic programming by maternal behavior Nat. Neurosci. 2004 7 847 854 10.1038/nn1276 15220929 
447. Liu D.  Diorio J.  Tannenbaum B.  Caldji C.  Francis D.  Freedman A.  Sharma S.  Pearson D.  Plotsky P.M.  Meaney M.J.   Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress Science 1997 277 1659 1662 10.1126/science.277.5332.1659 9287218 
448. Caldji C.  Tannenbaum B.  Sharma S.  Francis D.  Plotsky P.M.  Meaney M.J.   Maternal care during infancy regulates the development of neural systems mediating the expression of fearfulness in the rat Proc. Natl. Acad. Sci. USA 1998 95 5335 5340 10.1073/pnas.95.9.5335 9560276 
449. Dinan T.G.  Scott L.V.   Anatomy of melancholia: Focus on hypothalamic-pituitary-adrenal axis overactivity and the role of vasopressin J. Anat. 2005 207 259 264 10.1111/j.1469-7580.2005.00443.x 16185250 
450. de Kloet C.S.  Vermetten E.  Geuze E.  Kavelaars A.  Heijnen C.J.  Westenberg H.G.   Assessment of HPA-axis function in posttraumatic stress disorder: Pharmacological and non-pharmacological challenge tests, a review J. Psychiatr. Res. 2006 40 550 567 10.1016/j.jpsychires.2005.08.002 16214171 
451. Schechter D.S.  Moser D.A.  Paoloni-Giacobino A.  Stenz L.  Gex-Fabry M.  Aue T.  Adouan W.  Cordero M.I.  Suardi F.  Manini A.    Methylation of NR3C1 is related to maternal PTSD, parenting stress and maternal medial prefrontal cortical activity in response to child separation among mothers with histories of violence exposure Front. Psychol. 2015 6 690 10.3389/fpsyg.2015.00690 26074844 
452. Webster M.J.  Knable M.B.  O’Grady J.  Orthmann J.  Weickert C.S.   Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders Mol. Psychiatry 2002 7 985 994 10.1038/sj.mp.4001139 12399952 
453. Bailey M.T.   Influence of stressor-induced nervous system activation on the intestinal microbiota and the importance for immunomodulation Adv. Exp. Med. Biol. 2014 817 255 276 24997038 
454. Bailey M.T.  Dowd S.E.  Galley J.D.  Hufnagle A.R.  Allen R.G.  Lyte M.   Exposure to a social stressor alters the structure of the intestinal microbiota: Implications for stressor-induced immunomodulation Brain Behav. Immun. 2011 25 397 407 10.1016/j.bbi.2010.10.023 21040780 
455. Bharwani A.  Mian M.F.  Foster J.A.  Surette M.G.  Bienenstock J.  Forsythe P.   Structural & functional consequences of chronic psychosocial stress on the microbiome & host Psychoneuroendocrinology 2016 63 217 227 26479188 
456. De Palma G.  Blennerhassett P.  Lu J.  Deng Y.  Park A.J.  Green W.  Denou E.  Silva M.A.  Santacruz A.  Sanz Y.    Microbiota and host determinants of behavioural phenotype in maternally separated mice Nat. Commun. 2015 6 7735 10.1038/ncomms8735 26218677 
457. De Palma G.  Collins S.M.  Bercik P.  Verdu E.F.   The microbiota-gut-brain axis in gastrointestinal disorders: Stressed bugs, stressed brain or both? J. Physiol. 2014 592 2989 2997 10.1113/jphysiol.2014.273995 24756641 
458. Moloney R.D.  Desbonnet L.  Clarke G.  Dinan T.G.  Cryan J.F.   The microbiome: Stress, health and disease Mamm. Genome 2014 25 49 74 10.1007/s00335-013-9488-5 24281320 
459. Bridgewater L.C.  Zhang C.  Wu Y.  Hu W.  Zhang Q.  Wang J.  Li S.  Zhao L.   Gender-based differences in host behavior and gut microbiota composition in response to high fat diet and stress in a mouse model Sci. Rep. 2017 7 10776 10.1038/s41598-017-11069-4 28883460 
460. Huang E.Y.  Inoue T.  Leone V.A.  Dalal S.  Touw K.  Wang Y.  Musch M.W.  Theriault B.  Higuchi K.  Donovan S.    Using corticosteroids to reshape the gut microbiome: Implications for inflammatory bowel diseases Inflamm. Bowel Dis. 2015 21 963 972 10.1097/MIB.0000000000000332 25738379 
461. Unsal H.  Balkaya M.  Unsal C.  Biyik H.  Basbulbul G.  Poyrazoglu E.   The short-term effects of different doses of dexamethasone on the numbers of some bacteria in the ileum Dig. Dis. Sci. 2008 53 1842 1845 10.1007/s10620-007-0089-6 18049898 
462. Forsythe P.  Kunze W.A.  Bienenstock J.   On communication between gut microbes and the brain Curr. Opin. Gastroenterol. 2012 28 557 562 10.1097/MOG.0b013e3283572ffa 23010679 
463. Ait-Belgnaoui A.  Durand H.  Cartier C.  Chaumaz G.  Eutamene H.  Ferrier L.  Houdeau E.  Fioramonti J.  Bueno L.  Theodorou V.   Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats Psychoneuroendocrinology 2012 37 1885 1895 10.1016/j.psyneuen.2012.03.024 22541937 
464. Burokas A.  Arboleya S.  Moloney R.D.  Peterson V.L.  Murphy K.  Clarke G.  Stanton C.  Dinan T.G.  Cryan J.F.   Targeting the Microbiota-Gut-Brain Axis: Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice Biol. Psychiatry 2017 82 472 487 10.1016/j.biopsych.2016.12.031 28242013 
465. Gareau M.G.  Jury J.  MacQueen G.  Sherman P.M.  Perdue M.H.   Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation Gut 2007 56 1522 1528 10.1136/gut.2006.117176 17339238 
466. Hawkins U.A.  Gomez-Sanchez E.P.  Gomez-Sanchez C.M.  Gomez-Sanchez C.E.   The ubiquitous mineralocorticoid receptor: Clinical implications Curr. Hypertens. Rep. 2012 14 573 580 10.1007/s11906-012-0297-0 22843494 
467. Herman J.P.  Patel P.D.  Akil H.  Watson S.J.   Localization and regulation of glucocorticoid and mineralocorticoid receptor messenger RNAs in the hippocampal formation of the rat Mol. Endocrinol. 1989 3 1886 1894 10.1210/mend-3-11-1886 2558306 
468. Vallee S.M.  Grillo C.A.  Gonzalez S.  Cosen-Binker L.  de Kloet E.R.  McEwen B.S.  De Nicola A.F.   Further studies in deoxycorticosterone acetate treated rats: Brain content of mineralocorticoid and glucocorticoid receptors and effect of steroid antagonists on salt intake Neuroendocrinology 1995 61 117 124 10.1159/000126832 7753331 
469. Turner B.B.   Sex difference in glucocorticoid binding in rat pituitary is estrogen dependent Life Sci. 1990 46 1399 1406 10.1016/0024-3205(90)90340-W 2161067 
470. Castren M.  Patchev V.K.  Almeida O.F.  Holsboer F.  Trapp T.  Castren E.   Regulation of rat mineralocorticoid receptor expression in neurons by progesterone Endocrinology 1995 136 3800 3806 10.1210/endo.136.9.7649087 7649087 
471. Zennaro M.C.  Le Menuet D.  Lombes M.   Characterization of the human mineralocorticoid receptor gene 5′-regulatory region: Evidence for differential hormonal regulation of two alternative promoters via nonclassical mechanisms Mol. Endocrinol. 1996 10 1549 1560 8961265 
472. Wang J.  Li X.  Ke Y.  Lu Y.  Wang F.  Fan N.  Sun H.  Zhang H.  Liu R.  Yang J.    GPR48 increases mineralocorticoid receptor gene expression J. Am. Soc. Nephrol. 2012 23 281 293 10.1681/ASN.2011040351 22135314 
473. Kwak S.P.  Patel P.D.  Thompson R.C.  Akil H.  Watson S.J.   5′-Heterogeneity of the mineralocorticoid receptor messenger ribonucleic acid: Differential expression and regulation of splice variants within the rat hippocampus Endocrinology 1993 133 2344 2350 10.1210/endo.133.5.8404687 8404687 
474. Zennaro M.C.  Keightley M.C.  Kotelevtsev Y.  Conway G.S.  Soubrier F.  Fuller P.J.   Human mineralocorticoid receptor genomic structure and identification of expressed isoforms J. Biol. Chem. 1995 270 21016 21020 10.1074/jbc.270.36.21016 7673127 
475. Hesen W.  Karst H.  Meijer O.  Cole T.J.  Schmid W.  de Kloet E.R.  Schutz G.  Joels M.   Hippocampal cell responses in mice with a targeted glucocorticoid receptor gene disruption J. Neurosci. 1996 16 6766 6774 10.1523/JNEUROSCI.16-21-06766.1996 8824317 
476. Karst H.  Wadman W.J.  Joels M.   Corticosteroid receptor-dependent modulation of calcium currents in rat hippocampal CA1 neurons Brain Res. 1994 649 234 242 10.1016/0006-8993(94)91069-3 7953638 
477. Kerr D.S.  Campbell L.W.  Thibault O.  Landfield P.W.   Hippocampal glucocorticoid receptor activation enhances voltage-dependent Ca2+  conductances: Relevance to brain aging Proc. Natl. Acad. Sci. USA 1992 89 8527 8531 10.1073/pnas.89.18.8527 1528857 
478. Caprio M.  Feve B.  Claes A.  Viengchareun S.  Lombes M.  Zennaro M.C.   Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis FASEB J. 2007 21 2185 2194 10.1096/fj.06-7970com 17384139 
479. Marzolla V.  Armani A.  Zennaro M.C.  Cinti F.  Mammi C.  Fabbri A.  Rosano G.M.  Caprio M.   The role of the mineralocorticoid receptor in adipocyte biology and fat metabolism Mol. Cell. Endocrinol. 2012 350 281 288 10.1016/j.mce.2011.09.011 21945603 
480. Gomez-Sanchez E.P.  Gomez-Sanchez C.E.   Central regulation of blood pressure by the mineralocorticoid receptor Mol. Cell. Endocrinol. 2012 350 289 298 10.1016/j.mce.2011.05.005 21664417 
481. Harris A.P.  Holmes M.C.  de Kloet E.R.  Chapman K.E.  Seckl J.R.   Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour Psychoneuroendocrinology 2013 38 648 658 10.1016/j.psyneuen.2012.08.007 22980941 
482. De Kloet E.R.  Vreugdenhil E.  Oitzl M.S.  Joels M.   Brain corticosteroid receptor balance in health and disease Endocr. Rev. 1998 19 269 301 10.1210/er.19.3.269 9626555 
483. Ou X.M.  Storring J.M.  Kushwaha N.  Albert P.R.   Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene J. Biol. Chem. 2001 276 14299 14307 10.1074/jbc.M005363200 11278286 
484. Arriza J.L.  Weinberger C.  Cerelli G.  Glaser T.M.  Handelin B.L.  Housman D.E.  Evans R.M.   Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor Science 1987 237 268 275 10.1126/science.3037703 3037703 
485. Ackermann D.  Gresko N.  Carrel M.  Loffing-Cueni D.  Habermehl D.  Gomez-Sanchez C.  Rossier B.C.  Loffing J.   In vivo nuclear translocation of mineralocorticoid and glucocorticoid receptors in rat kidney: Differential effect of corticosteroids along the distal tubule Am. J. Physiol. Renal Physiol. 2010 299 F1473 F1485 10.1152/ajprenal.00437.2010 20861076 
486. Fuller P.J.  Brennan F.E.  Burgess J.S.   Acute differential regulation by corticosteroids of epithelial sodium channel subunit and Nedd4 mRNA levels in the distal colon Pflugers Arch. 2000 441 94 101 10.1007/s004240000366 11205067 
487. Lastra-Gonzalez G.  Manrique-Acevedo C.  Sowers J.R.   The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: An update Curr. Diabetes Rep. 2008 8 203 207 10.1007/s11892-008-0035-9 
488. Zennaro M.C.  Caprio M.  Feve B.   Mineralocorticoid receptors in the metabolic syndrome Trends Endocrinol. Metab. 2009 20 444 451 10.1016/j.tem.2009.05.006 19800255 
489. Vogt B.  Burnier M.   Aldosterone and cardiovascular risk Curr. Hypertens. Rep. 2009 11 450 455 10.1007/s11906-009-0076-8 19895757 
490. Tirosh A.  Garg R.  Adler G.K.   Mineralocorticoid receptor antagonists and the metabolic syndrome Curr. Hypertens. Rep. 2010 12 252 257 10.1007/s11906-010-0126-2 20563672 
491. Cheskis B.J.   Regulation of cell signalling cascades by steroid hormones J. Cell Biochem. 2004 93 20 27 10.1002/jcb.20180 15352158 
492. Grossmann C.  Gekle M.   New aspects of rapid aldosterone signaling Mol. Cell. Endocrinol. 2009 308 53 62 10.1016/j.mce.2009.02.005 19549592 
493. Grossmann C.  Gekle M.   Non-classical actions of the mineralocorticoid receptor: Misuse of EGF receptors? Mol. Cell. Endocrinol. 2007 277 6 12 10.1016/j.mce.2007.07.001 17692454 
494. Funder J.W.   Non-genomic actions of aldosterone: Role in hypertension Curr. Opin Nephrol. Hypertens. 2001 10 227 230 10.1097/00041552-200103000-00011 11224698 
495. Huang S.  Zhang A.  Ding G.  Chen R.   Aldosterone-induced mesangial cell proliferation is mediated by EGF receptor transactivation Am. J. Physiol. Renal Physiol. 2009 296 F1323 F1333 10.1152/ajprenal.90428.2008 19339632 
496. Krug A.W.  Schuster C.  Gassner B.  Freudinger R.  Mildenberger S.  Troppmair J.  Gekle M.   Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling J. Biol. Chem. 2002 277 45892 45897 10.1074/jbc.M208851200 12244120 
497. Michea L.  Delpiano A.M.  Hitschfeld C.  Lobos L.  Lavandero S.  Marusic E.T.   Eplerenone blocks nongenomic effects of aldosterone on the Na+ /H+  exchanger, intracellular Ca2+  levels, and vasoconstriction in mesenteric resistance vessels Endocrinology 2005 146 973 980 10.1210/en.2004-1130 15550504 
498. Krozowski Z.S.  Funder J.W.   Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity Proc. Natl. Acad. Sci. USA 1983 80 6056 6060 10.1073/pnas.80.19.6056 6310613 
499. Veldhuis H.D.  Van Koppen C.  Van Ittersum M.  De Kloet E.R.   Specificity of the adrenal steroid receptor system in rat hippocampus Endocrinology 1982 110 2044 2051 10.1210/endo-110-6-2044 7075547 
500. De Kloet E.R.  Reul J.M.   Feedback action and tonic influence of corticosteroids on brain function: A concept arising from the heterogeneity of brain receptor systems Psychoneuroendocrinology 1987 12 83 105 10.1016/0306-4530(87)90040-0 3037584 
501. Karst H.  Berger S.  Turiault M.  Tronche F.  Schutz G.  Joels M.   Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone Proc. Natl. Acad. Sci. USA 2005 102 19204 19207 10.1073/pnas.0507572102 16361444 
502. Seckl J.R.   11β-hydroxysteroid dehydrogenases: Changing glucocorticoid action Curr. Opin. Pharmacol. 2004 4 597 602 10.1016/j.coph.2004.09.001 15525550 
503. Yang H.  Dou W.  Lou J.  Leng Y.  Shen J.   Discovery of novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling Bioorg. Med. Chem. Lett. 2008 18 1340 1345 10.1016/j.bmcl.2008.01.020 18242087 
504. Zhang Z.H.  Kang Y.M.  Yu Y.  Wei S.G.  Schmidt T.J.  Johnson A.K.  Felder R.B.   11β-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation Hypertension 2006 48 127 133 10.1161/01.HYP.0000224296.96235.dd 16717146 
505. Chen J.  Gomez-Sanchez C.E.  Penman A.  May P.J.  Gomez-Sanchez E.   Expression of mineralocorticoid and glucocorticoid receptors in preautonomic neurons of the rat paraventricular nucleus Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014 306 R328 R340 10.1152/ajpregu.00506.2013 24381176 
506. Geerling J.C.  Loewy A.D.   Aldosterone-sensitive neurons in the nucleus of the solitary tract: Bidirectional connections with the central nucleus of the amygdala J. Comp. Neurol. 2006 497 646 657 10.1002/cne.21019 16739197 
507. Chantong B.  Kratschmar D.V.  Nashev L.G.  Balazs Z.  Odermatt A.   Mineralocorticoid and glucocorticoid receptors differentially regulate NF-κB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells J. Neuroinflamm. 2012 9 260 10.1186/1742-2094-9-260 23190711 
508. Vazquez D.M.  Lopez J.F.  Morano M.I.  Kwak S.P.  Watson S.J.  Akil H.   Alpha, β, and γ mineralocorticoid receptor messenger ribonucleic acid splice variants: Differential expression and rapid regulation in the developing hippocampus Endocrinology 1998 139 3165 3177 10.1210/endo.139.7.6095 9645690 
509. Munier M.  Meduri G.  Viengchareun S.  Leclerc P.  Le Menuet D.  Lombes M.   Regulation of mineralocorticoid receptor expression during neuronal differentiation of murine embryonic stem cells Endocrinology 2010 151 2244 2254 10.1210/en.2009-0753 20207834 
510. Gass P.  Kretz O.  Wolfer D.P.  Berger S.  Tronche F.  Reichardt H.M.  Kellendonk C.  Lipp H.P.  Schmid W.  Schutz G.   Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice EMBO Rep. 2000 1 447 451 10.1093/embo-reports/kvd088 11258486 
511. Brinks V.  van der Mark M.H.  de Kloet E.R.  Oitzl M.S.   Differential MR/GR activation in mice results in emotional states beneficial or impairing for cognition Neural Plast. 2007 2007 90163 10.1155/2007/90163 17710249 
512. Sterlemann V.  Ganea K.  Liebl C.  Harbich D.  Alam S.  Holsboer F.  Muller M.B.  Schmidt M.V.   Long-term behavioral and neuroendocrine alterations following chronic social stress in mice: Implications for stress-related disorders Horm. Behav. 2008 53 386 394 10.1016/j.yhbeh.2007.11.001 18096163 
513. Qi X.R.  Kamphuis W.  Wang S.  Wang Q.  Lucassen P.J.  Zhou J.N.  Swaab D.F.   Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients Psychoneuroendocrinology 2013 38 863 870 10.1016/j.psyneuen.2012.09.014 23137715 
514. Wu T.C.  Chen H.T.  Chang H.Y.  Yang C.Y.  Hsiao M.C.  Cheng M.L.  Chen J.C.   Mineralocorticoid receptor antagonist spironolactone prevents chronic corticosterone induced depression-like behavior Psychoneuroendocrinology 2013 38 871 883 10.1016/j.psyneuen.2012.09.011 23044404 
515. Okuhara D.Y.  Beck S.G.   Corticosteroids alter 5-hydroxytryptamine1A receptor-effector pathway in hippocampal subfield CA3 pyramidal cells J. Pharmacol. Exp. Ther. 1998 284 1227 1233 9495887 
516. Beck S.G.  Choi K.C.  List T.J.  Okuhara D.Y.  Birnsteil S.   Corticosterone alters 5-HT1A receptor-mediated hyperpolarization in area CA1 hippocampal pyramidal neurons Neuropsychopharmacology 1996 14 27 33 10.1016/S0893-133X(96)80056-X 8719027 
517. Anacker C.  Zunszain P.A.  Carvalho L.A.  Pariante C.M.   The glucocorticoid receptor: Pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 2011 36 415 425 10.1016/j.psyneuen.2010.03.007 20399565 
518. Maletic V.  Robinson M.  Oakes T.  Iyengar S.  Ball S.G.  Russell J.   Neurobiology of depression: An integrated view of key findings Int. J. Clin. Pract. 2007 61 2030 2040 10.1111/j.1742-1241.2007.01602.x 17944926 
519. Yagi S.  Akaike M.  Aihara K.  Iwase T.  Yoshida S.  Sumitomo-Ueda Y.  Ikeda Y.  Ishikawa K.  Matsumoto T.  Sata M.   High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension Hypertens. Res. 2011 34 74 78 10.1038/hr.2010.179 20861841 
520. Yau J.L.  Hibberd C.  Noble J.  Seckl J.R.   The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats Brain Res. Mol. Brain Res. 2002 106 117 123 10.1016/S0169-328X(02)00418-7 12393271 
521. Tytherleigh M.Y.  Vedhara K.  Lightman S.L.   Mineralocorticoid and glucocorticoid receptors and their differential effects on memory performance in people with Addison’s disease Psychoneuroendocrinology 2004 29 712 723 10.1016/S0306-4530(03)00103-3 15110920 
522. Yau J.L.  Olsson T.  Morris R.G.  Meaney M.J.  Seckl J.R.   Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: Relationship with spatial learning in young and aged rats Neuroscience 1995 66 571 581 10.1016/0306-4522(94)00612-9 7644021 
523. Yau J.L.  Noble J.  Hibberd C.  Rowe W.B.  Meaney M.J.  Morris R.G.  Seckl J.R.   Chronic treatment with the antidepressant amitriptyline prevents impairments in water maze learning in aging rats J. Neurosci. 2002 22 1436 1442 10.1523/JNEUROSCI.22-04-01436.2002 11850470 
524. Cornelisse S.  Joels M.  Smeets T.   A randomized trial on mineralocorticoid receptor blockade in men: Effects on stress responses, selective attention, and memory Neuropsychopharmacology 2011 36 2720 2728 10.1038/npp.2011.162 21881569 
525. Gruber C.J.  Tschugguel W.  Schneeberger C.  Huber J.C.   Production and actions of estrogens N. Engl. J. Med. 2002 346 340 352 10.1056/NEJMra000471 11821512 
526. Zhu B.T.  Han G.Z.  Shim J.Y.  Wen Y.  Jiang X.R.   Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor α and β subtypes: Insights into the structural determinants favoring a differential subtype binding Endocrinology 2006 147 4132 4150 10.1210/en.2006-0113 16728493 
527. Riant E.  Waget A.  Cogo H.  Arnal J.F.  Burcelin R.  Gourdy P.   Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice Endocrinology 2009 150 2109 2117 10.1210/en.2008-0971 19164473 
528. Carr M.C.   The emergence of the metabolic syndrome with menopause J. Clin. Endocrinol. Metab. 2003 88 2404 2411 10.1210/jc.2003-030242 12788835 
529. Gao Q.  Mezei G.  Nie Y.  Rao Y.  Choi C.S.  Bechmann I.  Leranth C.  Toran-Allerand D.  Priest C.A.  Roberts J.L.    Anorectic estrogen mimics leptin’s effect on the rewiring of melanocortin cells and Stat3 signaling in obese animals Nat. Med. 2007 13 89 94 10.1038/nm1525 17195839 
530. Wren B.G.   The benefits of oestrogen following menopause: Why hormone replacement therapy should be offered to postmenopausal women Med. J. Aust. 2009 190 321 325 19296814 
531. Flores R.  Shi J.  Fuhrman B.  Xu X.  Veenstra T.D.  Gail M.H.  Gajer P.  Ravel J.  Goedert J.J.   Fecal microbial determinants of fecal and systemic estrogens and estrogen metabolites: A cross-sectional study J. Transl. Med. 2012 10 253 10.1186/1479-5876-10-253 23259758 
532. Fuhrman B.J.  Feigelson H.S.  Flores R.  Gail M.H.  Xu X.  Ravel J.  Goedert J.J.   Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women J. Clin. Endocrinol. Metab. 2014 99 4632 4640 10.1210/jc.2014-2222 25211668 
533. Moreno-Indias I.  Sanchez-Alcoholado L.  Sanchez-Garrido M.A.  Martin-Nunez G.M.  Perez-Jimenez F.  Tena-Sempere M.  Tinahones F.J.  Queipo-Ortuno M.I.   Neonatal Androgen Exposure Causes Persistent Gut Microbiota Dysbiosis Related to Metabolic Disease in Adult Female Rats Endocrinology 2016 157 4888 4898 10.1210/en.2016-1317 27700135 
534. Mueller S.  Saunier K.  Hanisch C.  Norin E.  Alm L.  Midtvedt T.  Cresci A.  Silvi S.  Orpianesi C.  Verdenelli M.C.    Differences in fecal microbiota in different European study populations in relation to age, gender, and country: A cross-sectional study Appl. Environ. Microbiol. 2006 72 1027 1033 10.1128/AEM.72.2.1027-1033.2006 16461645 
535. Dominianni C.  Sinha R.  Goedert J.J.  Pei Z.  Yang L.  Hayes R.B.  Ahn J.   Sex, body mass index, and dietary fiber intake influence the human gut microbiome PLoS ONE 2015 10 e0124599 10.1371/journal.pone.0124599 25874569 
536. Yurkovetskiy L.  Burrows M.  Khan A.A.  Graham L.  Volchkov P.  Becker L.  Antonopoulos D.  Umesaki Y.  Chervonsky A.V.   Gender bias in autoimmunity is influenced by microbiota Immunity 2013 39 400 412 10.1016/j.immuni.2013.08.013 23973225 
537. Plottel C.S.  Blaser M.J.   Microbiome and malignancy Cell Host Microbe 2011 10 324 335 10.1016/j.chom.2011.10.003 22018233 
538. Kisiela M.  Skarka A.  Ebert B.  Maser E.   Hydroxysteroid dehydrogenases (HSDs) in bacteria: A bioinformatic perspective J. Steroid Biochem. Mol. Biol. 2012 129 31 46 10.1016/j.jsbmb.2011.08.002 21884790 
539. Raftogianis R.  Creveling C.  Weinshilboum R.  Weisz J.   Estrogen metabolism by conjugation J. Natl. Cancer Inst. Monogr. 2000 2000 113 124 10.1093/oxfordjournals.jncimonographs.a024234 
540. McBain A.J.  Macfarlane G.T.   Ecological and physiological studies on large intestinal bacteria in relation to production of hydrolytic and reductive enzymes involved in formation of genotoxic metabolites J. Med. Microbiol. 1998 47 407 416 10.1099/00222615-47-5-407 9879941 
541. Kwa M.  Plottel C.S.  Blaser M.J.  Adams S.   The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer J. Natl. Cancer Inst. 2016 108 10.1093/jnci/djw029 
542. Reddy B.S.  Weisburger J.H.  Wynder E.L.   Fecal bacterial β-glucuronidase: Control by diet Science 1974 183 416 417 10.1126/science.183.4123.416 4808971 
543. Cenci G.  Caldini G.  Mastrandrea V.  Votoni M.R.   Carbohydrate enriched diets and bacterial glycosidases in rat faeces Microbios 1993 76 143 151 8302195 
544. Eriyamremu G.E.  Osagie V.E.  Alufa O.I.  Osaghae M.O.  Oyibu F.A.   Early biochemical events in mice exposed to cycas and fed a Nigerian-like diet Ann. Nutr. Metab. 1995 39 42 51 10.1159/000177841 7872655 
545. Goldin B.R.  Gorbach S.L.   Alterations of the intestinal microflora by diet, oral antibiotics, and Lactobacillus: Decreased production of free amines from aromatic nitro compounds, azo dyes, and glucuronides J. Natl. Cancer Inst. 1984 73 689 695 6433097 
546. Martin F.  Peltonen J.  Laatikainen T.  Pulkkinen M.  Adlercreutz H.   Excretion of progesterone metabolites and estriol in faeces from pregnant women during ampicillin administration J. Steroid Biochem. 1975 6 1339 1346 10.1016/0022-4731(75)90363-5 1181489 
547. Adlercreutz H.  Martin F.  Tikkanen M.J.  Pulkkinen M.   Effect of ampicillin administration on the excretion of twelve oestrogens in pregnancy urine Acta Endocrinol. 1975 80 551 557 10.1530/acta.0.0800551 1242569 
548. Hamalainen E.  Korpela J.T.  Adlercreutz H.   Effect of oxytetracycline administration on intestinal metabolism of oestrogens and on plasma sex hormones in healthy men Gut 1987 28 439 445 10.1136/gut.28.4.439 3034744 
549. Flint H.J.  Duncan S.H.  Scott K.P.  Louis P.   Interactions and competition within the microbial community of the human colon: Links between diet and health Environ. Microbiol. 2007 9 1101 1111 10.1111/j.1462-2920.2007.01281.x 17472627 
550. Dabek M.  McCrae S.I.  Stevens V.J.  Duncan S.H.  Louis P.   Distribution of β-glucosidase and β-glucuronidase activity and of β-glucuronidase gene gus in human colonic bacteria FEMS Microbiol. Ecol. 2008 66 487 495 10.1111/j.1574-6941.2008.00520.x 18537837 
551. Nakamura J.  Kubota Y.  Miyaoka M.  Saitoh T.  Mizuno F.  Benno Y.   Comparison of four microbial enzymes in Clostridia and Bacteroides isolated from human feces Microbiol. Immunol. 2002 46 487 490 10.1111/j.1348-0421.2002.tb02723.x 12222935 
552. Van Eldere J.R.  De Pauw G.  Eyssen H.J.   Steroid sulfatase activity in a Peptococcus niger strain from the human intestinal microflora Appl. Environ. Microbiol. 1987 53 1655 1660 3477998 
553. Frankenfeld C.L.  Atkinson C.  Wahala K.  Lampe J.W.   Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein Eur. J. Clin. Nutr. 2014 68 526 530 10.1038/ejcn.2014.23 24569543 
554. Nakatsu C.H.  Armstrong A.  Clavijo A.P.  Martin B.R.  Barnes S.  Weaver C.M.   Fecal bacterial community changes associated with isoflavone metabolites in postmenopausal women after soy bar consumption PLoS ONE 2014 9 e108924 10.1371/journal.pone.0108924 25271941 
555. Usui T.  Tochiya M.  Sasaki Y.  Muranaka K.  Yamakage H.  Himeno A.  Shimatsu A.  Inaguma A.  Ueno T.  Uchiyama S.    Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status Clin. Endocrinol. 2013 78 365 372 10.1111/j.1365-2265.2012.04400.x 22469418 
556. Velicer C.M.  Heckbert S.R.  Lampe J.W.  Potter J.D.  Robertson C.A.  Taplin S.H.   Antibiotic use in relation to the risk of breast cancer JAMA 2004 291 827 835 10.1001/jama.291.7.827 14970061 
557. Boursi B.  Mamtani R.  Haynes K.  Yang Y.X.   Recurrent antibiotic exposure may promote cancer formation--Another step in understanding the role of the human microbiota? Eur. J. Cancer 2015 51 2655 2664 10.1016/j.ejca.2015.08.015 26338196 
558. Shimizu K.  Muranaka Y.  Fujimura R.  Ishida H.  Tazume S.  Shimamura T.   Normalization of reproductive function in germfree mice following bacterial contamination Exp. Anim. 1998 47 151 158 10.1538/expanim.47.151 9816490 
559. Green S.  Walter P.  Kumar V.  Krust A.  Bornert J.M.  Argos P.  Chambon P.   Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A Nature 1986 320 134 139 10.1038/320134a0 3754034 
560. Kuiper G.G.  Enmark E.  Pelto-Huikko M.  Nilsson S.  Gustafsson J.A.   Cloning of a novel receptor expressed in rat prostate and ovary Proc. Natl. Acad. Sci. USA 1996 93 5925 5930 10.1073/pnas.93.12.5925 8650195 
561. Kuiper G.G.  Lemmen J.G.  Carlsson B.  Corton J.C.  Safe S.H.  van der Saag P.T.  van der Burg B.  Gustafsson J.A.   Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β Endocrinology 1998 139 4252 4263 10.1210/endo.139.10.6216 9751507 
562. Enmark E.  Pelto-Huikko M.  Grandien K.  Lagercrantz S.  Lagercrantz J.  Fried G.  Nordenskjold M.  Gustafsson J.A.   Human estrogen receptor β-gene structure, chromosomal localization, and expression pattern J. Clin. Endocrinol. Metab. 1997 82 4258 4265 10.1210/jc.82.12.4258 9398750 
563. Sauerwein H.  Pfaffl M.  Hagen-Mann K.  Malucelli A.  Meyer H.H.   Expression of estrogen and androgen receptor in the bovine gastrointestinal tract Dtsch. Tierarztl. Wochenschr. 1995 102 164 168 7555698 
564. Pfaffl M.W.  Lange I.G.  Meyer H.H.   The gastrointestinal tract as target of steroid hormone action: Quantification of steroid receptor mRNA expression (AR, ERα, ERβ and PR) in 10 bovine gastrointestinal tract compartments by kinetic RT-PCR J. Steroid Biochem. Mol. Biol. 2003 84 159 166 10.1016/S0960-0760(03)00025-6 12710999 
565. Singh S.  Sheppard M.C.  Langman M.J.   Sex differences in the incidence of colorectal cancer: An exploration of oestrogen and progesterone receptors Gut 1993 34 611 615 10.1136/gut.34.5.611 8504960 
566. Foley E.F.  Jazaeri A.A.  Shupnik M.A.  Jazaeri O.  Rice L.W.   Selective loss of estrogen receptor β in malignant human colon Cancer Res. 2000 60 245 248 10667568 
567. Hess R.A.  Gist D.H.  Bunick D.  Lubahn D.B.  Farrell A.  Bahr J.  Cooke P.S.  Greene G.L.   Estrogen receptor (α and β) expression in the excurrent ducts of the adult male rat reproductive tract J. Androl. 1997 18 602 611 9432133 
568. Hileman S.M.  Handa R.J.  Jackson G.L.   Distribution of estrogen receptor-β messenger ribonucleic acid in the male sheep hypothalamus Biol. Reprod. 1999 60 1279 1284 10.1095/biolreprod60.6.1279 10330081 
569. Mitra S.W.  Hoskin E.  Yudkovitz J.  Pear L.  Wilkinson H.A.  Hayashi S.  Pfaff D.W.  Ogawa S.  Rohrer S.P.  Schaeffer J.M.    Immunolocalization of estrogen receptor β in the mouse brain: Comparison with estrogen receptor α Endocrinology 2003 144 2055 2067 10.1210/en.2002-221069 12697714 
570. Laflamme N.  Nappi R.E.  Drolet G.  Labrie C.  Rivest S.   Expression and neuropeptidergic characterization of estrogen receptors (ERα and ERβ) throughout the rat brain: Anatomical evidence of distinct roles of each subtype J. Neurobiol. 1998 36 357 378 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V 9733072 
571. Shughrue P.  Scrimo P.  Lane M.  Askew R.  Merchenthaler I.   The distribution of estrogen receptor-β mRNA in forebrain regions of the estrogen receptor-α knockout mouse Endocrinology 1997 138 5649 5652 10.1210/endo.138.12.5712 9389555 
572. Shughrue P.J.  Komm B.  Merchenthaler I.   The distribution of estrogen receptor-β mRNA in the rat hypothalamus Steroids 1996 61 678 681 10.1016/S0039-128X(96)00222-X 8987135 
573. Wang J.M.  Liu L.  Brinton R.D.   Estradiol-17β-induced human neural progenitor cell proliferation is mediated by an estrogen receptor β-phosphorylated extracellularly regulated kinase pathway Endocrinology 2008 149 208 218 10.1210/en.2007-1155 17962344 
574. Li H.  Ding C.  Ding Z.L.  Ling M.  Wang T.  Wang W.  Huang B.   17β-Oestradiol promotes differentiation of human embryonic stem cells into dopamine neurons via cross-talk between insulin-like growth factors-1 and oestrogen receptor β J. Cell. Mol. Med. 2017 21 1605 1618 10.1111/jcmm.13090 28244646 
575. Ogawa S.  Eng V.  Taylor J.  Lubahn D.B.  Korach K.S.  Pfaff D.W.   Roles of estrogen receptor-α gene expression in reproduction-related behaviors in female mice Endocrinology 1998 139 5070 5081 10.1210/endo.139.12.6357 9832446 
576. Hewitt S.C.  Korach K.S.   Oestrogen receptor knockout mice: Roles for oestrogen receptors α and β in reproductive tissues Reproduction 2003 125 143 149 10.1530/rep.0.1250143 12578528 
577. Herbison A.E.  Pape J.R.   New evidence for estrogen receptors in gonadotropin-releasing hormone neurons Front. Neuroendocrinol. 2001 22 292 308 10.1006/frne.2001.0219 11587554 
578. Dorling A.A.  Todman M.G.  Korach K.S.  Herbison A.E.   Critical role for estrogen receptor α in negative feedback regulation of gonadotropin-releasing hormone mRNA expression in the female mouse Neuroendocrinology 2003 78 204 209 10.1159/000073703 14583652 
579. Heine P.A.  Taylor J.A.  Iwamoto G.A.  Lubahn D.B.  Cooke P.S.   Increased adipose tissue in male and female estrogen receptor-α knockout mice Proc. Natl. Acad. Sci. USA 2000 97 12729 12734 10.1073/pnas.97.23.12729 11070086 
580. Okura T.  Koda M.  Ando F.  Niino N.  Ohta S.  Shimokata H.   Association of polymorphisms in the estrogen receptor α gene with body fat distribution Int. J. Obes. Relat. Metab. Disord. 2003 27 1020 1027 10.1038/sj.ijo.0802378 12917706 
581. Thomas M.L.  Ibarra M.J.   Effects of ovariectomy on duodenal calcium transport in the rat: Altered ability to adapt to low-calcium diet Proc. Soc. Exp. Biol. Med. 1987 185 84 88 10.3181/00379727-185-42521 3575329 
582. Hope W.G.  Bruns M.E.  Thomas M.L.   Regulation of duodenal insulin-like growth factor I and active calcium transport by ovariectomy in female rats Proc Soc. Exp. Biol. Med. 1992 200 528 535 10.3181/00379727-200-43466 1508945 
583. Xu Y.  Nedungadi T.P.  Zhu L.  Sobhani N.  Irani B.G.  Davis K.E.  Zhang X.  Zou F.  Gent L.M.  Hahner L.D.    Distinct hypothalamic neurons mediate estrogenic effects on energy homeostasis and reproduction Cell Metab. 2011 14 453 465 10.1016/j.cmet.2011.08.009 21982706 
584. Krezel W.  Dupont S.  Krust A.  Chambon P.  Chapman P.F.   Increased anxiety and synaptic plasticity in estrogen receptor β -deficient mice Proc. Natl. Acad. Sci. USA 2001 98 12278 12282 10.1073/pnas.221451898 11593044 
585. Imwalle D.B.  Gustafsson J.A.  Rissman E.F.   Lack of functional estrogen receptor β influences anxiety behavior and serotonin content in female mice Physiol. Behav. 2005 84 157 163 10.1016/j.physbeh.2004.11.002 15642619 
586. Donner N.  Handa R.J.   Estrogen receptor β regulates the expression of tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei Neuroscience 2009 163 705 718 10.1016/j.neuroscience.2009.06.046 19559077 
587. Rocha B.A.  Fleischer R.  Schaeffer J.M.  Rohrer S.P.  Hickey G.J.   17 Beta-estradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-β knockout (BERKO) mice Psychopharmacology 2005 179 637 643 10.1007/s00213-004-2078-1 15645223 
588. Walf A.A.  Rhodes M.E.  Frye C.A.   Antidepressant effects of ERβ-selective estrogen receptor modulators in the forced swim test Pharmacol. Biochem. Behav. 2004 78 523 529 10.1016/j.pbb.2004.03.023 15251261 
589. Walf A.A.  Frye C.A.   ERβ-selective estrogen receptor modulators produce antianxiety behavior when administered systemically to ovariectomized rats Neuropsychopharmacology 2005 30 1598 1609 10.1038/sj.npp.1300713 15798780 
590. Lund T.D.  Rovis T.  Chung W.C.  Handa R.J.   Novel actions of estrogen receptor-β on anxiety-related behaviors Endocrinology 2005 146 797 807 10.1210/en.2004-1158 15514081 
591. Burgess L.H.  Handa R.J.   Chronic estrogen-induced alterations in adrenocorticotropin and corticosterone secretion, and glucocorticoid receptor-mediated functions in female rats Endocrinology 1992 131 1261 1269 10.1210/endo.131.3.1324155 1324155 
592. Shapiro R.A.  Xu C.  Dorsa D.M.   Differential transcriptional regulation of rat vasopressin gene expression by estrogen receptor α and β Endocrinology 2000 141 4056 4064 10.1210/endo.141.11.7796 11089536 
593. Miller W.J.  Suzuki S.  Miller L.K.  Handa R.  Uht R.M.   Estrogen receptor (ER)β isoforms rather than ERα regulate corticotropin-releasing hormone promoter activity through an alternate pathway J. Neurosci. 2004 24 10628 10635 10.1523/JNEUROSCI.5540-03.2004 15564578 
594. Siiteri P.K.  Murai J.T.  Hammond G.L.  Nisker J.A.  Raymoure W.J.  Kuhn R.W.   The serum transport of steroid hormones Recent Prog. Horm. Res. 1982 38 457 510 6750727 
595. Barrett Mueller K.  Lu Q.  Mohammad N.N.  Luu V.  McCurley A.  Williams G.H.  Adler G.K.  Karas R.H.  Jaffe I.Z.   Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function Endocrinology 2014 155 4461 4472 10.1210/en.2014-1270 25051445 
596. Quinkler M.  Meyer B.  Bumke-Vogt C.  Grossmann C.  Gruber U.  Oelkers W.  Diederich S.  Bahr V.   Agonistic and antagonistic properties of progesterone metabolites at the human mineralocorticoid receptor Eur. J. Endocrinol. 2002 146 789 799 10.1530/eje.0.1460789 12039699 
597. Watzka M.  Beyenburg S.  Blumcke I.  Elger C.E.  Bidlingmaier F.  Stoffel-Wagner B.   Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus Neurosci. Lett. 2000 290 121 124 10.1016/S0304-3940(00)01325-2 10936692 
598. Kudielka B.M.  Kirschbaum C.   Sex differences in HPA axis responses to stress: A review Biol. Psychol. 2005 69 113 132 10.1016/j.biopsycho.2004.11.009 15740829 
599. Llorente R.  Miguel-Blanco C.  Aisa B.  Lachize S.  Borcel E.  Meijer O.C.  Ramirez M.J.  De Kloet E.R.  Viveros M.P.   Long term sex-dependent psychoneuroendocrine effects of maternal deprivation and juvenile unpredictable stress in rats J. Neuroendocrinol. 2011 23 329 344 10.1111/j.1365-2826.2011.02109.x 21219484 
600. Karandrea D.  Kittas C.  Kitraki E.   Contribution of sex and cellular context in the regulation of brain corticosteroid receptors following restraInt. stress Neuroendocrinology 2000 71 343 353 10.1159/000054555 10878496 
601. Kitraki E.  Kremmyda O.  Youlatos D.  Alexis M.N.  Kittas C.   Gender-dependent alterations in corticosteroid receptor status and spatial performance following 21 days of restraint stress Neuroscience 2004 125 47 55 10.1016/j.neuroscience.2003.12.024 15051144 
602. Cyranowski J.M.  Frank E.  Young E.  Shear M.K.   Adolescent onset of the gender difference in lifetime rates of major depression: A theoretical model Arch. Gen. Psychiatry 2000 57 21 27 10.1001/archpsyc.57.1.21 10632229 
603. Piccinelli M.  Wilkinson G.   Gender differences in depression: Critical review Br. J. Psychiatry 2000 177 486 492 10.1192/bjp.177.6.486 11102321 
604. Suzuki S.  Handa R.J.   Regulation of estrogen receptor-β expression in the female rat hypothalamus: Differential effects of dexamethasone and estradiol Endocrinology 2004 145 3658 3670 10.1210/en.2003-1688 15087431 
605. Isgor C.  Cecchi M.  Kabbaj M.  Akil H.  Watson S.J.   Estrogen receptor β in the paraventricular nucleus of hypothalamus regulates the neuroendocrine response to stress and is regulated by corticosterone Neuroscience 2003 121 837 845 10.1016/S0306-4522(03)00561-X 14580933 
606. Leret M.L.  Molina-Holgado F.  Gonzalez M.I.   The effect of perinatal exposure to estrogens on the sexually dimorphic response to novelty Physiol. Behav. 1994 55 371 373 10.1016/0031-9384(94)90148-1 8153180 
607. Palermo-Neto J.  Dorce V.A.   Influences of estrogen and/or progesterone on some dopamine related behavior in rats Gen. Pharmacol. 1990 21 83 87 10.1016/0306-3623(90)90600-Q 2298391 
608. Smanik P.A.  Liu Q.  Furminger T.L.  Ryu K.  Xing S.  Mazzaferri E.L.  Jhiang S.M.   Cloning of the human sodium lodide symporter Biochem. Biophys. Res. Commun. 1996 226 339 345 10.1006/bbrc.1996.1358 8806637 
609. Dai G.  Levy O.  Carrasco N.   Cloning and characterization of the thyroid iodide transporter Nature 1996 379 458 460 10.1038/379458a0 8559252 
610. Yen P.M.  Ando S.  Feng X.  Liu Y.  Maruvada P.  Xia X.   Thyroid hormone action at the cellular, genomic and target gene levels Mol. Cell. Endocrinol. 2006 246 121 127 10.1016/j.mce.2005.11.030 16442701 
611. Brent G.A.   Mechanisms of thyroid hormone action J. Clin. Investig. 2012 122 3035 3043 10.1172/JCI60047 22945636 
612. Braverman L.E.  Ingbar S.H.  Sterling K.   Conversion of thyroxine (T4 ) to triiodothyronine (T3 ) in athyreotic human subjects J. Clin. Investig. 1970 49 855 864 10.1172/JCI106304 4986007 
613. Kohrle J.   The selenoenzyme family of deiodinase isozymes controls local thyroid hormone availability Rev. Endocr. Metab. Disord. 2000 1 49 58 10.1023/A:1010012419869 11704992 
614. Sabatino L.  Iervasi G.  Ferrazzi P.  Francesconi D.  Chopra I.J.   A study of iodothyronine 5′-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues Life Sci. 2000 68 191 202 10.1016/S0024-3205(00)00929-2 11191637 
615. Galton V.A.  McCarthy P.T.  St Germain D.L.   The ontogeny of iodothyronine deiodinase systems in liver and intestine of the rat Endocrinology 1991 128 1717 1722 10.1210/endo-128-4-1717 2004598 
616. Rodriguez F.  Jolin T.   The role of somatostatin and/or dopamine in basal and TRH-stimulated TSH release in food-restricted rats Acta Endocrinol. 1991 125 186 191 10.1530/acta.0.1250186 1680265 
617. DeRuyter H.  Burman K.D.  Wartofsky L.  Smallridge R.C.   Thyrotropin secretion in starved rats is enhanced by somatostatin antiserum Horm. Metab. Res. 1984 16 92 96 10.1055/s-2007-1014705 6142853 
618. Bradley D.J.  Young W.S. 3rd  Weinberger C.   Differential expression of α and β thyroid hormone receptor genes in rat brain and pituitary Proc. Natl. Acad. Sci. USA 1989 86 7250 7254 10.1073/pnas.86.18.7250 2780568 
619. Bernal J.   Thyroid hormone receptors in brain development and function Nat. Clin. Pract. Endocrinol. Metab. 2007 3 249 259 10.1038/ncpendmet0424 17315033 
620. Horlein A.J.  Naar A.M.  Heinzel T.  Torchia J.  Gloss B.  Kurokawa R.  Ryan A.  Kamei Y.  Soderstrom M.  Glass C.K.    Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor Nature 1995 377 397 404 10.1038/377397a0 7566114 
621. Guigon C.J.  Zhao L.  Lu C.  Willingham M.C.  Cheng S.Y.   Regulation of β-catenin by a novel nongenomic action of thyroid hormone β receptor Mol. Cell. Biol. 2008 28 4598 4608 10.1128/MCB.02192-07 18474620 
622. Bauer M.  Whybrow P.C.   Thyroid hormone, neural tissue and mood modulation World J. Biol. Psychiatry 2001 2 59 69 10.3109/15622970109027495 12587187 
623. Farsetti A.  Desvergne B.  Hallenbeck P.  Robbins J.  Nikodem V.M.   Characterization of myelin basic protein thyroid hormone response element and its function in the context of native and heterologous promoter J. Biol. Chem. 1992 267 15784 15788 1379237 
624. Farsetti A.  Mitsuhashi T.  Desvergne B.  Robbins J.  Nikodem V.M.   Molecular basis of thyroid hormone regulation of myelin basic protein gene expression in rodent brain J. Biol. Chem. 1991 266 23226 23232 1720778 
625. Koibuchi N.  Fukuda H.  Chin W.W.   Promoter-specific regulation of the brain-derived neurotropic factor gene by thyroid hormone in the developing rat cerebellum Endocrinology 1999 140 3955 3961 10.1210/endo.140.9.6997 10465264 
626. Graff M.N.  Baas D.  Puymirat J.  Sarlieve L.L.  Delaunoy J.P.   The α and β thyroid receptors are expressed by cultured ependymal cells. Correlation with the effect of l -3,5,3′-triiodothyronine on glutamine synthetase mRNAs Neurosci. Lett. 1993 150 174 178 10.1016/0304-3940(93)90529-T 8097029 
627. Garcia-Fernandez L.F.  Rausell E.  Urade Y.  Hayaishi O.  Bernal J.  Munoz A.   Hypothyroidism alters the expression of prostaglandin D2  synthase/β trace in specific areas of the developing rat brain Eur. J. Neurosci. 1997 9 1566 1573 10.1111/j.1460-9568.1997.tb01514.x 9283811 
628. Yen P.M.   Physiological and molecular basis of thyroid hormone action Physiol. Rev. 2001 81 1097 1142 10.1152/physrev.2001.81.3.1097 11427693 
629. Dong H.  Yauk C.L.  Rowan-Carroll A.  You S.H.  Zoeller R.T.  Lambert I.  Wade M.G.   Identification of thyroid hormone receptor binding sites and target genes using ChIP-on-chip in developing mouse cerebellum PLoS ONE 2009 4 e4610 10.1371/journal.pone.0004610 19240802 
630. Gagne R.  Green J.R.  Dong H.  Wade M.G.  Yauk C.L.   Identification of thyroid hormone receptor binding sites in developing mouse cerebellum BMC Genom. 2013 14 341 10.1186/1471-2164-14-341 23701648 
631. Nayak B.  Hodak S.P.   Hyperthyroidism Endocrinol. Metab. Clin. N. Am. 2007 36 617 656 10.1016/j.ecl.2007.06.002 17673122 
632. Zamoner A.  Heimfarth L.  Pessoa-Pureur R.   Congenital hypothyroidism is associated with intermediate filament misregulation, glutamate transporters down-regulation and MAPK activation in developing rat brain Neurotoxicology 2008 29 1092 1099 10.1016/j.neuro.2008.09.004 18845185 
633. Joffe R.T.  Sokolov S.T.   Thyroid hormones, the brain, and affective disorders Crit. Rev. Neurobiol. 1994 8 45 63 8124730 
634. Rabie A.  Favre C.  Clavel M.C.  Legrand J.   Effects of thyroid dysfunction on the development of the rat cerebellum, with special reference to cell death within the internal granular layer Brain Res. 1977 120 521 531 10.1016/0006-8993(77)90405-X 832138 
635. Rabie A.  Legrand J.   Effects of thyroid hormone and undernourishment on the amount of synaptosomal fraction in the cerebellum of the young rat Brain Res. 1973 61 267 278 10.1016/0006-8993(73)90532-5 4773164 
636. Zhou L.  Li X.  Ahmed A.  Wu D.  Liu L.  Qiu J.  Yan Y.  Jin M.  Xin Y.   Gut microbe analysis between hyperthyroid and healthy individuals Curr. Microbiol. 2014 69 675 680 10.1007/s00284-014-0640-6 24969306 
637. Lauritano E.C.  Bilotta A.L.  Gabrielli M.  Scarpellini E.  Lupascu A.  Laginestra A.  Novi M.  Sottili S.  Serricchio M.  Cammarota G.    Association between hypothyroidism and small intestinal bacterial overgrowth J. Clin. Endocrinol. Metab. 2007 92 4180 4184 10.1210/jc.2007-0606 17698907 
638. Wu S.Y.  Green W.L.  Huang W.S.  Hays M.T.  Chopra I.J.   Alternate pathways of thyroid hormone metabolism Thyroid 2005 15 943 958 10.1089/thy.2005.15.943 16131336 
639. Rayman M.P.   Selenium and human health Lancet 2012 379 1256 1268 10.1016/S0140-6736(11)61452-9 22381456 
640. Ventura M.  Melo M.  Carrilho F.   Selenium and Thyroid Disease: From Pathophysiology to Treatment Int. J. Endocrinol. 2017 2017 1297658 10.1155/2017/1297658 28255299 
641. Nguyen T.T.  DiStefano J.J. 3rd  Yamada H.  Yen Y.M.   Steady state organ distribution and metabolism of thyroxine and 3,5,3′-triiodothyronine in intestines, liver, kidneys, blood, and residual carcass of the rat in vivo Endocrinology 1993 133 2973 2983 10.1210/endo.133.6.8243325 8243325 
642. Navarro A.M.  Suen V.M.  Souza I.M.  De Oliveira J.E.  Marchini J.S.   Patients with severe bowel malabsorption do not have changes in iodine status Nutrition 2005 21 895 900 10.1016/j.nut.2005.02.006 15979283 
643. Michalaki M.  Volonakis S.  Mamali I.  Kalfarentzos F.  Vagenakis A.G.  Markou K.B.   Dietary iodine absorption is not influenced by malabsorptive bariatric surgery Obes. Surg. 2014 24 1921 1925 10.1007/s11695-014-1255-5 24740595 
644. Vought R.L.  Brown F.A.  Sibinovic K.H.  McDaniel E.G.   Effect of changing intestinal bacterial flora on thyroid function in the rat Horm. Metab. Res. 1972 4 43 47 10.1055/s-0028-1094095 4110893 
645. Chung S.J.  Van M.   Absorption of Thyroxine from the Small Intestine of Rats Endocrinology 1964 74 694 700 10.1210/endo-74-5-694 14168556 
646. DiStefano J.J. 3rd  de Luze A.  Nguyen T.T.   Binding and degradation of 3,5,3′-triiodothyronine and thyroxine by rat intestinal bacteria Am. J. Physiol. 1993 264 E966 E972 10.1152/ajpendo.1993.264.6.E966 8333521 
647. Salvatore G.  Covelli I.  Roche J.   The fixation of thyroid hormones by Escherichia coli and its mechanism Gen. Comp. Endocrinol. 1963 3 15 25 10.1016/0016-6480(63)90042-X 13991215 
648. Mehdi Y.  Hornick J.L.  Istasse L.  Dufrasne I.   Selenium in the environment, metabolism and involvement in body functions Molecules 2013 18 3292 3311 10.3390/molecules18033292 23486107 
649. Drutel A.  Archambeaud F.  Caron P.   Selenium and the thyroid gland: More good news for clinicians Clin. Endocrinol. 2013 78 155 164 10.1111/cen.12066 23046013 
650. Lavu R.V.  Van De Wiele T.  Pratti V.L.  Tack F.  Du Laing G.   Selenium bioaccessibility in stomach, small intestine and colon: Comparison between pure Se compounds, Se-enriched food crops and food supplements Food Chem. 2016 197 382 387 10.1016/j.foodchem.2015.08.001 26616964 
651. Hrdina J.  Banning A.  Kipp A.  Loh G.  Blaut M.  Brigelius-Flohe R.   The gastrointestinal microbiota affects the selenium status and selenoprotein expression in mice J. Nutr. Biochem. 2009 20 638 648 10.1016/j.jnutbio.2008.06.009 18829286 
652. Kasaikina M.V.  Kravtsova M.A.  Lee B.C.  Seravalli J.  Peterson D.A.  Walter J.  Legge R.  Benson A.K.  Hatfield D.L.  Gladyshev V.N.   Dietary selenium affects host selenoproteome expression by influencing the gut microbiota FASEB J. 2011 25 2492 2499 10.1096/fj.11-181990 21493887 
653. Nguyen T.T.  DiStefano J.J. 3rd  Huang L.M.  Yamada H.  Cahnmann H.J.   5′- and 5-deiodinase activities in adult rat cecum and large bowel contents inhibited by intestinal microflora Am. J. Physiol. 1993 265 E521 E524 10.1152/ajpendo.1993.265.3.E521 8214060 
654. Kim J.  Combs G.F. Jr.   Effects of selenium on colonic fermentation in the rat Biol. Trace Elem. Res. 1997 56 215 224 10.1007/BF02785394 9164666 
655. Kryukov G.V.  Gladyshev V.N.   The prokaryotic selenoproteome EMBO Rep. 2004 5 538 543 10.1038/sj.embor.7400126 15105824 
656. Rother M.  Resch A.  Wilting R.  Bock A.   Selenoprotein synthesis in archaea Biofactors 2001 14 75 83 10.1002/biof.5520140111 11568443 
657. Gladyshev V.N.  Khangulov S.V.  Stadtman T.C.   Properties of the selenium- and molybdenum-containing nicotinic acid hydroxylase from Clostridium barkeri Biochemistry 1996 35 212 223 10.1021/bi951793i 8555176 
658. Schrader T.  Rienhofer A.  Andreesen J.R.   Selenium-containing xanthine dehydrogenase from Eubacterium barkeri Eur. J. Biochem. 1999 264 862 871 10.1046/j.1432-1327.1999.00678.x 10491134 
659. Visser T.J.   Pathways of thyroid hormone metabolism Acta Med. Austriaca 1996 23 10 16 8767510 
660. Boelen A.  Kwakkel J.  Thijssen-Timmer D.C.  Alkemade A.  Fliers E.  Wiersinga W.M.   Simultaneous changes in central and peripheral components of the hypothalamus-pituitary-thyroid axis in lipopolysaccharide-induced acute illness in mice J. Endocrinol. 2004 182 315 323 10.1677/joe.0.1820315 15283692 
661. Boelen A.  Kwakkel J.  Platvoet-ter Schiphorst M.  Mentrup B.  Baur A.  Koehrle J.  Wiersinga W.M.   Interleukin-18, a proinflammatory cytokine, contributes to the pathogenesis of non-thyroidal illness mainly via the central part of the hypothalamus-pituitary-thyroid axis Eur. J. Endocrinol. 2004 151 497 502 10.1530/eje.0.1510497 15476451 
662. de Herder W.W.  Hazenberg M.P.  Pennock-Schroder A.M.  Hennemann G.  Visser T.J.   Rapid and bacteria-dependent in vitro hydrolysis of iodothyronine-conjugates by intestinal contents of humans and rats Med. Biol. 1986 64 31 35 3724259 
663. Hazenberg M.P.  de Herder W.W.  Visser T.J.   Hydrolysis of iodothyronine conjugates by intestinal bacteria FEMS Microbiol. Rev. 1988 4 9 16 3078770 
664. Otten M.H.  Herder W.W.  Hazenberg M.P.  Boom M.  Hennemann G.   Iodothyronine sulfatase activity of two anaerobic bacterial strains from rat intestinal microflora FEMS Microbiol. Lett. 1983 18 75 77 10.1111/j.1574-6968.1983.tb00452.x 
665. Rutgers M.  Heusdens F.A.  Bonthuis F.  de Herder W.W.  Hazenberg M.P.  Visser T.J.   Enterohepatic circulation of triiodothyronine (T3 ) in rats: Importance of the microflora for the liberation and reabsorption of T3  from biliary T3  conjugates Endocrinology 1989 125 2822 2830 10.1210/endo-125-6-2822 2583041 
666. Beigneux A.P.  Moser A.H.  Shigenaga J.K.  Grunfeld C.  Feingold K.R.   Sick euthyroid syndrome is associated with decreased TR expression and DNA binding in mouse liver Am. J. Physiol. Endocrinol. Metab. 2003 284 E228 E236 10.1152/ajpendo.00155.2002 12388159 
667. Castro I.  Quisenberry L.  Calvo R.M.  Obregon M.J.  Lado-Abeal J.   Septic shock non-thyroidal illness syndrome causes hypothyroidism and conditions for reduced sensitivity to thyroid hormone J. Mol. Endocrinol. 2013 50 255 266 10.1530/JME-12-0188 23296981 
668. Virili C.  Bassotti G.  Santaguida M.G.  Iuorio R.  Del Duca S.C.  Mercuri V.  Picarelli A.  Gargiulo P.  Gargano L.  Centanni M.   Atypical celiac disease as cause of increased need for thyroxine: A systematic study J. Clin. Endocrinol. Metab. 2012 97 E419 E422 10.1210/jc.2011-1851 22238404 
669. Centanni M.  Marignani M.  Gargano L.  Corleto V.D.  Casini A.  Delle Fave G.  Andreoli M.  Annibale B.   Atrophic body gastritis in patients with autoimmune thyroid disease: An underdiagnosed association Arch. Intern. Med. 1999 159 1726 1730 10.1001/archinte.159.15.1726 10448775 
670. Cindoruk M.  Tuncer C.  Dursun A.  Yetkin I.  Karakan T.  Cakir N.  Soykan I.   Increased colonic intraepithelial lymphocytes in patients with Hashimoto’s thyroiditis J. Clin. Gastroenterol. 2002 34 237 239 10.1097/00004836-200203000-00008 11873103 
671. Sasso F.C.  Carbonara O.  Torella R.  Mezzogiorno A.  Esposito V.  Demagistris L.  Secondulfo M.  Carratu R.  Iafusco D.  Carteni M.   Ultrastructural changes in enterocytes in subjects with Hashimoto’s thyroiditis Gut 2004 53 1878 1880 10.1136/gut.2004.047498 15542532 
672. Adeniyi K.O.  Olowookorun M.O.   Gastric acid secretion and parietal cell mass: Effects of thyroidectomy and thyroxine Am. J. Physiol. 1989 256 G975 G978 10.1152/ajpgi.1989.256.6.G975 2735415 
673. Tseng C.C.  Johnson L.R.   Role of thyroxine in functional gastric development Am. J. Physiol. 1986 251 G111 G116 10.1152/ajpgi.1986.251.1.G111 3728669 
674. Jetten A.M.   Retinoid-related orphan receptors (RORs): Critical roles in development, immunity, circadian rhythm, and cellular metabolism Nucl. Recept. Signal. 2009 7 e003 10.1621/nrs.07003 19381306 
675. Yang X.O.  Pappu B.P.  Nurieva R.  Akimzhanov A.  Kang H.S.  Chung Y.  Ma L.  Shah B.  Panopoulos A.D.  Schluns K.S.    T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR α and ROR γ Immunity 2008 28 29 39 10.1016/j.immuni.2007.11.016 18164222 
676. Yissachar N.  Zhou Y.  Ung L.  Lai N.Y.  Mohan J.F.  Ehrlicher A.  Weitz D.A.  Kasper D.L.  Chiu I.M.  Mathis D.    An Intestinal Organ Culture System Uncovers a Role for the Nervous System in Microbe-Immune Crosstalk Cell 2017 168 1135 1148 10.1016/j.cell.2017.02.009 28262351

